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The abnormal tumour microenvironment, which is typically hypoxic, acidic and with 
poor blood flow, induces the endothelial expression of genes not found on normal 
microvessels. By selectively targeting these tumour endothelial markers (TEMs) it is 
possible to induce tumour regression, presenting a potential strategy for therapeutic 
intervention. Potential TEMs were predicted by bioinformatics data mining. 
Validation of these TEM candidates identified a novel TEM CLEC14A. Functional 
characterization suggests a regulatory role of CLEC14A in endothelial cell migration. 
Inhibition of endothelial migration by CLEC14A antisera or monoclonal antibody 
holds therapeutic promise for the treatment of cancer. Differential gene expression 
analysis of freshly isolated lung tumour endothelium by 2
nd
 generation sequencing 
identified 13 putative TEMs. Subsequent validation work confirmed six of which to 
be expressed on lung tumour vasculature. Finally, a pre-validated marker, Robo4, was 
investigated as a cancer vaccine. A strong antibody response was induced by delivery 
of pure mouse Robo4 protein or a Robo4 conjugate. The in vivo sponge assay in 
Robo4 vaccinated mice showed a significant reduction in vessel invasion. Tumour 
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1.1 Endothelial cells  
Endothelial cell 
Endothelial cells line the inner surface of all blood and lymphatic vessels, forming a 
barrier between the circulating blood or lymph and the rest of the vessel wall or tissue. 
The thin monolayer of endothelium controls the transport of proteins, solutes and 
gases as well as cells across the blood vessel wall [1, 2]. All vascular endothelium is 
supported by a basement membrane. A lumen of capillaries is formed by 2 to 5 
endothelial cells and is partially covered by pericytes. Unlike capillaries, arteries and 
veins are surrounded by vascular smooth muscle cells and collagenous connective 
tissue. The mural cells not only provide a structural support to the vasculature but also 
cross-talk with the endothelial cells and restrict endothelial motility [3].  
 
Endothelial cells are involved in various aspects of vascular biology, including blood 
coagulation, functional barrier, vasoconstriction/vasodilation and inflammation [4]. 
Furthermore, de novo vascular development and angiogenesis are processes that are 
orchestrated by endothelial cells [5]. ECs are normally quiescent in healthy tissue but 
are sensitive to signaling molecules from the extracellular environment. Inadequate 
activation or inactivation of endothelial cells by these signals has been associated with 
a variety of vascular disorders and disease [6].  
 
Types of endothelial cells 
Following the seminal work of Gerhardt and Betsholtz, the concept of endothelial tip 
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and stalk cells [7] and later the stabilized phalanx cell were introduced [8]. When 
growth factors reach the vessels, only a subpopulation of endothelial cells acquire the 
tip cell phenotype. Tip cells pioneer the formation of new blood vessels, termed 
angiogenesis, by projecting sprouts and talking to the guidance cues in the 
extracellular environment. Next to the tip cells, the stalk cells with less filopodia are 
actively proliferative to build up a lumen supporting the elongation of the new sprout. 
Unlike tip and stalk cells, phalanx cells are quiescent endothelial cells, which form a 
tight barrier to maintain vascular stability and control permeability. These cells rarely 
project filopodia and show poor motility. As active angiogenesis initiates with tip cells, 
much interest has centered on what switches a stabilized phalanx cell into a stalk or 
tip cell.  
 
1.2 Angiogenesis  
The human vascular network supplies nutrients and oxygen to almost all organs 
throughout the body while removing metabolic waste. Angiogenesis decribes the 
formation of new blood vessels from the pre-existing ones [9]. In all adults, 
physiological angiogenesis occurs in the wound healing process. While in women, it 
also takes place in the menstrual cycle and during pregnancy. Since the vessels 
connect to every part of the body, abnormal growth of vessels leads to numerous 
pathological conditions. So far, there are more than a hundred disorders have been 
implicated to be angiogenesis dependent. For instance, insufficient vessel growth or 
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vessel regression causes stroke, ischaemic heart disease, ulcerative disorders and 
neurodegeneration whilst excessive angiogenesis leads to rheumatoid arthritis, 
pulmonary hypertension, age-related macular degeneration and tumour progression in 
cancer [5].  
 
Vasculogenesis is the formation of a primitive vasculature and is a process that occurs 
before angiogenesis. During embryonic development, when diffusion of nutrients is 
no longer sufficient to meet the growth rate, mesoderm derived endothelial precursors, 
known as angioblasts, assemble into new vessels and differentiate into a primitive 
vascular network [10]. Angiogenesis further remodels the initial vasculature into 
arteries and veins by sprouting [11]. Mural cells, such as pericytes and smooth muscle 
cells, are then recruited to stabilize the vessel wall and allow perfusion [12, 13]. 
 
Types of angiogenesis   
Sprouting angiogenesis was the first described pattern of angiogenesis (Figure 1.1). 
This type of angiogenesis proceeds with the activation of surface receptors on the 
endothelial cells within the pre-existing vasculature by growth factors such as 
vascular endothelial growth factor (VEGF). The activated endothelial cells become 
unstable and invasive and change their morphology by protruding filopodia. These 
cells then begin to secrete proteolytic enzymes to dissolve the basement membrane 
supporting the existing blood vessels [14, 15]. This is followed by proliferation and 
migration, where endothelial cells form an entirely new lumen towards the source of 
5 
 
the growth factors. Pericytes are subsequently recruited to stabilize the newly formed 
vessels [16].  
 
Besides sprouting angiogenesis, other vessel growth patterns exist through different 
mechanisms. For example intussusceptive angiogenesis is the splitting of an existing 
vessel into two, initiated by the establishment of an endothelial cell junction within 
the capillary [17]. Since this type of angiogenesis can dramatically expand the 
capillary without increasing the number of endothelial cells, it is particularly 
important during embryonic development where the number of endothelial cells is 
limited [18]. Circulating endothelial precursor cells can also contribute to the 
expansion of the existing vasculature [19]. Despite the existence of these other vessel 
growth patterns, therapeutics targeting the tumour vasculature have focused on 
inhibiting sprouting angiogenesis or targeting the established vasculature within the 
tumour.  
 
Figure 1.1 Sprouting and intussusceptive angiogenesis. Sprouting angiogenesis; the 
formation of new blood vessels through degradation of basement membrane by 
proteases released from the activated endothelial cell, followed by migration and tube 
formation. Intussusceptive angiogenesis; the splitting of an existing vessel into two, 
initiated by the establishment of an endothelial cell junction within the capillary. 
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1.3 Tumour angiogenesis  
Like healthy organs, a tumour needs blood vessels to acquire oxygen and nutrients to 
allow its growth. Initially, micro-tumours survive by local diffusion. However, when a 
tumour reaches a certain size, approximately 3 mm
3
, diffusion is no longer sufficient 
to meet its growth rate. At this stage, the avascular tumour could become dormant for 
an indefinite period of time. However, tumours can overcome this inadequacy by 
building up a new blood supply through recruitment of new vessels from the adjacent 
existing vessels. This process is called tumour angiogenesis (Figure 1.2).  
 
 
Figure 1.2 Tumour angiogenesis Endothelial cells secret proteolytic enzymes that 
dissolve the basement membrane surrounding the existing blood vessels. Small 
capillaries form by the migration and proliferation of endothelial cells orchestrated by 
angiogenic growth factors. Stabilization of the newly formed vessels is achieved by 




Tumour cells secrete growth factors (pro-angiogenic factors) such as IL8, bFGF and 
VEGF that diffuse into the surrounding tissues. The existence of soluble angiogenic 
factors was elusive until Folkman and his colleagues proved it in a rabbit cornea 
model in the early 1970s. In that study, a small piece of tumour, about 0.5 mm
3
, was 
implanted into the stromal layers of a rabbit cornea away from the limbal edge. 10 
days later, new blood vessels from the limbus had reached the tumour. However, the 
tumour implanted into the centre of the cornea expanded slowly until the edge of the 
tumour extended to less than 2 mm from the limbus and the recruitment of new blood 
vessels eventually occurred [21]. 
 
Endothelial cells express many tyrosine kinase receptors that are highly sensitive to 
angiogenic factors. The binding of growth factors to their receptors activates 
intracellular signaling involved in endothelial migration and proliferation. As 
described earlier, upon activation, the quiescent endothelial cells start to form sprouts 
to sense the guidance cues. Later, a newly formed vessel is extended towards the 
source of the stimuli, a starving tumour. In order to survive, the tumour vasculature is 
being constantly remodeled. Therefore, like the proliferation of cancer cells, once 
occurred, tumour angiogenesis becomes an ever progressing process. It is widely 





1.4 Anti-angiogenic therapy  
Besides surgical removal of the malignant tissue, there exist two major therapies to 
treat cancer patients: chemotherapy and radiotherapy. Chemotherapy was designed to 
induce apoptosis of rapid proliferating tumour cells by disrupting their DNA 
replication or transcription. Radiotherapy uses photons or charged particles to damage 
the DNA chain, which subsequently causes cell death. Although chemotherapy and 
radiotherapy have been successful in reducing primary tumour burden, these two 
approaches rarely achieve lasting benefits for those with advanced or metastasized 
disease. This is mainly due to their unspecified toxicity that not only harms the rapid 
growing cancer cells but also healthy tissues that have relatively high proliferative 
rates; especially hair follicles and bone marrow. An ideal therapy for cancer should be 
able to kill tumours beyond its primary site but spare healthy tissue. Anti-angiogenic 
therapy has the advantage in both counts and has drawn much attention as a strategy 
to treat cancer. 
 
In 1971, Folkman and colleagues proposed that angiogenesis inhibitors can stop 
tumour growth by choking off its blood supply and that anti-angiogenesis held 
therapeutic potential in the treatment of cancer [25]. Since then anti-angiogenic 
therapy became an active field attempting to prevent or destroy tumour vasculature by 
manipulating the growth of new blood vessels. In principal, anti-angiogenic therapy 
would have a number of advantages over the traditional anti-cancer therapies. Firstly, 
cancer cells are genetically unstable which results in drug resistance. In contrast, 
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anti-angiogenic therapies mainly target the endothelial cells which have a much lower 
mutation rate, therefore drug resistance is less likely to develop. Secondly, one 
endothelial cell supports the survival of tens to hundreds of cancer cells. It is 
conceivable that taking one endothelial cell out could lead to a 10 – 100 fold 
increasing death of cancer cells that relied on it [26]. Thirdly, anti-cancer agents are 
difficult to deliver into the tumour because of the interstitial pressure. However, this 
problem could be avoided as the endothelial cells have direct contact with the blood 
stream which is highly accessible for anti-angiogenic agents. Finally, all tumours need 
angiogenesis to allow their growth and expansion. This indicates that anti-angiogenic 
agents have the ability to inhibit a wide range of tumour types [27]. Taken together, 
anti-angiogenic therapy is a promising strategy with many advantages over 
conventional treatments and development of such therapy is ongoing.  
 
The VEGF pathway has been the focus of this field and therefore extensively pursued 
for the last three decades [28, 29]. Accumulating evidence shows that blocking this 
pathway by neutralizing VEGF or disrupting their cognate receptor tyrosine kinases 
results in reduced tumour burden and increased survival [30].  
 
1.5 VEGF as a target 
Tumour angiogenesis is a complicated process that involves multiple regulators in 
which the most prominent one is vascular endothelial growth factor – VEGF (also 
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called VEGF-A). VEGF-A is a pro-angiogenic molecule that stimulates endothelial 
proliferation, migration, tube formation and survival [31-33].  Deletion of VEGF-A 
in mice is embryonic lethal due to abnormal development of blood vessels, suggesting 
VEGF-A is essential for the development of normal vasculature [34, 35].  
 
The VEGF family comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and 
placental growth factor (PlGF). VEGF receptors (VEGFRs) are single transmembrane 
proteins that belong to the receptor tyrosine kinase superfamily. The extracellular 
region of VEGFRs contains 7 immunoglobulin-like domains and the intracellular 
region composed of a split tyrosine kinase domain and a C-terminal tail. The receptors 
dimerize when cognate VEGF members bind to them on the cell surface, which is 
followed by phosphorylation and activation of the tyrosine kinase domain (Figure 
1.3).  
 
All VEGF(R) members are involved in angiogenesis and/or lymphoangiogenesis and 
have therapeutic potential. Among the VEGF members, VEGF-A is the most potent 
pro-angiogenic growth factor which strongly induces physiological and pathological 
angiogenesis by signaling through VEGFR-2 (also called FLK-1, KDR) [36]. The 
hypoxic environment of a tumour significantly induces the expression of VEGF-A 
[37]. As angiogenesis can be directly induced by the binding of VEGF to VEGFR2, 
this pathway provides an attractive pharmaceutical target for various vascular diseases, 
especially cancer. Expression of VEGFR2 is also found in lymphatic endothelium 
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which implied a role of VEGF-A in lymphoangiogenesis [38, 39]. VEGF-A also binds 
to VEGFR1 with a higher affinity but this receptor triggers a weaker phosphorylation 
signal compared to VEGFR2 [40, 41]. Since VEGFR1 has been involved in 
inflammation and cancer, this pathway has also offered a useful target [42-44]. 
VEGF-C and VEGF-D and their cognate receptor VEGFR3 are deeply involved in 
lymphoangiogenesis and have proven a critical system for lymph node metastasis [45, 
46]. VEGF-E specifically binds to VEGFR2 to induce angiogenesis [47]. VEGF-E has 
been investigated in proangiogenic therapy and showed less side effects compared 
with patients treated with VEGF-A [48, 49].  
 
 
Figure 1.3 VEGF and its receptor system. Major signals of angiogenesis are 
generated from VEGFR2. Although VEGFR1 has a weak tyrosine kinase activity, it 
also stimulates angiogenesis via recruitment of bone marrow-derived mononuclear 
cells. VEGFR1 plays an important role in inflammation and atherosclerosis. Soluble 
VEGFR1 is involved in placental regulation and avascularity in the cornea. Figure 




VEGF clinical achievements and challenges  
Owing largely to the essential role played by VEGF in vascular development and 
tumour angiogenesis, significant efforts have been invested to explore the therapeutic 
use of VEGF blocking agents. Numerous pre-clinical studies have shown that in 
either orthotopic or ectopic human xenograft tumour models, the disruption of VEGF 
signaling led to a dramatic reduction of tumour progression [51]. Collective evidence 
has paved the way for anti-angiogenic drugs towards clinical application. In 2004, the 
Food and Drug Administration (FDA) approval of Avastin, the first anti-angiogenic 
drug, led to a boost in the development of several drugs that target the VEGF 
signaling pathway, namely VEGF(R) blockers.  
 
Avastin is a humanized monoclonal antibody to VEGF-A that was designed for 
inhibiting tumour angiogenesis by neutralizing VEGF-A. Nowadays the use of 
Avastin has extended to metastatic non-squamous non small cell lung cancer, 
metastatic breast cancer and metastatic renal cell carcinoma in the form of 
chemotherapy or cytokine therapy combination or to recurrent glioblastoma 
multiforme as a monotherapy [52]. Another group of VEGF(R) blockers are 
multi-targeted tyrosine kinase inhibitors (TKIs) including sorafenib (targeting 
VEGFR2 and 3, PDGFR, Raf), sunitinib (targeting VEGFR2, PDGFR & c-kit
27
) and 
pazopanib (targeting VEGFR 1-3, PDGFR & c-kit
92
) and most of these have been 
approved for treating metastatic renal cell carcinoma. More recently, vandetanib 
(targeting VEGF1-3, PDGFR, EGFR & RET
30, 95
) has been approved to treat 
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unresectable or metastatic medullary thyroid cancer but the clinical outcome has not 
yet been released. These VEGF(R) blockers generally provide an improvement of 
progression-free survival of up to a few months in cancer patients [5]. Besides the 
treatment of cancer, Avastin and two other anti-VEGF drugs: pegaptanib (VEGF 
aptamer) and ranibizumab (VEGF Fab antibody), have been approved to treat 
age-related macular degeneration that often causes blindness due to damage to the 
vasculature [53-56].  
 
Despite these successes in the treatment of cancer, the clinical data has shown that the 
use of anti-angiogenic therapy was not as potent as it was hoped for. The initial goal 
of the anti-angiogenic therapy was to inhibit angiogenesis and reduce the vascular 
supply to the tumour. However, their benefit was limited by the insufficient capability 
or the initial refractoriness and later, resistance [57]. Increasing evidence from 
pre-clinical and clinical studies suggests that VEGF blockers cause normalization of 
the tumour vasculature and that the conversion of abnormal tumour vessels into 
functional ones has become a complementary therapeutic paradigm [58]. This is 
mainly because the normalized tumour vessels can facilitate the delivery of 
chemotherapeutic drugs and immune cells [59]. This also explained, to some extent, 
why cancer patients have not benefited from single agent anti-angiogenic treatment.  
 
More recent studies have shown that VEGF targeting strategies, including 
anti-VEGFR2 and VEGFR tyrosine kinases, suppressed primary tumour growth but 
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also accelerated metastasis and shortened survival time in mice [60, 61]. One possible 
mechanism is that these anti-angiogenic drugs often increase tumour hypoxia due to 
their efficiency of pruning the tumour vasculature, in turn leading to a hypoxic niche, 
facilitating the selection of more aggressive, hypoxia-resistant cancer cell clones [62]. 
Ebos et al. also reported that pre-treating healthy mice with VEGF inhibitors caused 
increased metastasis in ectopic tumour models [60]. These findings implied a 
pre-conditioning of the blood vessel system, which, possibly due to an unknown 
effect on the normal vasculature, facilitates tumour cell seeding and revascularization.  
 
1.6 Tumour vascular targeting  
Targeting the tumour vasculature is different from anti-angiogenic therapy. Vascular 
targeting aims to limit tumour growth by specifically destroying the established 
vasculature that supports tumour survival, expansion and metastasis, while exempting 
the normal vasculature from the same effects. Instead of preventing neo-vessels from 
growing, the established vasculature in tumours has been explored as a target for 
cancer treatment.  
 
The study which provided proof of principle that vascular targeting can be used to 
eradicate solid tumours in mice came from the work of Burrows and Thorpe in 1993 
[63]. In this study, a neuroblastoma tumour line was engineered to secrete interferon 
gamma (IFN-γ) that is known to induce the expression of MHC class II antigens on 
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endothelial cells residing in the tumour. They then coupled ricin to an anti-mouse 
MHC class II antibody and showed that a single injection resulted in extensive 
haemorhagic necrosis and elimination of the tumours [63]. A later study supported 
this strategy by directing a thrombogen, tissue factor to the tumour vasculature, which 
led to complete tumour eradication in mice [64]. A recent study targeting 
phosphatidylserine that is normally intracellular but exposed on the luminal surface of 
tumour endothelial cells, also showed inhibitory effects on tumour growth, again 
supporting a vascular targeting strategy [65].  
 
Despite success in animal models, the translation of vascular targeting agents to the 
clinic has been slow, owing largely to the absence of a rigorously characterized 
tumour vascular target in man. The success of antibody and vaccine approaches will 
be reflected by the specificity of the target for tumor endothelium, and this has 
prompted the search for well-defined targets. Indeed, as targeting can be achieved 
with antibodies, antibody conjugates, and more recently, vaccines and modified T 
cells (reviewed in [22]; [66, 67]), a naturally occurring marker of tumor endothelial 
cells would provide significant therapeutic promise. Unfortunately, the expression of 
some of these targets is not as widespread as was hoped for [22], and there remains a 




1.7 Tumour endothelial markers (TEMs) 
Fundamental differences between tumour and normal vasculature present unique 
targets for anti-cancer therapy [68]. A major cause of these differences is the influence 
of the extracellular environment on the endothelial transcriptome. Endothelial cells 
resident within a tumour are exposed to an extracellular environment markedly 
different from that of endothelial cells resident in healthy tissue. For example, an 
endothelial cell within the tumour microenvironment will experience hypoxia and that 
alone can change the expression of up to 2000 genes [69]. Tumours also show glucose 
deprivation, acidic extracellular pH, high interstitial pressure [70], excess of 
pro-angiogenic factors and increased mechanical compression [71]. Each of these 
factors may influence the transcriptome of the endothelial cells residing within 
tumours. Considerable effort has been invested to identify and validate the genes that 
are restricted to the tumour vessel, known as Tumour Endothelial Markers (TEMs). 
Although the putative TEMs to date have not been studied in clinical trials, the 
investigation of their potential in the treatment of cancer has raised wide interest [23].  
 
Identification of TEMs 
Numerous endothelial specific genes have now been identified and functional studies 
have shown that many play a role in angiogenesis [72, 73]. Attempts to identify TEMs 
have included construction of SAGE libraries from freshly isolated endothelium [74], 
use of microarray platforms [75], proteomic analysis of freshly isolated endothelial 
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cell membranes [75, 76] as well as bioinformatics data mining [77, 78]. These efforts 
succeeded in identifying candidates including the EDB domain of fibronectin, a series 
of numbered TEM’s, annexin A and Robo4 reviewed in [79]. There nevertheless 
remains an urgent need to identify novel and improved vascular targets.   
 
In order to identify the genes that are only expressed in tumour endothelium but not 
that in normal tissue, our group have predicted novel putative tumour endothelial 
markers by bioinformatics data mining in public EST and SAGE libraries [78]. In 
brief, endothelial genes were firstly identified by in-silico subtraction of genes 
expressed in endothelial cells versus those in non-endothelial cells. Tumour genes 
were then identified by subtracting bulk tumour libraries from bulk normal ones. The 
genes present in both lists were considered putative tumour endothelial markers [78]. 
In this study, three putative TEMs have been chosen for validation based on the level 
of association with endothelial cells, previously published work, intellectual property, 




CLEC14A (C-type lectin domain family 14 member A), also called EGFR5 or 
C14orf27, is a type I transmembrane protein that belongs to the C-type lectin domain 
family. A C-type lectin is a type of sugar-binding protein domain [80]. The C-type 
18 
 
originated from the requirement of calcium for carbohydrate binding. Proteins 
containing the C-type lectin domain have a wide range of biological functions such as 
cell-cell contact, immune response to pathogens [81] and apoptosis [82]. CLEC14A is 
a member of the Endosialin family that has three other members: Endosialin, CD93 
and thrombomodulin (Figure 1.4). Endosialin was originally reported to be found in 
small blood vessels in tumours, however its expression was later found on fibroblasts 
and pericytes [83]. CD93 is expressed on endothelium, myeloid cells, platelets and 
stem cells and is involved in leukocyte and endothelial cell adhesion. It also can have 
a role in the regulation of phagocytosis of apoptotic cells and antibody production 
[84]. Thrombomodulin is an endocytic receptor expressed in endothelial cells. It is 
involved in sequestration of thrombin and the activation of protein C [85, 86]. The 
function of CLEC14A remains unknown.  
 
Full length CLEC14A is a 51.6 kDa protein which has 490 amino acids. The 
extracellular domain (amino acids 23 to 398) includes a C-type lectin domain or 
carbohydrate recognition domain and a single EGF-like domain. The transmembrane 
domain of amino acids 399 to 421 is followed by a small cytoplasmic tail of 69 amino 
acids. Bioinformatic analysis of potential sites of glycosylation predicted one highly 
conserved N-glycosylation site and nine poorly conserved potential O-glycosylation 
sites. 
 
Previous work in our group has shown selective expression of CLEC14A in 
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endothelial cells by PCR on various cell lines. Weak expression was detected in 
fibroblasts and placenta (site of active angiogenesis). No expression could be detected 
in a variety of primary cells or cell lines. We also found that the expression of 
CLEC14A was induced by low shear stress which strongly correlates with the reduced 
blood flow in ill formed tumour vessels [87].  
 
 
Figure 1.4 Structures of members in the endosialin family. C-type lectin domain 
(pink). 1-6 EGF domains (green). Pro/Ser/Thr rich domain (pink bar). A 
transmembrane domain (blue). 
 
GBP4 
GBP4 (Guanylate binding protein 4) is a member of the guanylate binding protein 
family which belongs to the GTPase superfamily. Seven members have been 
discovered in man: hGBP1-7 and all members are expressed by endothelial cells and 
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inducible by IFN-γ [88].  
 
GBP1 is the best characterized member in the family. In vitro studies showed that 
GBP1 can be induced by many inflammatory cytokines including IFN-γ, 
interleukin-1β (IL-1β), IL-1α and TNF-α [89]. Emerging evidence demonstrated that 
GBP1 plays a role in angiogenesis and cancer. The helical domain of GBP1 is tightly 
associated with the inhibition of endothelial cell proliferation and invasion induced by 
inflammatory cytokines [90]. The most recent publication demonstrated that induction 
of GBP1 by doxycycline inhibits tumour growth in mice [91]. GBP2 was recently 
characterized as a p53-regulated tumour marker in esophageal squamous cell 
carcinomas [92]. Three GBP5 splicing variants (gbp-5a, -5b and -5ta) that lead to two 
proteins: GBP-5a/b and GBP-5ta were identified in cutaneous T-cell lymphoma and 
melanoma cell lines at a high expression level [93].  
 
The whole GBP4 gene is 6160 bp with 10 exons (Cds 1923 bp), located on 
chromosome 1. Its protein product contains 640 aa and the molecular weight is 
predicted to be 73 kDa. It has a GTP binding site motif at aa 60-67 and aa 112-116 
and a coiled-coil domain at aa 498-612. In endothelial cells, GBP4 can be induced by 
IFN-γ but not TNF-α. Its subcellular localization was revealed in both the cytoplasm 
and the nucleus [88]. At present, there is little known about GBP4 in respect of 





IKBKE (Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase epsilon), 
also named IKKi or IKKз, belongs to the IKK family which includes another three 
members: IKKα, IKKβ and a regulatory subunit IKKγ (NEMO) that play a key role in 
the NF-κB signaling pathway [94]. 
 
In the classic NF-κB pathway, IKKα, IKKβ and NEMO form a core IKK complex 
that is firstly activated by the upstream stimuli and subsequently phosphorylates the 
NF-κB inhibitory protein IκBα. This leads to the ubiquitination of IκBα and allows 
NF-κB to translocate into the nuclear and activates the transcription of target genes 
[94].  
 
IKBKE is a serine/threonine protein kinase which consists of 716 amino acids with 
predicted molecular weight of 70 kDa. The protein sequence of IKBKE shares 33% 
and 31% homology to IKKα and IKKβ respectively. Although IKBKE processes the 
function in the activation of NF-κB, it was not induced by TNF-α and IL-1 like IKKα 
and IKKβ but it is activated by interferon, phorbol12-myrisate 13-acetate or the T-cell 
receptors. Therefore IKBKE has also been described as a non-canonical IKK family 
member [95-97]. 
 
In 2007, IKBKE was characterized as a breast cancer oncoprotein using integrative 
genomic approaches. The gene was overexpressed in over 30% of breast carcinomas 
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and breast cancer cell lines [98]. The same group later reported that serine 418 of the 
tumour suppressor CYLD was directly phosphorylated by IKBKE and promotes cell 
transformation [99]. IKBKE has also been associated with tumour progression and 
cisplatin resistance in ovarian cancer [100]. These findings suggested a link between 
the IKBKE pathway and the initiation and progression of cancer where active 
angiogenesis is strongly involved.  
 
A validated TEM 
Robo4  
Robo4 was first identified as an endothelial specific gene in 2000 [77] and later 
shown by our group and others to be a gene preferentially expressed in the tumour 
compared to healthy tissue endothelium [73]. Robo4 is the smallest member of the 
roundabout family and the only one to have restricted tissue expression. The other 
Roundabouts were originally identified and are primarily characterized as axon 
guidance receptors [101], although there is increasing evidence that they are also 
involved in angiogenesis [102]. Robo4 contains two of the five Ig like regions and 
two of the three fibronectin like regions present in the Robo1~3 extracellular domain, 
a transmembrane domain and an intracellular region with two conserved motifs for 
intracellular signal transduction (Figure 1.5). Multiple functions have been identified 
for Robo4, reviewed in [103]. Robo4 is specifically expressed in endothelial cells in 
vitro, is involved in endothelial motility, which is an essential process in tumour 
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angiogenesis [104-107]. The over expression of Robo4 in placenta, as determined by 
in situ hybridization, indicates that Robo4 is preferentially expressed at sites of active 
angiogenesis. More importantly, in adult tissues, Robo4 is abundantly present on the 
endothelium in a wide range of solid tumours whereas it is almost or completely 
absent in normal tissues [73, 108, 109]. A recent study showed that in a B16/F10 
mouse melanoma model, Robo4 antibody coupled nanoparticles targeted vasculature 




Figure 1.5 Structure of Robo4 Robo4 is comprised of two Ig and two fibronectin 
domains in the extracellular region, one transmembrane region and two conserved 
motifs in the intracellular region.  
  
1.8 Identification of novel TEMs in lung cancer 
Lung cancer remains the leading cause of cancer related death in the world and there 
is still a lack of an effective treatment. Platinum-based chemotherapies achieved a 
modest improvement of survival time for 6 months however most patients 
subsequently developed progressive disease. Although tyrosine kinase inhibitors of 
EGFR initially showed promising outcomes in several trials, resistance eventually 
developed in all patients [111]. The ineffectiveness of the classic treatments prompted 
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the search for alternative approaches for non-small cell lung cancer. More recently, 
the development of anti-angiogenic drugs such as VEGF (receptor) blockers has 
drawn greater focus to the tumour vasculature. The use of such drugs or compounds 
in treating NSCLC patients have been investigated in early clinical trials. Profiling 
differentially expressed genes in lung tumour will not only enhance our understanding 
of the molecules involved in this disease but may also provide biomarkers or targets 
that have therapeutic potential.  
 
Isolation of endothelial cells 
The first successful isolation and culture of primary human endothelial cells was 
achieved in the early 1970s, independently by Gimbrone et al. [112] and Jaffe et al. 
[113]. These findings paved the way for detailed research in vascular biology. 
However conventional tissue culture involved multiple factors such as a lack of flow 
and acidic stress that have profound effects on the transcriptome of endothelial cells. 
In rat, 40% of the original endothelial surface proteins in lung disappeared when in 
culture [114]. Thus a prerequisite for success in molecular profiling of endothelium is 
to obtain a pure endothelial specimens from in vivo physiological and pathological 
samples. To profile differential gene expression of endothelial cells in normal and 




Laser capture microdissection  
Laser capture microdissection (LCM), often called microdissection, is a technology to 
isolate specific microscopic regions of tissue. The LCM isolating process involves a 
pre-lineation of desired regions from a tissue slide. Then a laser beam, in most cases a 
UV laser, follows the defined trajectory to microdissect the region of interest. This 
region is then transported into a cap by a laser pressure catapult. This technology has 
the advantage of maintaining the chemistry of the dissected sample, which permits an 
effective retrieval of DNA and RNA and in some cases protein. For this reason, LCM 
has been widely used for molecular profiling downstream work. LCM can precisely 
dissect and collect the desired tissue at a cellular level which is particularly useful as 
endothelium only accounts for a minor proportion of the whole tissue. There are a 
number of endothelial profiling studies published using this technology [115-117]. 
The main challenge for LCM is to obtain enough high quality RNA material to 
perform gene expression profiling analysis. 
 
Ulex-bead approach 
Ulex europaeus agglutinin I is a lectin that specifically binds to L-fucose residues on 
the human endothelial surface [118, 119]. Previous studies have shown high purity of 
endothelial isolates using Ulex-conjugated beads [120-124].  
 
The Ulex-bead isolation approach is preferentially performed on fresh tissue, 
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therefore requiring a fresh clinical specimen. A major benefit from this approach is 
that the RNA integrity is high and the yield is good. Therefore, the bead isolation 
approach permits studies using 2
nd
 generation sequencing platforms, whereas the laser 
microdissection technique, due to its low RNA yield, is only suitable for microarray 
analyses.  
 
Although both techniques have been previously described in isolating endothelium 
from various types of tissue [115, 117, 125-127], an attempt in lung cancer has not yet 
been reported and remains a challenge.  
 
2nd generation sequencing (Deep sequencing)  
RNA-seq deep sequencing or 2nd generation sequencing is a parallel sequencing 
method for transcriptome analysis. It facilitates RNA snapshots of a tissue by 
sequencing millions of short reads that can be assembled into a transcriptome and be 
used to measure differential gene expression. The two major systems of 2nd 
generation sequencing are Applied Biosystems SOLiD4 and Illuminas Gene Analyser 
II/Hiseq sequencers [128]. These technologies have the advantage of querying both 
known and previous undescribed transcripts and therefore, unlike microarrays, do not 
rely on prior knowledge of transcripts. In the same way, it neither suffers from probe 
cross hybridization of closely similar genes. Deep sequencing also provides rich 
information splice variants, isoform switching and non-coding RNAs such 
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microRNAs and pseudogenes.  
 
1.9 Targeting tumour vasculature by vaccination 
Cancer immunotherapy  
Immunotherapy is the use of the host immune system to treat disease, often involving 
the elicitation, enhancement or suppression of an immune response. Cancer 
immunotherapy is particularly designed to stimulate a cancer patients’ immune system 
to kill malignant cells and in turn, achieve tumour regression. Administration of 
therapeutic antibodies can direct one’s immune system to specifically attack tumour 
cells. Cell based immunotherapy involves in vivo or ex vivo activation of immune 
cells including natural killer (NK) cells, cytotoxic T cells (CTL) and dendritic Cells 
(DCs) followed by transfusing them back into patients.  
 
Immunotherapy that targets the tumour vasculature has been explored in the last two 
decades. Although the use of VEGF blockers in combination with chemotherapies 
have shown clear clinical benefit, in certain types of cancer resistance eventually 
developed and disease progressed in almost all patients [129]. Cancer vaccination is a 
strategy to boost the patient’s own immune system against tumour cells by inducing 





The vaccine approach has been used to protect people from diseases for decades, for 
instance: measles, chicken pox and the flu. The idea of a cancer vaccine is to treat 
existing cancer or prevent cancer occurring in people at high risk. At present, two 
vaccines have been approved by the FDA for preventing cancer but only one cancer 
vaccine, Sipuleucel-T, was approved by FDA for the treatment of metastatic 
hormone-refractory prostate cancer [130]. Although promising, the development of an 
effective cancer vaccine is slow and proven difficult. A major obstacle for developing 
an effective vaccine is the choice of appropriate targets.  
 
Most identified vascular targets associated with tumour angiogenesis are endogenous 
proteins, which are considered a self-antigen for immunization. These self-antigens 
normally have considerably low immunogenicity of which the immune surveillance 
often are unaware so that the cells that express them are well tolerated and easily 
escape immunity [131]. Therefore, it is essential to develop an effective strategy to 
break the immunogenic tolerance to such molecules. 
 
A vaccine against tumour vasculature 
Advanced knowledge of the molecular signatures of the tumour vasculature has 
provided several promising targets that can be used as the vaccine immunogen. These 
targets are specifically present on the new formed tumour vasculature but low in or 
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absent from normal vasculature. Accumulating pre-clinical data suggests that 
vaccination against these molecules is a feasible and promising strategy that holds 
therapeutic potential [132, 133]. Compared to the anti-angiogenic drugs, such as 
monoclonal antibodies or inhibitors, vaccination is particularly preferential because of 
its long lasting effects and low cost. 
 
Vaccination against VEGF receptors provided first proof of principle of this strategy. 
As described earlier, VEGF is a critical signaling molecule involved in physiological 
and tumour angiogenesis. All members of the VEGF family activate the cellular 
signaling pathways by a ligand-binding to their corresponding tyrosine kinase 
receptors present on the cell membrane. VEGFR2 is upregulated in activated 
endothelial cells in tumours and involved in critical steps in angiogenesis such as 
endothelial cell proliferation, migration and survival. VEGFR2 targeting by oral DNA 
vaccination showed significant inhibition of tumour growth and increase of the 
median survival rate in mice [134-136]. Similar effects were also observed when mice 
were immunised with VEGFR1 or VEGFR2 derived peptides [137, 138]. However, 
the wide expression of VEGF receptors in many healthy tissues might raise a safety 
concern when considering their uses in the clinic [139]. Other targets that are 
preferentially expressed on the tumour vasculature have been investigated as a 
vaccine and resulted in anti-angiogenic and anti-tumour effects. These targets are 
fibroblast growth factor receptor-1 [140], endothelial specific Tie2 [141], endoglin 




More recently, encouraging results were seen in vaccination against targets that are 
predominantly present on the tumour vasculature. Olsson and colleagues 
demonstrated that vaccination against the extra domain-B of fibronectin evoked 
antibody response which, resulted in a 70% tumour size reduction in mice [67]. 
Listeria-based vaccination directly against CD105 led to a 20% prevention of tumour 
occurrence in an autochthonous breast cancer model [145]. Targeting delta-like ligand 
4 that is present in endothelial tip cells by plasmid DNA vaccination dramatically 
decreased orthotopically implanted tumour growth [146]. No evidence of adverse 
effects on physiological angiogenesis were found from the above studies which 
further prove that selective targeting of the tumour vasculature holds clear therapeutic 
potential.  
 
Compared to currently available anti-angiogenic drugs such as small molecule 
tyrosine kinase inhibitors or monoclonal antibodies, vaccination is a less advanced but 
a promising approach that has many advantages. Instead of using externally 
administered drugs, vaccination induces anti-angiogenic effects by the immune 
system within individual patients and such immunity provides long-term protection. 
Such protection otherwise can only be achieved by repeated administration of 
anti-angiogenic substances. Potentially, the specificity of the immune response 
elicited by a vaccine is expected to be more restricted to the target which means less 




Targeting the tumour vasculature has many attractive advantages compared with a 
vaccine against cancer cells. As mentioned earlier, endothelial cells are genetically 
more stable than cancer cells and thus the chance of developing resistance to the 
vaccine is minimized when endothelial cells are used as the target. Targeting tumour 
vasculature may also be effective in a wider spectrum of cancer patients, because the 
angiogenic processes are similar in different tumour types. In contrast, vaccination 
against cancer cells tends to be more specific to the cancer type due to the restriction 
of their expressed cancer associated antigens. Finally, the immune cells are much 
more accessible to the vasculature compared to tumour cells. To target the tumour 




1.10 Aims and objectives 
Validation of putative tumour endothelial markers 
A list of putative TEMs, CLEC14A, GBP4 and IKBKE will be validated by IHC or 
IHF on human tissue arrays or clinical samples. 
 
Functional characterization of CLEC14A in endothelial cell biology 
The aim is to determine the function of CLEC14A in endothelial cell biology. 
Silencing or overexpression of CLEC14A in HUVEC will be achieved with siRNA or 
lentiviral system respectively. Manipulated cells were studied in a scratch wound 
assay to determine CLEC14A’s role in endothelial migration. Polyclonal antisera to 
CLEC14A will also be tested in a wound healing assay. Recombinant CLEC14A 
protein will be purified to enable the generation of monoclonal CLEC14A antibodies. 
To facilitate future in vivo functional work, a CLEC14A KO mouse will be generated.  
 
Identification of novel TEMs in non-small cell lung carcinoma 
Two methods, laser microdissection and Ulex-bead isolation will be compared in their 
success in isolating endothelial cells from frozen and fresh tissue respectively. Gene 
expression in the isolated endothelial cells from normal and tumour lung tissue will be 
analysed by deep sequencing and microarray analysis. Data derived from both 





Investigation of Robo4 as a cancer vaccine 
This will explore the possibility of using the validated TEM Robo4 as a cancer 
vaccine. As Robo4 is a self-antigen, the immune tolerance will be broken by protein 
immunization with adjuvants. The effect of vaccination on angiogenesis will be 
investigated in a rodent sponge assay. Whether vaccination against Robo4 has an 
effect on tumour growth will also be tested in Lewis lung carcinoma model.  
 
This thesis covers a broad area of tumour vascular targeting, ranged from validation 
of identified putative TEMs, functional characterization of a validated TEM in 
endothelial biology, using deep sequencing to identify novel TEMs in lung cancer and 
exploring the use of a pre-validated TEM as a cancer vaccine. These objectives are 
interlinked and build a picture of tumour vascular targeting; from discovery to 


















Centrifuge Source  
Bench centrifuge Biofugepico Heraeus, Newport Pagnell, UK 
Mikro 22R Centrifuge Hettich Zentrifugen, Tuttlingen, Germany 
Biofuge Primo Centrifuge Heraeus, Newport Pagnell, UK 
Avanti J-20 XP Beckman Coulter, Brea, USA 
MC 6 Centrifuge Sarstedt, Leicester, UK 
 
Microscopes  Source 
DM 1000 light microscope Leica, London, UK 
USB 2.0 2M Xli camera Xli, Carrollton, US 
Leica MZ 16 Leica, London, UK 
Leica DME Leica, London, UK 
Axiovert 100M laser confocal microscope Carl Zeiss, Göttingen, Germany 
 
Plate reader and spectrophotometer  Source 
1420 Multilabel Coulter VICTOR
3 
, Singapore  
ND-1000 Spectrophotometer Nanodrop Technologies, Wilmington, USA 




Equipment for biochemistry  Source 
XCell SureLock™ Mini-Cell electrophoresis 
apparatus 
Invitrogen, Paisley, UK 
Xcell II™ Blot Module wet transfer apparatus Invitrogen, Paisley, UK 
Electrophoresis Power supply EPS 301 Amersham Biosciences, Sweden 
Polyvinylidene difluoride membranes Immobilon-P, Billerica, USA 
Chromatography paper Whatman, Brentford, UK 
Block heater SBH 200D Stuart, Stone, UK 
AccuBlock
TM
 Digital Dry Bath Labnet International, Inc, Woodbridge, USA 
Gyro-rocker SSL3 Stuart, Stone, UK 
Rocker 25  Labnet International, Inc, Woodbridge, USA 
Rotator SB3 Stuart, Stone, UK 
Heating Magnetic stirrer FB15001 Fisher Scientific, Loughborough, UK 
3510 pH meter Jenway, Stone, UK 
Scale EK-300i A&D, Seoul, Korea 
ROTO-SHAKE Scientific Industries, New York, USA 
Compact x4 X-ray film developer  Xograph Imaging System, Tetbury, UK 
LKB Pump P-1 Pharmacia, Uppsala, Sweden 
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Hitrap Protein A column GE Healthcare Life Sciences , Little Chalfont, 
UK 
AKTA purifier (FPLC) Biotech, London, UK 
 
Equipment for molecular biology Source 
Gallenkamp Orbital Incubators Gallenkamp, Loughborough, UK 
BIO Imaging system Gene Genius, UK 
Electrophoresis tank Jencons, Leighton Buzzard, UK 
Incubator for Bacteria Cellstar Borolabs, Basingstoke, UK 
Peltier Thermal Cycler PTC-225 MJ Research, Waltham, USA 
Rotor-Gene RG3000 thermal cycler Corbett Research, Cambridge, UK 
MilliQ water purification system Millipore, Billerica, USA 
 
Equipment for cell biology Source 
Cell culture sterile hood, Advanced Bio Safely 
Cabinet Class 2 
Microflow, Andover, UK 
Incubator, 37
o
C, 5% CO2, 95% filtered air Heraeus, Newport Pagnell, UK 
BD FACSCalibur Flow Cytometer Becton Dickinson, Franklin Lakes, USA 
Water bath  Fisher Scientific, Loughborough, UK 
Amaxa nucleofector II Amaxa, Wolverhampton, UK 
20 µl filter tip Starlab, Milton Keynes, UK 
Glass cell counter Marienfeld, Lauda-Königshofen, Germany 
FastRead counting slides Immune system, Devon, UK 
Glass micro-well chambers  Nunc, Loughborough, UK 
 
Facilities  Source 
CRUK animal service  Clare Hall, London, UK 
Histology units  NHS, Birmingham, UK 
High speed cell sorter MoFlo Beckman Coulter, High Wycombe, UK 
Plasmid sequencing service  Technology Hub, Birmingham, UK 
Microarray scanning Technology Hub, Birmingham, UK 
Microarray data analysis Technology Hub, Birmingham, UK 
Deep sequencing service (SOLiD 4
TM
) Technology Hub, Birmingham, UK 
Deep sequencing data analysis  Technology Hub, Birmingham, UK 
 
2.1.2 Consumables, chemicals and reagents  
Biochemistry Source 
Bio-Rad Dc Protein assay Bio-Rad, Hemel Hempstead, UK 
Protein A Sepharose Sigma, Gillingham, UK 
Protein G Sepharose Sigma, Gillingham, UK 
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Histoclear  National diagnostics, Hessle, UK 
20x SSC Eppendorf, Stevenage, UK 
Ultra pure ProtoGel GeneFlow, Lichfield, UK 
Phosphate Buffered Saline tablets Sigma, Gillingham, UK 
Tween 20 Sigma, Gillingham, UK 
Ponceau S Sigma, Gillingham, UK 
Enhanced chemiluminescent substrate Amersham Biosciences, Amersham, UK 
Hyperfilm MP GE Healthcare Life Sciences , Little Chalfont, UK 
Igepal (NP-40) Sigma, Gillingham, UK 
Precision plus protein standard 250 – 10 kDa Bio-Rad, Hemel Hempstead, UK 
Papain  Sigma, Gillingham, UK 
L-Cysteine Sigma, Gillingham, UK 
Iodoacetic acid Sigma, Gillingham, UK 
OPD (o-Phenylenedia mine dihydrochloride) Sigma, Gillingham, UK 
Phosphate-citrate buffer tablets  Sigma, Gillingham, UK 
Calcium chloride powder Sigma, Gillingham, UK 
Protease Inhibitor tablet Sigma, Gillingham, UK 
Ammonium persulphate  Amresco, Solon, USA 
TEMED Sigma, Gillingham, UK 
PMSF Sigma, Gillingham, UK 
Azide  Sigma, Gillingham, UK 
 
Molecular biology  
SensiMix
TM
 NoRef Bioline, London, UK 
ProbeLibrary Real-time PCR Assay System Exiqon, Woburn, USA 
TRI reagent  Sigma, Gillingham, UK 
Agarose Sigma, Gillingham, UK 
SYBR safe DNA gel stain Invitrogen, Paisley, UK 
10 mM dNTP Fermentas, Cambridge, UK 
6x DNA loading buffer New England Biolabs, Herts, UK 
High-Capacity cDNA Archive kit Applied Biosystems, Paisley, UK 
Fusion DNA polymerase New England Biolabs, Herts, UK 
Taq DNA polymerase Bioline, London, UK 
EcoRI New England Biolabs, Herts, UK 
NotI New England Biolabs, Herts, UK 
PacI New England Biolabs, Herts, UK 
PmeI New England Biolabs, Herts, UK 
T4 ligase New England Biolabs, Herts, UK 
α-Select competent cells Gold efficiency  Bioline, London, UK 
α-Select competent cells Bronze efficiency  Bioline, London, UK 
 
Cell biology   
Lymphoprep Axis-Shield, Stockport, UK 
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Trypan blue Sigma, Gillingham, UK 
Lipofectamine RNAiMax Invitrogen, Paisley, UK 
Recombinant hRobo4-Fc protein CRT, London, UK 
Recombinant human IgG-Fc fragment Bethyl, Montgomery, USA 
Papain cleaved human / mouse Robo4 Bicknell lab, Birmingham, UK 
 
2.1.3 Water 
NF water was used in all molecular biology experiments, purchased from Qiagen, 
Crawley, UK. Solutions and buffers were made using MilliQ filtered water.  
 
2.1.4 Antibodies and probes 
Catalogue Specificity  Characteristics Appl. / dilution Source  






















Ab5512 Human ROS1 Rabbit polyclonal antibody 
0.25 mg/ml 
IHC: 1/50 Abcam, 
Cambridge, 
UK 
Ab117257 Human STEAP1 Rabbit polyclonal antibody 
0.2 mg/ml 
IHC: 1/40 Abcam, 
Cambridge, 
UK  
Ab469 Human BIRC5 Rabbit polyclonal antibody 
0.97mg/ml  
IHC: 1/100 Abcam, 
Cambridge, 
UK 
Ab38584 Human GJB2 Rabbit polyclonal antibody 
0.25 mg/ml 
IHC: 1/50 Abcam, 
Cambridge, 
UK 
Ab55506 Human PCDH7 Mouse polyclonal antibody 
0.5 mg/ml 
IHC: 1/50 Abcam, 
Cambridge, 
UK 
Ab118492 Human PROM2 Rabbit polyclonal antibody 
0.5 mg/ml 





JC70 Human CD31 Mouse monoclonal antibody  
0.5 mg/ml 


















Sheep IgG (H+L) Rabbit polyclonal antibody - 
FITC 






Mouse IgG (H+L) Rabbit polyclonal antibody - 
FITC 




A3673 Mouse IgG 
(γ-chain specific) 














A1949 Rabbit IgG 
(γ-chain specific) 
Mouse monoclonal antibody 
peroxidase conjugated 
6.5 mg/ml 
WB: 1/10000 Sigma, 
Gillingham, 
UK 







A6029 Human IgG 
(γ-chain specific) 
Goat polyclonal antibody 
peroxidase conjugated 
6.5 mg/ml 





Rabbit polyclonal antibody 
0.5 mg/ml  
IF: 1/500 Dako, 
Glostrup, 
Denmark 
553123 Mouse (Gr-1) Ly6G 
and Ly-6C 
Rat monoclonal antibody 
0.5 mg/ml 




RL-1062  Endothelium Ulex europaeus agglutinin I 
(UEAI)- rhodamine 








Nucleus  Prolong gold anti-fade 
reagent including DAPI 
Neat  Invitrogen, 
Paisley, UK 





2.1.5 DNA vectors and plasmids 
Vector Characteristics Sources 
pWPI  Lentivector, EF1α promoter,  
separated GFP driven by IRES  
Bicknell group, Birmingham, 
UK 
pMD2G Envelop plasmid for lentivirus 
expression system 
Bicknell group, Birmingham, 
UK 
psPAX2 Packaging plasmid for lentivirus 
expression system 
Bicknell group, Birmingham, 
UK 
pIG vector Mammalian expression vector, 
human Fc tag in C-terminus 
with a short span 
Bicknell group, Birmingham, 
UK 
pcDNA3.1 Mammalian expression vector, 
human Fc tag in C-terminus 
Invitrogen, Paisley, UK 
pEGFP-N1 Mammalian expression vector, 
CMV promoter, GFP tag in 
C-terminus 
BD Bioscience, Oxford, UK 
Plasmids  Source / cloning strategy Application  
FL-hCLEC14A-pEGFP1 Bicknell group, Birmingham, 
UK 
Template for sub cloning  
FL-mCLEC14A-pCMV6 OriGene, Cambridge, UK Template for sub cloning 
FL-hCLEC14A-pWPI PCR with PacI & SwaI 
overhangs primers 
Transduction of HUVEC 
Ex-hCLEC14A-pIG PCR with EcoRI & NotI 
overhangs primers 
Template for sub cloning into 
pWPI lentivector 
Ex-mCLEC14A-pIG PCR with EcoRI & NotI 
overhangs primers 
Template for sub cloning into 
pWPI lentivector 
Ex-hCLEC14A-Fc-pWPI PCR with PmeI & PacI 
overhangs primers 
Recombinant hCLEC14A-Fc 
protein production  




Ex-mRobo4-pIG CRT, London, UK Template for sub cloning into 
pWPI lentivector 




2.1.6 Oligonucleotides  





CD31-qPCR qPCR 5’-GCAACACAGTCCAGATAGTCGT-3’ 
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qPCR 5’-TGTTGTGGTTCCGACTATAAACAG-3’  
5’-GGGCTGCAACGTCATAATCT-3’ 
Mouse CLEC14A 400/R600 




Expected size: 404 bp 
Genotyping 5’-TCATTCTCAGTATTGTTTTGCC-3’ 
5’-GAATAGGAAAATGTCTCTTGCC-3’ 














Negative control duplexes siRNA Scrambled 
Ex-mRobo4-Fc  
















5’ – GCGGCCGCTGGAGGAGTCGAAAGCCTGAGGAGTGGC – 3’ 
Ex-mCLEC14A 




5’ – TAGTAGGAATTCTATGAGGCCAGCGCTTGCCCTGTGC – 3’ 
Reverse:  
5’ – GCGGCCGCTCGTGGAAGAGGTGTCGAAAGTCAG – 3’ 
FL-hCLEC14A 






5’- CTACTAGTTTAAACCTATGCATCACTAGAGCCAAG – 3’ 
Ex-hCLEC14A-Fc 






5’-TAGTAGGTTTAAACTCATTTACCCGGAGACAGGGAGAG -3’    
Ex-mCLEC14A-Fc 




5’- TAGTAGTTAATTAATCCAGGATGAGGCCAGCGCTTGCCCTGTGC -3’  
Reverse:  
5’-TAGTAGGTTTAAACTCATTTACCCGGAGACAGGGAGAG -3’   
2.1.7 Primary isolates, cell lines and culture media 
Primary isolates Source  
Human umbilical vein endothelial cells (HUVEC) Processed within Bicknell lab, Birmingham, UK 
Human dermal microvascular endothelial cells 
(HDMEC)  
TCS Cell Works, Buckingham, UK 
Human aortic smooth muscle cells (HASMC) TCS Cell Works, Buckingham, UK 
Human bronchial epithelial cells (HBE) TCS Cell Works, Buckingham, UK 
Human lung fibroblasts (MRC5) CRUK Central Services, London, UK 
Human peripheral blood mononuclear cells 
(PBMCs) 
University of Birmingham, Birmingham, UK 
Hepatocytes Dr Patricia Lalor University of Birmingham, 
Birmingham, UK 
Cell lines  
293T cells TCS Cell Works, Buckingham, UK 
4T1 cell line TCS Cell Works, Buckingham, UK 
EL4 University of Birmingham, Birmingham, UK 
SEND University of Oxford, Oxford, UK 
Lewis lung carcinoma cells CRUK Central Services, London, UK 
Media  
Fetal calf serum CRUK Central Services, London, UK 
M199 media  Sigma, Gillingham, UK 
Large vessel endothelial cell growth supplement TCS Cell Works, Buckingham, UK 
Bronchial Epithelial cell medium TCS Cell Works, Buckingham, UK 
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OptiMEM serum low media Invitrogen, Paisley, UK 
Collagenase type I A Sigma, Gillingham, UK 
Type I gelatin from porcine skin  Sigma, Gillingham, UK 
Aim V serum low media Invitrogen, Paisley, UK 
 
2.1.8 Physiological and pathological specimens  
Materials Company  
Normal / cancer tissues CRUK Central Services, London, UK 
Cancer / matching normal tissue array SuperBiochips Inc, Seoul, Korea 
Umbilical cords  NHS, Birmingham, UK 
Fresh lung tissue Heartlands hospital, Birmingham, UK 
Heparinised whole blood  QEH, Birmingham, UK  
Human serum  QEH, Birmingham, UK 
Mouse serum CRUK Central Services, London, UK 
Basic fibroblast growth factor R&D system, Abingdon, UK 
2.1.9 Buffers and solutions  
Buffer  Recipe  
HBS buffer (2x) 2.73 mM NaCl, 48.5 mM KCl, 15.2 μM  
Na2HPO4x2H2O, 0.11 mM Dextrose, 0.42 mM 
HEPES, pH 7.05; sterilized with 0.22-micron 
filter 
NP40 lysis buffer  50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, pH 
8.0 with addition of protease inhibitors tablets 
6x SDS Loading Buffer 30 % (v/v) glycerol, 0.25 % (w/v) bromophenol 
blue, 0.25 % (w/v) xylene cyanol FF 
2x SDS Loading Buffer 100 mM Tris-Cl, pH 6.8, 20% (v/v) 
β-mercaptoethanol, 4% (w/v) SDS, 0.2% (w/v) 
bromophenol blue, 20% (v/v) glycerol 
Coomassie staining buffer 
 
40 % (v/v) methanol, 10 % (v/v) acetic acid, 0.2 g 
Coomassie Brilliant Blue dye 
Running buffer 25 mM Tris, 250 mM glycine, 5% SDS  
Transfer buffer 25 mM Tris, 192 mM glycine, 20% methanol pH 
8.3 
Tris-Buffered Saline Tween-20 (TBST) 1 M Tris pH 7.5, 5 M NaCl, 20% (v/v) Tween-20 
Blocking buffer 5% dried skimmed milk in TBST 
pH 3 buffer Sodium Citrate 100 mM 
pH 7 buffer Sodium phosphate 20 mM 




10x Papain buffer 1.5 M NaCl, 6.7 mM EDTA, 50 mM L-Cysteine, 
100 mM Na2HPO4, pH 7.3 
Tris buffer pH 9 CRUK Central Services 
0.5M EDTA CRUK Central Services 
 
 
2.2 Molecular biology methods 
2.2.1 DNA / RNA handling and quantification 
All DNA and RNA work was carried out using sterile tips and NF water. DNA 
samples were resuspended in elution buffer (Sigma, Gillingham, UK) and stored at 
-20
o
C. RNA or siRNA duplexes were resuspended in nuclease free water and stored at 
-80
o
C. The quantification of DNA or RNA was performed on a Nano-drop 
spectrophotometer. The OD 260/280 ratio was used as a measure of sample purity.  
 
2.2.2 DNA preparation 
Mini-prep, Midi-prep or Maxi-prep kits (Sigma, Gillingham, UK) were used for 
different scales of DNA preparation according to manufacturer’s instructions. In brief, 
a starting culture from a bacterial clone was initiated for 16 - 18 hs. The overnight 
culture was then subjected to alkaline lysis followed by the removal of RNA by 
treatment with RNAse A. The debris and genomic DNA were removed by SDS 
precipitation. The eluted DNA was further concentrated by adding a DNA 
precipitation step using isopropanol. After 70% ethanol washing, plasmid DNA was 
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dissolved in elution buffer.  
 
2.2.3 RNA extraction 
Total RNA was isolated from primary cells or cell lines using TRI reagent (Sigma, 
Gillingham, UK) following manufacturer’s instructions. In brief, for one well of a 
6-well plate, 500 μl of TRI reagent was applied to lyse the cells. 200 μl of chloroform 
was added to the cell lysate and incubated on ice for 30 mins. Following 15 mins 
centrifugation at 14000 x g and 4
o
C, two phases were separated. RNA was 
precipitated from upper aqueous phase with 750 μl of isopropanol. After washing 
once with 70% ethanol, the RNA pellet was dissolved in NF water.  
 
2.2.4 Agarose gel electrophoresis  
1% agarose gel was prepared in TAE buffer with appropriate dilution of SYBR safe 
DNA gel stain (Invitrogen, Paisley, UK). DNA or RNA samples were mixed with 6x 
loading buffer and loaded into each well. The loaded samples were run at 60 to 80 V 
for 1 h. A picture of the gel was then taken using the BIO Imaging system machine 
under ultraviolet light. These were further modified using GeneSnap software (Gene 




2.2.5 Polymerase chain reaction 
For screening purpose  
Reaction mix µl 
Template 1 
10x NH4 buffer 5 
10 mM dNTPs 1 
Forward primer (10 µM) 0.5 
Reverse primer (10 µM) 0.5 
MgCl2 (50 mM) 2.5 




Temperature Time Cycle 
94
 o
C 2 min 1 
94
 o
C 1 min 
30 60
 o
C 30 sec 
72
 o
C 1 min 
72
 o
C 5 min 1 
4
 o
C Hold  
 
For cloning purpose 
Reaction mix µl 
Template 1 
5x buffer 10 
10 mM dNTPs 1 
Forward primer (10 µM) 0.5 
Reverse primer (10 µM) 0.5 




Temperature Time Cycle 
98
 o
C 30 sec 1 
98
 o
C 10 sec 
24 60
 o
C 30 sec 
72
 o
C 1 min 
72
 o





C Hold  
 
2.2.6 Restriction enzyme digestion 
Restriction enzymes were supplied with appropriate reaction buffers and 100x BSA. 
The digestion was performed following the manufacturer’s instructions. In brief, 1 µg 
of DNA vector was mixed with 1 µl of enzyme (normally 10 units) for 5 hs at 37
o
C. 
An overnight incubation was used for PCR products to ensure complete digestion. A 
sequential digestion was performed when the double digestion was not feasible 
because of buffer incompatibility.  
 
2.2.7 Genotyping of knockout mice 
Ear clips were collected from mice for genotyping. Genomic DNA was isolated using 
extraction mix (25 mM NaOH, 0.2 mM EDTA; shake at 1200 rpm for 30 min at 98
o
C). 
PCR reactions were performed to identify wild type, heterozygous and homozygous 
mice. Two primer sets: F400/R600 (internal WT CLEC14A) and UNeo-Fwd/SD 
(selection from the cassette insert linked to downstream CLEC14A) were used to 
discriminate the genotype of mice. The PCR mix and program are shown below:  
 
 1 x 20 µl reaction (µl) 
Template 1 
10 x NH4 buffer 2 
10 mM dNTP 0.4 
50 mM MgCl2 1 
10 µm Primer 1 2 
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10 µm Primer 2 2 
10 µm Primer 3 2 
10 µm Primer 4 2 




Temperature Time Cycle 
94
 o
C 5 min 1 
94
 o
C 15 sec 
35 62
 o
C 30 sec 
72
 o
C 1 min 
72
 o
C 5 min 1 
15
 o
C Hold  
 
2.2.8 Ligation 
T4 ligase was used for the generation of all DNA constructs. A 20 µl reaction was 
routinely carried out. The reaction mix was incubated at RT for 1 h followed by a 
heat-shock transformation (see below).  
 Vector + Insert (µl) Vector only (µl) 
Insert 15 - 
Vector 3 3 
10x Buffer 2 2 
T4 ligase 1 1 
H2O 0 15 
Total 20 20 
 
2.2.9 E. coli Transformation  
‘Gold efficiency α-Select’ competent cells were used for cloning while ‘Bronze 
efficiency α-Select’ competent cells were used for the amplification of plasmid. A 50 
µl aliquot of frozen competent cells was thawed on ice for 30 mins. 10 µl of the 
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ligation mix was added to the thawed competent cells and mixed well. Heat shock 
was achieved by placing the tube into a heated block at 42
o
C for 45 seconds. After 2 
mins incubation on ice, 250 µl of LB was added and the tube was placed at 37
o
C on 
bacterial shaker at 220 rpm for 1 h. The mix was then spread on an LB agar place 
with ampicillin or kanamycin antibiotic at 100 µg/ml.  
 
2.2.10 Long-term bacteria storage 
500 µl of overnight bacterial culture in LB broth was added to an equal volume of 30% 




2.2.11 Complementary DNA synthesis 
In order to perform real time PCR analysis, RNA isolated from primary cells or 
tissues was converted to cDNA using a High-Capacity cDNA Archive kit (Applied 
Biosystems, Warrington, UK). In brief, RNA was diluted in NF water at 0.2 mg/ml. 2 
µg of RNA was added to 10 µl of 2x RT master mix which was made up following the 
manufacturer’s instructions. The synthesis reaction was performed in the PCR 
machine following the program below: 














2.3 Mammalian cell isolation and culture 
2.3.1 HUVEC isolation from umbilical cords 
HUVECs were isolated from umbilical cords donated by the NHS with donor consent 
and in accordance with UK Ethics approval from the Birmingham Biobank. Cords 
were dissected from placentas and the vein was washed with sterile PBS to remove 
blood. 1 mg/ml of collagenase type I A diluted in M199 medium was injected into the 
vein and then incubated at 37˚C for 20 mins to detach the endothelial cells. HUVEC 
were collected by washing in M199 complete medium containing 10% FCS, 10% 
large vessel endothelial cell growth supplement, 4 mM L-glutamine and then seeded 
on plates coated with 0.1% Type 1 gelatin from porcine skin. 
 
2.3.2 Adherent cell culture  
Culture was performed at 37
o
C in a 5% CO2 atmosphere. HUVEC and HDMEC were 
both cultured on a 1% gelatin coated plates with M199 media containing 10% FCS, 4 
mM L-glutamine and 10% large vessel endothelial cell growth supplement. Cells 
were passaged 1 in 3 when they reached confluence. MRC5 and HASMC were 
cultured in DMEM media containing 10% FCS and 4 mM L-glutamine. Bronchial 
epithelial cell medium supplied by TCS Cell Works was used specifically for human 
bronchial epithelial cells culture. Cell lines including HEK 293T, SEND, 4T1 and 
Lewis lung carcinoma were cultured in DMEM media containing 10% FCS and 4 
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mM L-glutamine. These cell lines can be passaged 1 in 10 due to their fast growth 
rate.  
 
2.3.3 Release by exposure to trypsin 
Media was removed and the plate washed with sterile PBS. 2 ml of trypsin/EDTA was 
applied for one 10 cm tissue culture dish followed by 3 mins incubation at 37
o
C. Cells 
were totally detached by gently tapping the plate. 8 ml of PBS or complete media was 
used to neutralize the trypsin and wash the cells off the plate. After 5 mins 
centrifugation at 1000 rpm, the cell pellet was resuspended in an appropriate volume 
for cell counting. 
 
2.3.4 Cell counting  
Released adherent cells or non-adherent cells were resuspended in an appropriate 
volume of media. 10 µl of 5 x trypan blue was added to 40 µl of cell suspension and 
mixed well by pipetting up and down. 10 µl of the mix was loaded onto the glass cell 
counter or into a pocket of the FastRead counting slideswhen multiple samples needed 
to be counted. The cell number was calculated using the following formula: (average 
count from one 4 x 4 grid) x 10
4




2.3.5 Freezing and thawing of mammalian cells 
To cryo-preserve, released adherent cells or non-adherent cells were centrifuged at 
1000 rpm for 5 min and resuspended in pre-cooled filtered FCS containing 10% 
DMSO. The cryovials were placed at RT in a freezing container (Thermo Scientific, 
Langenselbold, Germany) and immediately transferred to the -80
o
C freezer. The next 
day, the cells were transferred to the liquid nitrogen storage. When thawing cells, the 
cryovials were submerged in the waterbath at 37
o
C. Contents were transferred to a 15 
ml tube, and diluted with 9 ml of media. Cells were spun down and then resuspended 
in 10 ml of DMSO free media after the two washes.  
 
2.3.6 Blood sampling 
Fresh blood from healthy donors or cancer patients was collected with patient consent 
and ethics approval (Project Licence PPL 70/6082). 60 ml of whole blood from each 
collection was mixed with 0.5 ml of 1000 U/ml preservative-free sodium heparin. 
 
2.3.7 Preparation of PBMC and serum 
Heparinised blood was diluted 1:1 in RPMI 1640 at 37
o
C. 25 ml of diluted blood was 
slowly layered onto 15 ml of lymphoprep and centrifuged at 1600 rpm for 30 min. 
The upper layer of the supernatant which contains the serum was collected and stored 
at -20
o
C. PBMC at the interface were collected and pooled followed by three washes 
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with warm RPMI. Cell number and viability was determined by trypan blue exclusion. 
PBMCs need a recovery procedure before putting into an assay. In brief, 10 ml of cell 
suspension after thawing was transferred into a 25 cm
2





2.3.8 Isolation of endothelial cells from lung tissues using Ulex magnetic beads 
Surgically removed bulk lung tissues were obtained from Heartlands hospital with 
patient consent and ethics approval (Heartlands hospital, REC reference no. 
07/MRE08/42). Tumour tissue was resected near the tumour core while the matched 
healthy tissue was resected at least 10 cm away from the tumour. The endothelial 
isolation procedure was performed within 2 hs. Tissues were weighed and minced, 
then digested for 1.5 h with DMEM containing 2 mg/ml collagenase type V (Sigma, 
Gillingham, UK), 7.4 mg/ml of actinomycin (Sigma, Gillingham, UK) and 30 kU/ml 
of DNAse I (Qiagen, Crawley, UK) at 37
o
C on a shaker. Streptavidin-coated 
Dynabeads (Invitrogen, Paisley, UK) were incubated with 20 mg/ml of biotinylated 
Ulex lectin (Vectorlabs, Orton Southgate, UK) for 30min at 37
o
C on a shaker. The 
digested cell suspension was filtered through a 70 μm cell strainer following three 
washes with cold DMEM. Endothelial cells were then isolated by positive selection 
using Ulex coated beads and a magnet. This method was modified from previously 




2.3.9 Isolation of endothelial cells from lung sections using laser microdissection 
Cresyl violet or CD31 stained slides were used for laser microdissection on a P.A.L.M. 
machine to collect blood vessels for downstream applications. In brief, the stained 
slides were air dried in a fume hood for 10 min then placed on the P.A.L.M. section 
platform. 20 μl of RNA extraction buffer from miRNeasy Mini kit (Qiagen, Crawley, 
UK) was pipetted into the inner ring of the cap to which the dissected tissue is 
catapulted. Upon completion of microdissection, the captured tissue was centrifuged 
for 1 min at 13000 rpm and stored at -80
o
C until RNA extraction. Due to the low yield 
of RNA, multiple laser dissected samples were pooled before RNA extraction. 
 
2.4 Transfection and transduction of mammalian cells 
2.4.1 Calcium-phosphate transfection 
Calcium phosphate transfection is a transient transfection method and was used to 
transfect 293T cells. In brief, 3 x 10
6
 of 293T cells were plated in a 10 cm tissue 
culture dish at 37
o
C overnight. Medium (DMEM, 10% FCS, 4 mM glutamine) was 
changed 1 h before the transfection. 5 µg of plasmid DNA, 63 µl of 2 M CaCl2 and an 
appropriate volume of water were mixed to make up a final volume of 500 µl. An 
equal volume of 2x HBS was added to the mixture dropwise and left on ice for 10 
mins. Media was replaced by complete media or OptiMEM low serum media the 




2.4.2 Lentivirus production 
The gene of interest was cloned into the lenti-vector pWPI containing an untagged 
GFP expressed from an IRES site. A standard calcium phosphate method was used to 
produce Lentivirus from 293T cells. In brief, 3 x 10
6
 of 293T cells were seeded in 10 
cm dishes and transfected with 20 µg transfer vector (pWPI containing the gene of 
interest), along with 15 µg of the packaging plasmid (2nd generation, psPAX2) and 6 
µg of the envelope plasmid (PMD2G). 48 h post-transfection, the supernatant which 
contains the virus was harvested and stored at -80
o
C. 
 Normal cal-phosphate Lentivirus 
Vector with gene 5 µg 20 µg 
psPAX2 - 15 µg 
pMD2G - 6 µg 
CaCl2 63 µl 63ul 
H2O Up to 500 µl Up to 500 µl 
2 x HBS 500 µl 500 µl 
Total 1 ml 1 ml 
 
2.4.3 Lentiviral transduction of 293T cells and HUVECs 
To transduce 293T cells or HUVECs, the frozen viral supernatant was thawed at RT. 3 
ml of the viral supernatant was added to 3 x 10
6 
cells and incubated at 37
o
C for 7 h. 





2.4.4 Generation of lentivector containing human Fc tagged Robo4 or CLEC14A 
The extracellular mouse Robo4-Fc was subcloned into a pWPI lentivector from the 
pIG vector using PacI and SwaI ended primers. The extracellular domain of human or 
mouse CLEC14A was first cloned into a pIG vector which contains a C-terminal Fc 
tag using EcoRI and NotI ended primer set. Then the human or mouse CLEC14A-Fc 
was subcloned into an empty pWPI lentivector containing a GFP expressed from an 
IRES site, using PacI and PmeI ended primers. In brief, inserts were amplified by 
PCR reaction using Fusion polymerase. EcoRI, NotI, PacI, PmeI or SwaI was chosen 
as the restriction sites for different inserts. A sequential or double digestion was 
performed to create the inserts and the open vector. Overnight ligation was performed 
using T4 ligase followed by a heat shock transformation using ‘α-Select Gold 
efficiency’ competent cells. Colonies were picked and screened by PCR reaction 
using EF1α primer which is from the vector and a reverse primer from the gene. Each 
generated lentivector with the Fc fusioned insert was verified by sequencing. The 




2.4.5 Generation of a stable line expressing Fc fusion protein by FACs sorting 
The procedure for lentivirus generation is described above. FACs sorting was used to 
generate a population that stably produces recombinant protein. Cells transduced with 
mRobo4-Fc-pWPI, hCLEC14A-Fc-pWPI or mCLEC14A-Fc-pWPI were passed 
through a MoFlo high speed cell sorter and GFP positive cells were collected and 
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cultured in 10 % FCS DMEM. The selected cells were then expanded for a large scale 
production of the Fc fusion protein. FACs sorting was also used to obtain a population 
of CLEC14A overexpressing cells for functional assays from FL-CLEC14A-pWPI 
transduced HUVEC. 
 
2.5 Protein analysis methods 
2.5.1 Protein quantification  
Protein was quantified using either a Bio-Rad Dc protein assay or the Nano-drop 
machine. Bio-Rad assay was used when the protein sample was at a low concentration 
or a relative accurate readout was required. The Nano-drop machine was used for 
approximate concentrations.  
 
2.5.2 Western blotting 
Cell lysates were prepared using NP40 lysis buffer. Protein samples were mixed with 
6x protein loading buffer and denatured by boiling for 3 mins before loading onto a 
SDS-PAG gel. After SDS PAG electrophoresis, the gel was blotted onto a PVDF 
membrane at 30 Volt for 2 hs at 4
o
C. The membrane was blocked with 5% milk in 
wash buffer (PBS 0.1% Tween-20) for 1 h at RT. The membrane was washed (4 x 5 
min) and primary antibody diluted in blocking buffer was applied and incubated for 1 
h at RT or overnight at 4
o
C. After washing, horseradish peroxidase conjugated 
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secondary antibody with 1 in 10000 dilution in blocking buffer was applied for 1 h at 
RT. Following antibody staining, the membrane was again washed and 400 µl of ECL 
western blotting detection reagents was added for 3 mins. A piece of Hyperfilm was 
then exposed to the membrane for different lengths of time and the luminescence 
created by horseradish peroxidase detected. 
 
2.5.3 Membrane antibody stripping  
When a single membrane was to be probed with more than one antibody, a membrane 
stripping procedure was carried out. In brief, the membrane was washed 3 times with 
PBS 0.1% Tween-20 and incubated in stripping buffer at 70
o
C for 45 mins. The 
membrane was washed 3 times with PBS containing 0.1% Tween-20 followed by 
blocking with 5% milk for 1 h at RT.   
 
2.5.4 Coomassie brilliant blue staining 
Gels were stained with Coomassie brilliant in the microwave at high power for 1 min. 




2.6 Protein purification and Fc fragment removal 
2.6.1 Purification of Fc fusion proteins using a protein A column 
FACs sorted lentivirus transduced 293T cells (mRobo4-Fc, hCLEC14A or 
mCLEC14A) were expanded with complete media in 15 cm tissue culture dishes. 
Once 80% confluent, the old media was replaced with fresh OptiMem low serum 
media. 5 collections within 10 days produced 1~3 L of conditioned media. The 
collected media was adjusted to pH 8.0. 1 mM EDTA and a few PMSF crystals were 
added to inhibit serine proteases. A protein A column was prepared by washing with 
20% ethanol and then equilibrated with pH 7 buffer (sodium phosphate 20 mM). 
Conditioned media was run through a Hi-Trap protein A column at 2 ml/min at 4
o
C 
followed by a 5x column volume wash with pH 7 buffer. pH gradient elution was 
achieved by FPLC chromatography using pH 3 buffer (sodium citrate 100 mM). The 
major products were eluted at pH 3.5 ~ 4. 0.1% Azide was added to the eluate to 




2.6.2 Papain cleavage of recombinant human or mouse Robo4-Fc 
In brief, 10x buffer (1.5 M NaCl, 6.7 M EDTA, 5 mM L-Cysteine) was prepared and 
stored at -20 
o
C. Papain at 20 mg/ml was diluted 1 in 100 in PBS (0.2 mg/ml). The 
final mixture for a 1 ml reaction contained 1.6 μg/ml papain, 600 μg/ml of human or 
mouse Robo4-Fc protein in 1x buffer. Reaction was performed at 37
o
C for 40 mins. 
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For optimization of papain cleavage, samples were collected every 10 mins. 50 µl of 
iodoacetic acid (130 mM, pH 6.8) was added to quench a 1 ml reaction [147, 148]. 
 
2.6.3 Depletion of Fc fragments from a papain reaction mix 
To remove the Fc fragments from 1 ml of papain reaction mix, 50 µl of cold PBS 
washed protein G beads have added to the mix and placed on a wheel at 4 
o
C for 2 hs. 
Protein G beads were pelleted down and the supernatant was collected followed by a 
western blot to confirm cleavage and depletion. The supernatant containing the 
untagged protein was stored at 4
o
C. This protein was used for Robo4 antibody 
detection or monoclonal CLEC14A antibody screening. 
 
2.7 Methods used in expression analysis  
2.7.1 Real time PCR analysis 
Following cDNA synthesis, the ProbeLibrary Real-time PCR Assay System was 
employed in the primary cell screening of gene expression. Flotillin 2 was chosen as 
the housekeeping gene to which the expression of each putative TEM was normalized. 
Primer and probe sets were designed by ProbeFinder software. Quantitative PCR was 
performed with the Rotor-Gene RG3000 thermal cycler. Reaction mix was prepared 
in triplicate for each primary cell type and 5 ng of cDNA was used in each reaction. 





2.7.2 Paraffin embedded section preparation for immunostaining 
Paraffin embedded tissue arrays or single tissues (CRUK histology service, REC 
reference no. 06/Q2707/338) were used. Paraffin was removed by washing the slides 
three times with histoclear and re-hydrated by incubation in a series of ethanol, water 
and then PBS. For antigen retrieval, slides were placed in citrate buffer (pH 6.0) and 
microwaved at medium power for 5 min twice. When cooled, sections were washed 
with PBST 0.1% for 2 min twice followed by 1 h blocking with 10% FCS 3% BSA 
PBS. 
 
2.7.3 Immunohistochemical staining 
Antigen retrieved and serum blocked tissue was incubated with the diluted primary 
antibody in PBS for 1 h. For frozen lung tissue, sections were fixed in acetone at 
-20
o
C for 5 min before staining with primary antibodies. Following a PBS 1% 
Tween-20 wash, sections were visualized using Vector ImmPRESS universal antibody 
kit and Vector NovaRed chromagen (Vectorlabs, Orton Southgate, UK) following 
manufacturer’s instructions. Finally sections were counterstained with Mayers 
hematoxylin (Surgipath, Peterborough, UK), dehydrated, cleared and mounted in 
distyrene-plasticizer-xylene (DPX, Surgipath, Peterborough, UK) resin. Slides were 
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examined on a Nikon Eclipse E400 microscope (Nikon, Kingston upon Thames, UK) 
and images captured with a Nikon Coolpix 995 camera. Cresyl violet staining was 
performed using the LCM Staining Kit (Ambion, Paisley, UK) following the 
manufacturer’s instructions.  
 
2.7.4 Immunofluorescence staining  
For co-localization studies, slides were then incubated in primary antibodies at the 
appropriate concentration overnight at 4 
o
C. After 3 washes with PBS 1% Tween-20, 
sections were probed with 1 in 100 diluted fluorescence conjugated secondary 
antibodies. Endothelium was visualized with 1 in 100 diluted Ulex europaeus 
agglutinin I conjugated to rhodamine. Slides were permanently mounted with 
‘Prolong gold anti-fade’ reagent with DAPI to counterstain cell nuclei. Sections were 
then examined using an Axiovert 100M laser scanning confocal microscope.  
 
2.8 Gene expression profiling methods 
2.8.1 Microarray  
Total RNA extracted from laser microdissected or Ulex-bead isolated samples were 
first converted to cRNA, then subjected to amplification and labeling using Low Input 
Quick Amplification labeling kit (Agilent, Wokingham, UK) following the 
manufacturer’s protocol. The input RNA samples were confirmed to be of good 
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quality (RIN > 7) on a Bioanalyzer machine prior to the array. The specific activity of 
Cy3 labeled cRNA samples was determined on a NanoDrop spectrophotometer. 
Labeled cRNA samples were then hybridized to an Agilent whole human gene 
expression microarray. After washing steps using Gene expression and hybridization 
and wash buffer kits (Agilent, Wokingham, UK), the slide was scanned for feature 
extraction using Agilent Feature Extraction software v.11.0.1.1 (Agilent, Wokingham, 
UK). The Bioconductor packages Core and Limma were used to back ground subtract 
and Quantile normalize probe signal intensities prior to performing differential gene 
expression analyses Correlation distances, 2d-clustering and principle component 
analyses were performed in R.  
 
2.8.2 Next generation sequencing and data analysis 
Reads were mapped to the Human genome (University California Santa Cruz, version 
hg19) with Tophat 1.3.3 [149]. Default parameters for colour space mapping were 
used with the exception of the following;  
1. -g/--max-multihits was set to 1 to only report best uniquely mapping reads 
2. –library-type was set to fr-secondstrand to reflect the sequencing library 
preparation 
3. –G provided Tophat with a model set of gene annotation genome positions 
from the Refseq hg19 transcriptome.  
The Tophat output bam files were sorted using samtools (Version: 0.1.8, [150]), and 
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'HTSeq-count' version 0.4.7p4 [151] was used, in conjunction with the Human 
transcriptome GTF Refseq version 19, to assign gene counts to produce a tab 
delimited file of transcript/gene counts. Differential gene expression analysis and 
p-value generation on the count data was carried out using the R Bioconductor 
package DESeq v1.5 [152]. This method was provided by John Herbert (Bicknell 
group, Birmingham, UK). 
 
2.9 In vitro angiogenesis assays  
2.9.1 Small interfering RNA (siRNA) knockdown of HUVECs 
2.5 x 10
5
 HUVEC were seeded into one well of a 6-well plate the day before 
transfection. Two siRNA duplexes were designed by the online SMARTselection 
siRNA design software. Negative control duplexes (scrambled) were included in all 
experiments. The transfection was performed using 0.3% lipofectamine RNAiMax 
with 10 nM duplex in OptiMEM. The transfection mix was incubated with the cells 
for 4 hs before replacing with complete HUVEC media (antibiotic free). Cells were 
used 48 hs post transfection and knockdown of protein expression was assessed by 
western blotting.  
 
2.9.2 Scratch wound assay  
The scratch wound assay was performed on HUVECs in a 6-well plate. A scratch was 
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made with a 10 µl sterile tip. Migration of HUVECs was assessed by acquiring 
images of wound closure at time 0, 8, 12 and 24 hs. Images were acquired with a 
Leica DM 1000 light microscope and USB 2.0 2M Xli camera. The open area of the 
wound was highlighted and quantitated using the ImageJ or Photoshop CS4 software.  
 
2.10 In vivo angiogenesis assay  
2.10.1 Sponge assays 
C57BL/6 mice received a sponge subcutaneously under the dorsal skin. 200 µl of 10 
ng/ml of bFGF was injected into the sponge on alternate days. On day 14, sponges 
were excised, fixed in 4% formalin for no longer than 24 h followed by 70% ethanol. 
The fixed sponges were then paraffin embedded and sectioned. H&E staining was 
performed on the sections. Slides were then mounted with DPX. The picture of the 
whole sponge was acquired using a Leica MZ 16 microscope at 10x lens. The 
invasive edge of the sponge which was acquired using Leica DME microscope at 40X. 
The invaded area was highlighted and analysed using Photoshop CS4 and Image J 
software. 
 
2.10.2 Tumour growth experiments 
C57BL/6 mice were implanted with 10
6
 Lewis lung carcinoma cells subcutaneously. 
Tumour size was measured at three day interval. Tumour size was measured twice 
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weekly. The tumour volume was calculated using the formula: length x width
2
 x 0.4 
[153]. ANOVA analysis was performed for comparison of tumour growth between 
Robo4 vaccinated and control mice.  
 
2.11 Generation of CLEC14A knockout mice 
ES cells containing CLEC14A targeting vector were purchased from the Knockout 
Mouse Project (KOMP, Davis, USA). The targeting vector contains a β-galactosidase 
coding sequence from the E.coli lacZ gene and a coding sequence for neomycin. To 
target the CLEC14A gene locus, 5’ and 3’ homology arms of 2 kb were used (Figure 
2.1). The cryovial preserved targeted ES cells were expanded and injected into the 
inner cell mass of blastocysts which were then implanted into pseudopregnant 
C57BL/6 mice. Chimeric mice were mated to Albino mice to screen for germline 
transmission by color recognition of the offspring. This identified #15 mouse as 
having germline transmission. Mouse #15 was used to generate heterozygous 
offspring on a C57BL/6 background. Three pairs of CLEC14A heterozygous crossing 






Figure 2.1 Targeting strategy for generation of CLEC14A knockout mice. Top: 
Wild type CLEC14A allele. Middle: Targeting vector containing a cassette of a lacZ 
reporter gene, a neomycin resistant gene. 5’ and 3’ homology arms of 2 kb each end 
(in gray) were used to target the gene locus. Bottom: Targeted allele after homologous 
recombination in ES cells. 
 
2.12 Immunogenicity assay 
2.12.1 Generation of a standard curve for antibody assay  
ELISA plate was coated with papain cleaved human or mouse Robo4 (25 µl - 0.008 µl) 
at 4oC overnight. The wells were blocked with 100 µl of blocking buffer (3% BSA, 
PBS) for 1 h at RT. Serial dilutions of primary Robo4 antibody (MR7 against human 
Robo4 raised from mouse; Abcam antibody against human/mouse Robo4 raised from 
rabbit) from 1 µg/ml to 0.008 µg/ml were applied. After 1 h incubation at RT and 6 
washes with wash buffer (0.1 % Tween-20 PBS), peroxidase conjugated anti-mouse 
IgG or anti-rabbit IgG antibody was diluted 1/10000 in the blocking buffer and 100 µl 
was applied to each well followed by a 1 h incubation at RT. After 6 washes with wash 
buffer, 100 µl of substrate contained OPD (o-phenylenediamine dihydrochloride) at 0.4 
mg/ml in 0.05 M phosphate citrate buffer containing 0.03 % sodium perborate was 
applied to each well. The reaction was stopped by adding 50 µl of 3M HCl. The ELISA 
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plate was read at 490 nm (0.1 s) absorbance on an ELISA plate reader. 
 
2.12.2 Investigation of Robo4 antibody in human and mouse serum  
An ELISA plate was coated with 5 µl per well of papain cleaved human or mouse 
Robo4 protein stock overnight at 4
o
C. After 1 h blocking with 3% BSA PBS, 5 µl of 
serum from man or mouse were diluted in 45 µl of PBS and applied to the antigen 
coated plate. After 6 washes, peroxidase conjugated anti-human IgG or anti-mouse 
IgG antibody was applied as the secondary. For characterizing antibody isotypes from 
mouse serum, peroxidase conjugated anti-mouse IgG1, 2a, 2b and 3 and IgM 
secondary antibody (Southern Biotech, Cambridge, UK) was applied. The rest of the 
procedure was as previously described. 
 
2.13 Mouse immunization  
2.13.1 Immunization with Robo4 protein and Freud’s adjuvant in mice 
FPLC purified mouse Robo4 protein or commercial human-Fc protein control was 
subcutaneously injected into C57BL/6 mice with 2 weekly intervals. Two groups of 
mice received 50 µg of mouse Robo4-Fc protein or human Fc protein respectively 
with complete Freunds for the first injection and incomplete Freunds afterwards. 20 µl 
of serum from each mouse was collected before each injection. The level of Robo4 
specific antibody was tested by ELISA assay using papain cleaved mouse Robo4 as 
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the coating protein. Organs including brain, heart, lung, liver, kidney and spleen from 
both groups were collected and fixed in 4% formalin. The tissues were then paraffin 
embedded and sectioned following H&E staining. The pictures from the stained 
sections were acquired using a Leica DM IL microscope and USB 2.0 2M Xli camera. 
Larger scale experiments were performed for further in vivo angiogenesis assays.  
 
2.13.2 Immunization with Robo4-CGG conjugate in CGG primed mice 
Purified mouse Robo4-Fc protein was cross-linked to CGG (Chicken γ globulin) 
using glutaraldehyde as previously described [154]. In brief, 2 µl of glutaraldehyde 25% 
stock (Sigma, Gillingham, UK) was added to 1 ml of reaction mix containing 1 mg of 
mouse Robo4-Fc protein and 1 mg of CGG in PBS (pH 7.5 - 8). The human Fc 
protein alone was also CGG crosslinked following an identical procedure. The 
reaction mix was incubated at RT for 10 min. The reaction was quenched by adding 
100 µl of 1 M Tris-HCl (pH 8) and left at RT for 15 min. Before injecting into mice, 
the mix was dialysed (10,000 MWCO) with PBS overnight.  
 
50 µg of Robo4-CGG or Fc-CGG conjugate was subcutaneously injected into 5-week 
CGG primed mice. Simultaneously, each mouse received 10
6
 Lewis lung carcinoma 




2.14 Bioinformatics websites and programs 
Websites  














SVMtm Transmembrane Domain Predictor:  
http://bioinformatics.org.au/ 
 
TMHMM Server v. 2.0:  
http://www.cbs.dtu.dk/services/TMHMM/ 
 
BioInformatics and Molecular Analysis Section:  
http://www-bimas.cit.nih.gov/index.shtml 
 
NEBcutter V2.0:  
http://tools.neb.com/NEBcutter2/index.php 
 


















Rotor-Gene RG-3000  
 
2.15 Statistical methods 
Excel was used to generate graphs and perform statistical analysis. The parametric 
Student t-test and Two-way analysis of variance test (ANOVA) with Dunnett’s 
Multiple comparison post-hoc test were used to compare the means of two and among 
more than two independent groups respectively. A minimum 95% confidence interval 
was used in all statistical tests. All error bars depict the standard error of the mean 
(SEM). 
 
P value Summary 
< 0.001 *** 
to 0.01 ** 
0.01 to 0.05 * 



















Bioinformatics predicted several putative TEMs [78]. cDNA libraries were used to 
predict putative TEMs essentially by various methods involving in silico subtraction 
of libraries. The predicted TEM candidates needed validation by profiling their 
expression in human tissues. An ideal TEM should fulfill the following criteria: 
1. Expression in endothelial cells  
2. Expression on tumour vessels 
3. Absent or low expression in healthy adult tissues. 
 
In this chapter, three putative TEMs: CLEC14A, GBP4 and IKBKE are respectively 
validated as a TEM on a human cancer array and healthy adult tissues by various 





3.2 CLEC14A is predominantly expressed in endothelial cells 
To confirm the endothelial specificity of CLEC14A, real-time PCR using CLEC14A 
primers was performed across a range of primary cell isolates including HUVEC, 
HDMEC (human dermal microvascular endothelial cells), MRC5 (fibroblasts), 
HASMC (human aortic smooth muscle cells), PBMC (peripheral blood mononuclear 
cells), hepatocytes and HBE (human bronchial epithelium). Flotillin 2 was employed 
as the house keeping gene to which CLEC14A expression was normalized [155]. The 
ΔΔCt method was used to calculate the fold change.  
 
As shown in Figure 3.1, CLEC14A was predominantly expressed in endothelial cells 
with some expression in MRC5 fibroblasts. We note, however, that MRC5 is a diploid 
cell line derived from fetal lung tissue [156] and not a primary cell isolate. Aside from 






Figure 3.1 Expression analysis of CLEC14A in primary cell isolates by real-time 
PCR. HUVEC: human umbilical vein endothelial cells; HDMEC: human dermal 
microvascular endothelial cells; MRC5: MRC5 fibroblasts; HASMC: human aortic 
smooth muscle cells; PBMC: peripheral blood mononuclear cells; HEPAT: 
hepatocytes; HBE: human bronchial epithelium. The experiment was repeated three 
























3.3 CLEC14A siRNA knockdown in HUVEC 
Two CLEC14A specific duplexes were transfected into HUVECs at a concentration of 
10 nM. Scrambled negative control siRNA duplex, with no homology to known 
human DNA sequences, was used as control. Mock control with no siRNA but 
transfection reagent alone was also used to show that the transfection process alone 
had no effect on cell behavior.  
 
The efficiency of the knockdown was evaluated by western blotting of cell lysate. The 
predicted molecular weight of CLEC14A is 51.6 kDa. As CLEC14A is heavily 
glycosylated (one highly conserved N- and nine poorly conserved O-glycosylation 
sites), the band at around 100 kDa is presumably the glycosylated form of the full 
length CLEC14A (Figure 3.2). No band was detected at 51.6 kDa. The level of 
tubulin expression was used as the protein loading control. Antisera failed to detect 
CLEC14A in knockdown cells but clear bands were seen in mock and scrambled 
siRNA controls. Thus, the specificity of the commercial CLEC14A antisera used later 





Figure 3.2 Western blot of CLEC14A siRNA knock-down in HUVEC. Western 
blot of CLEC14A knockdown in HUVECs shows that both siRNA duplexes were 
effective. Tubulin was used as the protein loading control. M: Mock, S: Scrambled; 
D1: Duplex1, D2: Duplex2. 
 
3.4 CLEC14A is expressed on vessels in tumours but not those in 
healthy tissue  
To investigate CLEC14A expression, we performed double immunofluorescence 
staining with CLEC14A antibody and the human endothelial marker Ulex lectin. 
Commercial polyclonal antibody to the extracellular domain of CLEC14A was used 
to define its expression pattern. FITC conjugated anti-sheep antisera was used to 
visualize CLEC14A expression in green. Ulex is a lectin that specifically binds to the 
alpha-L-fucose containing glycocoproteins present on the surface of human 
endothelial cells [119]. Rhodamine conjugated Ulex was used to visualize the 
endothelium in red. Co-staining was performed on human tissue arrays which had 12 
different types of carcinoma and matching adjacent healthy tissue and 10 samples of 
each. A confocal microscope was used to acquire the fluorescent images. 
Fluorescence detected within the vessel lumen was the autofluorescence of 




Widespread expression of CLEC14A co-localized with Ulex on tumour vessels 
(Figure 3.3 a-c). In contrast we failed to detect CLEC14A on vessels in most of the 
adjacent healthy tissues. The result of the multiple tissue array staining has been 
summarized in Figure 3.4. Some adjacent healthy tissues showed positive CLEC14A 
antibody staining that may be due to its proximity to the tumour. 
 
To determine whether CLEC14A is truly absent from healthy tissue, the co-staining 
was performed on non-tumour related clinical samples derived from various organs. 
As shown in Figure 3.5a-b, CLEC14A was undetectable in healthy bladder, breast, 
liver, ovary, brain, colon, lung and kidney. Taken together, the expression profile 












Figure 3.3a Confocal microscopic images (63X) of a human cancer tissue array 
stained with CLEC14A antibody. Endothelial cells were stained with 
rhodamine-conjugated Ulex europeaus lectin (Red). CLEC14A antibody was labeled 
with a FITC conjugated secondary antibody (Green). (i) oesophageal carcinoma (ii) 






Figure 3.3b Confocal microscopic images (63X) of a human cancer tissue array 
stained with CLEC14A antibody. Endothelial cells were stained with 
rhodamine-conjugated Ulex europeaus lectin (Red). CLEC14A antibody was labeled 
with a FITC conjugated secondary antibody (Green). (v) liver carcinoma (vi) stomach 






Figure 3.3c Confocal microscopic images (63X) of a human cancer tissue array 
stained with CLEC14A antibody. Endothelial cells were stained with 
rhodamine-conjugated Ulex europeaus lectin (Red). CLEC14A antibody was labeled 
with a FITC conjugated secondary antibody (Green). (ix) bladder carcinoma (x) ovary 






Figure 3.4 Summary of CLEC14A expression in cancer and matched adjacent 













































Figure 3.5a Confocal microscopic images (63X) of healthy tissues stained with 
CLEC14A antibody. Endothelial cells were stained with rhodamine-conjugated Ulex 
europeaus lectin (Red). CLEC14A antibody was labeled with a FITC conjugated 
secondary antibody (Green). Nuclei were stained with DAPI (Blue). (i) brain (ii) 





Figure 3.5b Confocal microscopic images (63X) of healthy tissues with CLEC14A 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). CLEC14A antibody was labeled with a FITC conjugated secondary 
antibody (Green). Nuclei were stained with DAPI (Blue). (v) kidney (vi) bladder (vii) 
colon (viii) ovary. 
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3.5 Confirmation of CLEC14A as a tumour endothelial marker 
by immunohistochemistry 
To further confirm that CLEC14A is differentially expressed between healthy and 
tumour tissues, immunohistochemistry staining was performed on a hepatocellular 
carcinoma tissue using the same commercial polyclonal antisera to CLEC14A. In a 
liver cancer section, the tumour tissue was delineated from the adjacent healthy tissue 
by a fibrotic capsule, strong CLEC14A staining on the vessels was observed in the 
tumour area but not in the healthy tissues (Figure 3.6, top). Higher magnification of 
the images of vessels in tumour and adjacent healthy tissues are shown in Figure 3.6, 
bottom. Comparison of CLEC14A expression between healthy and tumour tissues 
derived from other organs was then performed using the same technique. As shown in 
Figure 3.6, CLEC14A was strongly present on tumour vessels in prostate, breast, 





Figure 3.6 Immunostaining of human liver showing adjacent healthy liver and 
hepatocellular carcinoma in the same section. White arrows indicate invasion of 
the nearby carcinoma into the healthy tissue. Scale bar = 200 mm (top). Intense 
staining of vessels in hepatocellular carcinoma while lack of immunostaining of 
vessels in healthy liver tissue was observed (bottom). Scale bars = 25 mm. (Data 






Figure 3.7 Comparison of CLEC14A immunostaining of healthy and tumor 
tissue. (A-B) prostate, (C-D) breast, (E-F) kidney and (G-H) thyroid. Scale bars = 100 




3.6 GBP4 is highly expressed on tumour vessels and on vessels in 
some adjacent tissue 
To determine whether there is a differential expression pattern of GBP4 in cancer and 
healthy tissues, we performed immunofluorescence staining on human tissue arrays 
using a polyclonal antisera to GBP4. The specificity of the antibody was verified by 
siRNA knockdown of GBP4 in HUVECs (Figure 3.8). The efficiency of knockdown 
was confirmed by Western blotting of cell lysate. GBP4 antibody detected a clear 
band at 74 kDa which is consistent with the predicted molecular weight of GBP4 (74 
kDa).  
 
FITC conjugated secondary antibody was used to demonstrate GBP4 expression. Ulex 
was used to visualize the blood vessels. Tissue arrays were used as previously 
described. The results demonstrated that GBP4 displayed a differential expression 
pattern across a wide range of cancer tissues (Figure 3.9a-c). GBP4 expression was 
restricted to the endothelium in thyroid, pancreas, kidney, bladder, ovarian and colon 
carcinoma while in the liver and prostate carcinoma, it is present in both endothelium 
and tumour cells. The percentage of positive sections was summarized in Figure 3.10. 
With the exception of stomach where there were more GBP4 positive tissues in the 
adjacent healthy than that in the cancer tissues, the overall percentage of GBP4 






Figure 3.8 Western blot on HUVEC of GBP4 siRNA knock-down. Western blot of 
HUVECs with GBP4 knockdown using the commercial GBP4 antibody shows that 
both siRNA duplexes worked efficiently. The level of tubulin expression was used as 






Figure 3.9a Confocal microscopic images (63X) of a human cancer array with 
GBP4 antibody. Endothelial cells were stained with rhodamine-conjugated Ulex 
europeaus lectin (Red). GBP4 antibody was labeled with a FITC conjugated 
secondary antibody (Green). Nuclei were stained with DAPI (Blue). (i) oesophageal 






Figure 3.9b Confocal microscopic images (63X) of a human cancer array with 
GBP4 antibody. Endothelial cells were stained with rhodamine-conjugated Ulex 
europeaus lectin (Red). GBP4 antibody was labeled with a FITC conjugated 
secondary antibody (Green). Nuclei were stained with DAPI (Blue). (v) liver 





Figure 3.9c Confocal microscopy images (63X) of a human cancer array with 
GBP4 antibody. Endothelial cells were stained with rhodamine-conjugated Ulex 
europeaus lectin (Red). GBP4 antibody was labeled with a FITC conjugated 
secondary antibody (Green). Nuclei were stained with DAPI (Blue). (ix) bladder 






Figure 3.10 Summary of GBP4 expression in cancer and matched adjacent 
healthy tissue arrays 
 
3.7 GBP4 is absent from vessels in healthy tissue  
In order to determine whether GBP4 is present in the non-cancer related healthy 
tissues, we performed a screen on tissues derived from healthy donors. 
Immunofluorescence was performed on a wide range of healthy tissues using the 
same GBP4 antibody. As shown in Figure 3.11a-b, the expression of GBP4 was 
absent or essentially low in all healthy tissues include brain, breast, lung, liver, kidney, 




































Figure 3.11a Confocal microscopy images (63X) of healthy tissues with GBP4 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). GBP4 antibody was labeled with a FITC conjugated secondary antibody 






Figure 3.11b Confocal microscopy images (63X) of healthy tissues with GBP4 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). GBP4 antibody was labeled with a FITC conjugated secondary antibody 





3.8 Validation of an IKBKE antibody by siRNA knockdown 
Two IKBKE specific siRNA duplexes were transfected into HUVECs at a 
concentration of 10 nM. The efficiency of the knockdown was evaluated by western 
blotting of the cell lysate. Consistent with predicted molecular weight, IKBKE 
appeared at 75 kDa, which was weakly detectable in the siRNA knockdown lysates. 
The expression level of tubulin control remained the same (Figure 3.12). This 
experiment not only confirmed the efficiency of both siRNA duplexes but also 
validated the specificity of the commercial IKBKE antibody, which permitted 
expression profiling of clinical tissue. 
 
 
Figure 3.12 SiRNA knock-down of GBP4 in HUVEC. Western blot of HUVECs 
with IKBKE knockdown shows that both siRNA duplexes worked efficiently. The 








3.9 Immunofluorescence of IKBKE on tissue samples 
To determine whether IKBKE is present in healthy tissues, a preliminary screen of 
IKBKE expression on multiple healthy samples was performed using the commercial 
IKBKE antibody (green). Rhodamine conjugated Ulex (red) was used as the positive 
control for endothelium.  
 
The tissue screen showed that IKBKE has a widespread expression and is seen in 
most healthy tissues being particularly high in the ovary and in tissues involved in the 
immune system including lymph nodes and spleen. It is also present in vessel 
surrounding cells in healthy liver, colon and bladder. The expression of IKBKE is 
relatively rare in brain and heart (Figure 3.13a-c). The initial screen suggests that 
IKBKE is not a TEM due to its expression pattern in the healthy tissues. 
 
We also performed immunofluorescence staining to investigate IKBKE expression in 
tumour sections including breast, rectal, bladder and endometrial carcinoma. The 
results showed that IKBKE is also expressed in the tumour cells. However IKBKE 
expression was found in endothelial cells from breast, bladder and endometrial 





Figure 3.13a Confocal microscopy images (63X) of healthy tissues with IKBKE 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). IKBKE antibody was labeled with a FITC conjugated secondary 





Figure 3.13b Confocal microscopy images (63X) of healthy tissues with IKBKE 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). IKBKE antibody was labeled with a FITC conjugated secondary 
antibody (Green). Nuclei were stained with DAPI (Blue). (v) liver (vi) kidney (vii) 





Figure 3.13c Confocal microscopy images (63X) of healthy tissues with IKBKE 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). IKBKE antibody was labeled with a FITC conjugated secondary 













Figure 3.14 Confocal microscopy images (63X) of cancer tissues with IKBKE 
antibody. Endothelial cells were stained with rhodamine-conjugated Ulex europeaus 
lectin (Red). IKBKE antibody was labeled with a FITC conjugated secondary 
antibody (Green). Nuclei were stained with DAPI (Blue). (i) breast carcinoma (ii) 






Three putative TEM's were validated using various techniques. CLEC14A was 
predominantly found in endothelial cells by qPCR analysis of primary cell isolates. 
Immunofluorescence and immunohistochemical staining of human cancer tissue 
arrays using CLEC14A antisera revealed a differential expression pattern in the 
tumour compared to healthy tissue. Across a wide range of common cancers, 
CLEC14A was strongly expressed on vessels in ovarian cancer (100%), liver cancer 
(100%), bladder cancer (90%), prostate cancer (90%), breast cancer (80%) and kidney 
cancer (70%) but completely absent from all non-cancer related healthy tissues. This 
data identifies CLEC14A as a novel TEM. Similar validation approaches performed 
on GBP4 showed a tumour-vessel preferential expression in most common cancers. 
There was some expression in adjacent healthy tissue but GBP4 was completely 
undetectable in non-cancer related healthy tissue, indicating potential as a tumour 
vascular target. IKBKE has been ruled out as a TEM in this study, based on its 
widespread expression in healthy human tissues. Nevertheless, it is worth noting that 

















Functional characterization of CLEC14A
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4.1 Introduction  
Validation of putative TEM expression in human cancer and healthy tissue confirmed 
CLEC14A as a novel TEM. Past evidence suggested that endothelial specific genes 
are often functionally involved in endothelial biology and angiogenesis [103, 157]. 
This chapter explores the function of CLEC14A in endothelial biology, particularly its 
role in endothelial cell migration, which is a critical step engaged in tumour 
angiogenesis [16].  
 
In vitro angiogenesis assays are important tools for understanding the molecular 
mechanisms and identifying new regulators of the angiogenesis cascade [158]. The 
most widely used in vitro assays involve working with cultured endothelial cells, in 
most cases HUVEC, in systems mimicking each step of the angiogenesis process such 
as migration, proliferation and tube formation. The scratch wound assay is a well 
established approach to investigate endothelial cell migration in vitro. The assay 
involves making a ‘wound’ in a confluent cell monolayer and subsequently 
monitoring the closure of the wound by migrating cells at different time points. This 
method has been widely used with siRNA knockdown technology to investigate the 
function of genes in cell migration [159].  
 
The possibility of using CLEC14A antibodies to block endothelial migration is also 
investigated in this chapter. To further characterize CLEC14A’s role in physiological 
angiogenesis and tumour angiogenesis, CLEC14A knockout mice were generated. 
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4.2 CLEC14A knockdown inhibits endothelial cell migration  
To investigate whether CLEC14A plays a role in endothelial cell migration, a scratch 
wound assay was performed on HUVEC after CLEC14A knockdown by siRNA. 
Reagent only (Mock) and negative duplex (Scrambled) were employed as controls. 
The effect of CLEC14A knockdown on closure of a scratch wound in a confluent 
HUVEC monolayer was measured at 0, 6 and 12 hours after injury. At the end of the 
assay, cells were collected to confirm the knockdown of CLEC14A lasted to the end 
of the assay.  
 
Figure 4.1a shows representative images of the wound area at each time point for 
mock, scrambled, D1 and D2 treated cells. Cells treated with mock or control siRNA 
had fully closed the wound at 12 hours while 50 - 60% of the wound area remained 
open in the CLEC14A knockdown cells (Figure 4.1b). Western blot analysis was 
performed on the cell lysates at the end of the scratch wound assay (Figure 4.1c). 
This confirmed that CLEC14A was knocked down during the assay. The results 







Figure 4.1 siRNA knockdown of CLEC14A inhibits endothelial cell migration. 
Scratch wound healing assay in a HUVEC monolayer transfected with mock, 
scrambled, CLEC14A siRNA duplex 1 or duplex 2. (a) Images at 0, 12 and 24 hour 
time points were acquired after wounding. The open wound area was highlighted and 
quantified using ImageJ software. (b) Values represent the means from three 
independent experiments. Error bars depict the standard error of the mean (Two-way 
ANOVA, P < 0.001). (c) CLEC14A knockdown was confirmed by western blotting 






4.3 Polyclonal antisera to CLEC14A inhibits endothelial cell 
migration  
To investigate whether commercial CLEC14A polyclonal antisera had an effect on 
endothelial cell migration, antisera at 5, 10 or 20 μg/ml was added to HUVEC cells 
immediately after wounding. The closure of the wound area of each treatment was 
than recorded at 0, 12 and 24 hours.  
 
Figure 4.2a shows the delay in wound closure in cells treated with 5, 10 or 20 μg/ml 
of CLEC14A antibody compared with the untreated cells. Quantification of the 
remaining area relative to the initial wound showed that 14% of the wound area 
remained open after 24 hour when HUVECs were treated with 10 or 20 μg/ml of 
anti-CLEC14A antisera. Controls had almost closed (Figure 4.2b). This result 
suggests that there may be an epitope in CLEC14A that mediates the cell motility that 
is blocked by polyclonal antibody. If so, it could be possible to generate a monoclonal 
antibody to CLEC14A that specifically inhibits endothelial cell migration.  
 
The effect of antisera on HUVEC tube formation was examined in the Matrigel assay 
by colleagues. The formation of the tube-like structures was impaired when cells were 







Figure 4.2 CLEC14A polyclonal antisera inhibits cell migration. Scratch wound 
healing assay in HUVECs, showing a retardation of wound closure in the presence of 
5, 10 and 20 μg/ml of CLEC14A polyclonal antisera. Pictures were taken at 0, 12 and 
22 h post wounding. (n = 2). Due to the cost of the antisera, replication of this data 






4.4 Production of human and mouse CLEC14A protein using 
lentivirus 
Given the inhibitory effects on endothelial migration and tube formation by the 
commercial CLEC14A polyclonal antiesra, a monoclonal antibody to both human and 
mouse CLEC14A that has the same function would be of therapeutic interest. Pure 
CLEC14A protein was required for mouse immunization. Mouse CLEC14A protein 
was used to immunize mice while the human protein was for the screening. 
 
To express these proteins, the extracellular domain of human or mouse CLEC14A-Fc 
was inserted into a lentivector (pWPI) which contains a separate GFP expressed from 
an IRES site. GFP facilitated FACs sorting of the infected cells. The lentivector was 
transfected with an envelope plasmid and a packaging plasmid into 293T cells for 
viral production. The supernatant containing the virus was then added to fresh 293T 
cells following a FACs sorting procedure for a positive selection of GFP expressing 
cells. A pure population of 293T cells stably expressing human or mouse 
CLEC14A-Fc was obtained. The recombinant protein was secreted into low serum 
media and purified by pH gradient (pH 7 to pH 3) elution from a protein A column. 
Each eluted protein fraction was collected and quantified on a Nanodrop machine at 
280 nm (Figure 4.3a). The purity of the protein was confirmed by coomassie staining 
(Figure 4.3b). Since the extracellular domain of mouse CLEC14A was predicted to 
be 85 kDa and human Fc tag was 25 kDa, the band running at 110 kDa is recombinant 
mouse CLEC14A-Fc protein. The recombinant human CLEC14A-Fc protein was also 
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purified following the same procedure. To further confirm the purified product, 
western blot analysis was performed using in house rabbit anti human and mouse 




Figure 4.3 Purification of mouse CLEC14A-Fc protein. (a) Elution of protein was 
performed by pH gradient and the concentration of each fraction was quantified by 
Nanodrop at 280 nm. (b) The purity of each fraction was confirmed by running the 
samples on a SDS PAGE followed by coomassie staining. 
 
 
Figure 4.4 Western blot of purified human and mouse CLEC14A-Fc protein. The 
purified protein fractions were pooled and run on a SDS gel following a western blot 
against in house rabbit anti mouse CLEC14A antisera. The purified CLEC14A protein 




















4.5 Generation of monoclonal antibodies to both human and 
mouse CLEC14A 
Monoclonal antibodies to CLEC14A were generated by Serotec (Oxford, UK). The 
aim was to produce monoclonal antibodies that recognize both human and mouse 
CLEC14A-Fc, which can then be used in functional assays with human or mouse 
endothelial cells. Purified mouse CLEC14A-Fc protein was used in the immunization. 
Human and mouse CLEC14-Fc protein and a commercial purified human Fc fragment 
were used in the screening process to identify the monoclonal antibodies that 
recognize both human and mouse CLEC14A and not the human Fc tag. Five 
monoclonal antibodies were identified following affinity purification (Table 1).  
 
Code Concentration Isotype Buffer 
CRT1 5.2 mg/ml IgG1 PBS 
CRT2 5.8 mg/ml IgG1 PBS 
CRT3 6.1 mg/ml IgG1 PBS 
CRT4 7.7 mg/ml IgG1 PBS 
CRT5 6.7 mg/ml IgG1 PBS 
 




4.6 Papain cleavage of CLEC14A-Fc protein and Fc fragment 
depletion 
To confirm reactivity of the monoclonal antibodies to human and mouse CLEC14A 
and not the Fc tag, an ELISA assay with CLEC14A minus the Fc tag was required. 
The protease papain has been used to cleave the Fc region of antibodies to release a 
Fab fragment and was used to cleave the Fc tag off recombinant CLEC14A-Fc protein 
(Figure 4.5). 
 
Optimization of the papain digestion reaction was performed on Fc tagged Robo4 
protein described in Chapter five, 5.1. Using this protocol, papain reaction mix was 
added to human or mouse CLEC14A-Fc protein followed by an Fc fragment depletion 
using protein G beads. Digestion was followed by western blotting for CLEC14A or 
Fc.  
 
Multiple bands were seen in both papain cleaved human and mouse CLEC14A 
Figure 4.5 (left). CLEC14A minus Fc is seen at 80 kDa. Other bands at 60 and 37 
kDa were further breakdown products. Western blot for Fc showed it had all been 
removed by the beads (Figure 4.5, right). As the purpose of this experiment is to 
release the Fc tag from CLEC14A, the mixture of CLEC14A protein fractions should 







Figure 4.5 Papain cleavage of human/mouse CLEC14A-Fc following Fc fragment 
depletion. Recombinant human and mouse CLEC14-Fc protein were digested in a 
papain reaction. The cleaved Fc fragments were depleted by protein G beads. The 
final protein stocks were run on an SDS gel followed by a western blot using 
homemade rabbit anti mouse CLEC14A antibody (left) or a commercial anti human 








4.7 Evaluation of the CLEC14A monoclonal antibodies 
An ELISA assay was designed to evaluate the specificity of the CLEC14A 
monoclonal antibodies. Human or mouse CLEC14A protein was coated onto ELISA 
plates. CLEC14A monoclonal antibodies were diluted 1 in 500 (10 μg/ml) and added 
to the coated wells. Homemade rabbit antisera to both mouse and human CLEC14A 
was used as the positive control for the coated antigens. PBS or rabbit pre-bleed was 
used as negative controls for the monoclonal antibodies and anti sera respectively.  
 
As shown in Figure 4.6, all monoclonal antibodies recognized both human and mouse 
CLEC14A. In general, higher absorbance was observed for human CLEC14A coated 
wells compared to wells coated with the mouse CLEC14A protein. This was probably 
due to the variable concentrations of the two coating antigens. There is also a 
possibility that the monoclonal antibodies had higher affinity to human CLEC14A 
than mouse CLEC14A. This data confirms that these monoclonal antibodies 





Figure 4.6 Confirmation of the specificity of monoclonal antibodies to human 
and mouse CLEC14A protein. An ELISA assay was performed in human or mouse 
CLEC14A protein coated wells by applying each CLEC14A monoclonal antibody into 
the assay. PBS and rabbit pre-bleed was used as the negative control for the 








4.8 Monoclonal antibody to CLEC14A inhibits endothelial cell 
migration  
Given the inhibitory effect of the commercial CLEC14A antisera on endothelial 
migration, a monoclonal antibody which can functionally block endothelial cell 
motility holds therapeutic potential. The five CLEC14A monoclonal antibodies were 
screened to determined whether they inhibited endothelial cell migration using a 
HUVEC scratch wound assay. 
 
1 μg/ml or 10 μg/ml of each monoclonal antibody was added to the assay. PBS 
containing 0.09% sodium azide was used as control treatment. Wound areas for each 
condition were captured at 0, 4 and 12 hours after injury. Among these five 
monoclonal antibodies, only CRT3 showed a significant delay of the wound closure in 
a dosage dependant manner (P < 0.05). Other monoclonal antibodies failed to show 
any effect in this assay.  
 
Images of the effect on wound closure by CRT3 monoclonal antibody are shown in 
Figure 4.7a. After 12 hours, 25% and 15% of the original wound remained open 
when cells were treated with 10 μg/ml and 1 μg/ml of CRT3 respectively compared to 
the control (Figure 4.7b). Although the inhibitory effect was not dramatic, a statistical 
significance was observed in a dosage dependent manner. The cross reactivity 
between human and mouse would also allow future assessments of this particular 
CLEC14A monoclonal antibody in other HUVEC based in vitro assays or in vivo 
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Figure 4.7 A monoclonal antibody to CLEC14A inhibits endothelial cell 
migration. Scratch wound healing assay in HUVECs, showing a retardation of 
wound closure in the presence of 1 and 10 μg/ml of CLEC14A monoclonal antibody 
(CRT3). Images were taken at 0 and 12 h post wounding. Values represent the means 
from three independent experiments. Error bars depict the standard error of the mean 










4.9 Overexpression of CLEC14A in HUVEC using a lentiviral 
system  
Given that CLEC14A knockdown and antisera treatment inhibited endothelial cell 
migration, we further explored how overexpression of this protein would affect 
endothelial cell motility. The lentiviral expression system was used to achieve stable 
overexpression of CLEC14A in HUVECs.  
 
Full length human CLEC14A was constructed into a lentivector (pWPI) which 
contains independent GFP driven by an IRES site. Production of the virus from 293T 
cells was performed as described previously. HUVECs were then transduced with this 
lentivirus following a positive FACs sorting procedure for GFP to obtain a pure 
population of CLEC14A overexpressing HUVECs. Western blot was performed on 
the HUVEC lysates to confirm the overexpression (Figure 4.8). Tubulin staining 







Figure 4.8 Western blot of CLEC14A transfected cells. HUVECs were transduced 
with lentivector containing full length human CLEC14A and IRES linked GFP. Cells 
were FACs sorted and then analyzed by Western blot against CLEC14A antibody. 









4.10 Overexpression of CLEC14A inhibits HUVEC migration  
To assess whether overexpression of CLEC14A has an effect on endothelial cell 
migration, FACs sorted HUVECs overexpressing CLEC14A were used in a scratch 
wound assay. The uninfected or solely GFP infected HUVECs were used as negative 
controls. Images of the wound area were captured at 0, 4, 8 and 12 hour and the open 
wound area was quantified using ImageJ software.  
 
A significant delay in the wound closure was observed in the CLEC14A 
overexpressing cells compared to the control cells (Figure 4.9). Thus, overexpression 
of CLEC14A phenocopied the effect caused by CLEC14A knockdown. Migration is 















Figure 4.9 Overexpression of CLEC14A inhibits cell migration. Scratch wound 
healing assay in HUVECs, showing a retardation of wound closure in the CLEC14A 
overexpressing cells. Images were taken at 0, 4, 8 and 12 hours post wounding. 
Values represent the means from three independent experiments. Error bars depict the 









4.11 Generation of germline transmission mice carrying a 
CLEC14A knockout allele  
In vitro functional assays have shown that CLEC14A plays a role in endothelial cell 
migration and tube formation. The inhibitory effect of CLEC14A monoclonal 
antibodies on endothelial cell migration indicates a possible therapeutic potential for 
anti-vascular or anti-angiogenesis treatment. It is important to determine the function 
of CLEC14A in vivo to further understand its role in development and physiological 
and pathological angiogenesis.  
 
Targeted vector transfected embryonic stem cells [160] were purchased and injected 
into the inner cell mass of blastocysts which was then implanted into pseudopregnant 
C57BL/6 mice. 22 Chimeric mice were born and mated to Albino mice for germline 
transmission screening. Chimera No.15 showed germline transmission by offspring 
color recognition (Figure 4.10). Chimera No.15 was then used to generate 
heterozygous offspring on a C57BL/6 background.  
 





4.12 Generation of CLEC14A knockout mice 
Chimera No.15 was crossed with wild type C57BL/6 mice to generate heterozygous 
mice. Three pairs of CLEC14A heterozygous crossings were set up to generate 
complete knockout offspring. Two sets of primers were optimized to genotype the 
genomic DNA isolated from ear clips of the offspring (Figure 4.11). The resulting 
offspring were born in the expected Mendelian ratios (Table 2) 
 
 
Figure 4.11 PCR on wild type and crossed arm of target vector and CLEC14A in 
wild type, CLEC14A heterozygous and KO mice. Ear clips were collected for 
genomic DNA isolation. Genotyping was performed using an internal CLEC14A 
primer set and a crossed neomycin and downstream arm of CLEC14A primer set 
which generated a 200 bp and 404 bp fragment respectively.  
 
 
Genotype Mice generated Mendelian genetics prediction 
+/+ 24%, 18 25%, 18.75 
+/- 48%, 36 50%, 37.5 
-/- 28%, 21 25%, 18.75 
 
Table 2 Number of offspring of each genotype from CLEC14A heterozygous 




4.13 Confirmation of CLEC14A knockout in mice at the protein 
level 
Organs including brain, heart, lung, liver, spleen, kidney and colon from wild type and 
CLEC14A KO mice were snap-frozen in liquid nitrogen. Each organ was lysed and 
analyzed by western blot using rabbit anti mouse CLEC14A anti sera. A band detected 
at 30 kDa was due to non specific binding of the anti serum and it was used as the 
loading control. As shown in Figure 4.13, CLEC14A runs between 75 and 100 kDa. 
This was detected in lung and weakly in kidney from the wild type C57BL/6 mice 
while the protein was completely absent in the CLEC14A KO mice. Endothelial 
specific genes are most easily detected in the lung where 30% of the cells are 
endothelial compared to the 1 – 3% in most tissues. No obvious developmental defect 
was observed in all CLEC14A KO mice. These mice are fertile and remain healthy 







Figure 4.12 Confirmation of CLEC14A KO at the protein level. Organs including 
brain, heart, lung, liver, spleen, kidney and colon were collected from wild type and 
CLEC14A KO mice. Each organ was lysed in protein lysis buffer. The lysates were 






To begin to understand the role of CLEC14A in endothelial biology and angiogenesis, 
this chapter describes a preliminary functional characterization. Endothelial cell 
migration was the focus of the study. Silencing of CLEC14A in HUVEC using siRNA 
technology showed an inhibitory effect on endothelial migration, suggesting a 
pro-angiogenic role of CLEC14A. Unexpectedly, overexpression of CLEC14A in 
endothelial cells resulted in the same effect, indicating that a fine tuning of CLEC14A 
expression is critical for endothelial cell function. Furthermore, an identical inhibitory 
effect on migration was observed when HUVEC were treated with polyclonal 
CLEC14A antisera, which prompted the idea of generating monoclonal antibodies 
that may also be inhibitory to endothelial migration. Five monoclonal antibodies to 
CLEC14A were produced and indeed one of them (CRT3) phenocopied the 
polyclonal antisera. To address the in vivo role of CLEC14A, a knockout mouse was 
generated. CLEC14A KO mice are fertile, showing no developmental defect and 
remained healthy throughout their lifetime. Others in the group have investigated 
tumour growth in CLEC14A KO mice. Regulation of CLEC14A expression in tumour 















5.1 Introduction  
Lung cancer remains difficult to treat largely due to the lack of a well-defined target. 
Here we attempt to identify novel TEMs in lung cancer using 2
nd
 generation 
sequencing technology.  
 
To profile the differential gene expression between normal and tumour lung 
vasculature, endothelial cells need to be isolated from whole tissue. To this end, two 
independent approaches were investigated (Figure 5.1).  
 
Laser microdissection was specially designed for acquiring a pure cell population 
from heterogeneous tissue samples. The advantage of this approach was that it can 
precisely dissect and collect the desired tissue at a cellular level. The technology was 
chosen to dissect endothelial cells from blood vessels of frozen lung slides. In 
addition, such technology is meant to be particularly useful due to its accuracy 
because endothelium accounts for only a minor proportion of the whole tissue. Laser 
microdissection normally yields a small amount of RNA allowing downstream work 
such as qPCR and microarray.  
 
The magnetic bead isolation approach is performed on fresh tissue from surgery. A 
major benefit of this approach is that the RNA integrity is secured and the yield is 
greater. Thus, the bead isolation approach not only permits downstream gene profiling 
work involving microarray but also allows 2
nd
 generation sequencing, with which 
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laser microdissection is not compatible (Figure 5.1). 
 
Although both approaches have been used in isolating endothelium from several 
tumour types, the attempt to do so in lung cancer has not yet been reported and 




Figure 5.1 Scheme of strategies to identify TEMs in lung cancer. Two strategies 
were used to enrich the endothelial population from normal and tumour lung tissue. 
The laser capture microdissection technique was used to isolate vessels from frozen 
sections for microarray, but not for 2
nd
 generation sequencing due to the limited yield 
of RNA. The bead isolation performed on fresh lung tissue would permit both 
microarray and 2
nd




5.2 Laser microdissection approach  
5.2.1 Comparison of staining methods to visualize vessels and preserve RNA 
integrity  
To obtain quality RNA from endothelium using laser microdissection, there exists a 
major technical challenge, namely, visualizing the blood vessels while preserving 
RNA quality. To this end, two staining methods (i) Cresyl violet and (ii) 
immunohistochemistry for the endothelial marker CD31 were tested on frozen lung 
tumour sections.  
 
Cresyl violet is a basic dye that stains the negatively charged nucleus and is often 
used for visualization of malignant cells and revealing basic tissue morphology [161]. 
Although its rapid staining protocol preserves the RNA quality, whether the cresyl 
violet method would help visualizing vessels in lung is not clear. CD31 is a 
well-validated endothelial marker and the monoclonal antibody (JC70, Dako) has 
been long-known to label endothelium. However the immunostaining procedure 
involves multiple washing and incubation steps and may result in RNA degradation. 
Thus RNA integrity number (RIN) derived from the Bioanalyzer was used to assess 
the quality of RNA extracted from slides stained by both methods. A RIN above 7 was 
taken as high enough quality to permit downstream applications [162, 163].  
 
Frozen lung tumour slides were stained with cresyl violet or CD31 
immunohistochemistry. RNA integrity was then analysed on a Bioanalyzer. As shown 
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in Figure 5.2 left, although the RIN was well preserved (RIN = 8.8), Cresyl violet 
staining failed to highlight the blood vessels in the tissue, making it impossible to 
distinguish blood vessels from small bronchial tubes (Figure 5.2 left, white arrows). 
On the other hand, immunohistochemistry of CD31 clearly delineated the 
endothelium within the tumour however significant degradation of RNA was observed 
after the staining process (RIN = 5), (Figure 5.2, right). This probably arose from 
multiple incubation and washing steps where the tissue was exposed to aqueous 
solutions that reactivate endogenous nucleases. Thus, neither method could achieve 
the vessel visualization and RNA preservation at the same time.  
 
 
Figure 5.2 Comparison of Cresyl violet and CD31 staining in the use of vessel 
dissection and RNA preservation. Cresyl violet or CD31 immunohistochemistry 
staining was performed on frozen lung tumour tissue. After staining, RNA was 




5.2.2 Mapping strategy, the combination of two staining methods 
A combined strategy was developed to overcome the drawbacks of each staining 
method. Firstly, one slide was immune stained with CD31 antibody to highlight the 
blood vessels and this slide was used as a ‘map’. Secondly, the adjacent two slides 
derived from either side of the ‘map’ were cresyl violet stained. Cresyl violet staining 
revealed a basic tissue morphology which facilitated the reorientation according to the 
‘map’. Eventually, the vessels that need to be laser dissected were selected on the 
CD31 stained ‘map’ and the laser microdissection was carried out on adjacent cresyl 
violet stained slides (Figure 5.3a). Total RNA was then isolated from the dissected 








Figure 5.3 Mapping strategy to obtain high quality RNA from laser 
microdissected samples. (a) A ‘map’ slide was stained with CD31 antibody to 
visualize blood vessels. The adjacent two slides were cresyl violet stained to display 
basic morphology and used for laser microdissection. (b) The RIN value of laser 







5.2.3 Microarray of laser microdissected samples 
Using the mapping strategy, good quality and sufficient RNA was obtained. Two laser 
microdissected endothelial samples from lung tumour (LCM1 and LCM2) were 
amplified and labeled using an Agilent Quick-Amp kit. Two RNA samples extracted 
from fresh lung tissue were included as controls. The specific activity of all samples 
was above 6, which is considered the minimal requirement for array analysis.  
 
Single color microarray analysis was performed on an Agilent 4x44k chip. The 
analysis of microarray data was performed using the Quantile normalization method 
and the gene expression level was normalized to Flotilin 2, a house keeping gene. The 
expression level of epithelial cell adhesion molecule (EPCAM) which is expressed on 
most normal epithelial cells and almost all carcinomas was used as a measure of 
purity. Figure 5.4a shows that CD31 and EPCAM were expressed at an equal level in 
the laser dissected samples indicating considerable epithelial/carcinoma 
contamination. Despite that an equal amount of labeled cRNA was applied to the 
microarray. Weaker signals were detected in the laser dissected samples than that in 







Figure 5.4 Microarray of laser microdissected samples. (a) Comparison of 
endothelial and epithelial compartments in two laser dissected samples: LCM1 and 
LCM2; (b) Weak signals were detected in laser microdissected samples compared 

































5.2.4 Potential difficulty of capturing vessels from normal lung tissue by laser 
microdissection  
To make a comparison of gene expression between normal and tumour endothelial 
cells, laser microdissection also needs to be performed on normal lung tissues. To first 
understand the morphology and vessel distribution, CD31 immunohistochemistry was 
performed on normal lung tissue. Figure 5.5a shows intense staining throughout the 
whole lung tissue. This was presumably due to the high endothelium content of 
normal lung, which adds extra difficulty to identify vessels for laser dissection. To 
avoid damaging the RNA, the vessel area for laser dissection has to be delineated. It 
proved unavoidable to exclude mural cells (pericytes and smooth muscle cells) in the 
dissected materials, due to their proximity to the endothelium (Figure 5.5b).  
 
In conclusion, laser microdissection proved unsuitable to isolate endothelial cells, 
particular those in lung tissue. In parallel, an alternative, Ulex-bead isolation approach 







Figure 5.5 Potential difficulties for laser microdissection of normal and tumour 
lung. (a) Frozen normal lung sections were stained with CD31 monoclonal antibody. 
Images were captured under a light microscope. (b) Examples of laser 






5.3 Endothelial isolation using Ulex coated beads 
Endothelial cells were isolated from fresh healthy and tumour lung tissue using 
Ulex-conjugated beads. To determine the endothelial enrichment, total RNA extracted 
from endothelial isolates or whole tissue was converted to cDNA. The expression of 
CD31 in bead isolated samples was compared with that in whole tissue by real-time 
PCR.  
 
As shown in Figure 5.6a, a 15 fold increase of CD31 expression was achieved in the 
bead isolated samples compared to the whole lung tumour extracts. A 4 fold 
enrichment of endothelial cells was seen in endothelial cells isolated from normal 
lung compared to the whole tissue. The different fold increase of CD31 expression 
between normal and tumour samples was due to the fact that the proportion of 
endothelial cells is higher in normal (30%) than in tumour (3-5%). Therefore, the 
endothelial enrichment was expected to be more dramatic in the tumour sample than 
in the normal tissue. RNA quality of the Ulex-bead isolated samples were confirmed 
to be good (RIN > 7) on a Bioanalyzer (Figure 5.6b).  
 
Generally a lower RNA yield was seen from endothelial cells isolated from healthy 
lung tissue compared with that from tumour. This was possibly due to the endothelial 
cells in the healthy lung tissue being in a quiescent state. In the tumour, endothelial 
cells are active and transcription possibly more extensive. To obtain sufficient RNA (5 
μg) to perform the deep sequencing, three endothelial isolates of normal lung were 
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pooled together to make up 4.8 μg while 6.1 μg of RNA was isolated from the 







Figure 5.6 Confirmation of endothelial enrichment and RNA integrity of 
Ulex-coated bead isolated endothelial samples. Endothelial cells were isolated from 
lung normal or tumour tissue using Ulex coated beads. (a) Real-time PCR using a 
primer set for CD31 was performed on the bead isolated endothelial cells and bulk 
tissue. The expression level of CD31 in the bead isolated sample was normalized to 
that in the bulk tissue. (b) RNA was extracted from the bead isolated endothelial cells 
from normal lung or tumour tissue. The RNA integrity of normal and tumour lung 






5.4 RNA-seq of lung endothelium 
RNA-seq using deep sequencing (2nd generation sequencing) is a large scale parallel 
sequencing method for transcriptome analysis. It utilizes short read sequencing 
technologies such as the SOLiD 4 platform to sequence millions of reads from a 
cDNA library prepared from RNA. RNA-seq has the advantage of querying both 
known and novel transcripts and does not rely on a prior knowledge and annotation. 
Neither does it suffer from probe cross hybridization of closely similar genes that can 
occur on a microarray.  
 
As described earlier, RNA of endothelial cells isolated from three normal lung tissues 
(pooled) and one tumour lung tissue were sequenced as 1 tumour and 1 normal 
sample on a SOLiD4 sequencer. Bioinformatics analysis of the deep sequencing data 
confirmed the purity of the endothelium by comparing the expression level of CD31 
to EPCAM, CD68, PDGFR2 and CD11b. As shown in Figure 5.7a, the level of 
markers for non-endothelial cell types including epithelium, macrophage, pericytes 
and leukocytes was absent or at a low level compared to that of CD31. 
 
Angiogenesis occurs with proteolysis of the extracellular matrix followed by 
endothelial proliferation and migration [164, 165]. MMPs open the path for 
endothelial migration by remodeling and degrading the extracellular matrix. To test 
whether known angiogenic associated genes and MMPs were elevated in lung tumour 
endothelium, a differential gene expression analysis was performed using the DESeq 
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v1.5 package. The results showed a number of known angiogenic genes and MMPs to 





Figure 5.7 RNA-seq confirmation of endothelial enrichment and elevation of 
MMPs and angiogenic associated genes. (a) According the analysis of RNA-seq 
data, expression of EPCAM, CD68, PDGFR2 and CD11b in both normal and tumour 
samples were normalized to that of CD31/PECAM1, confirming the endothelial 
enrichment by the Ulex-bead isolation approach. Differential gene expression analysis 






































5.5 Microarray of biological replicates 
As described earlier, the large amount of RNA (5 µg) and high cost restricted deep 
sequencing to one tumour and normal sample. Therefore, to perform differential gene 
expression analysis that compensates for patient variability, a microarray was 
experiment was performed on 4 pairs of normal and tumour endothelial isolates from 
lung on an 8x60k microarray chip (Figure 5.8a). 
 
A PCA plot in Figure 5.8b shows variation in both tumour and normal samples and 
between samples of each group. This was to be expected as samples were collected 
and extracted from different patients and statistically significant genes are those that 
are consistent across replicate samples. Nevertheless, it is clear that all normal 







Figure 5.8 Microarray of endothelial isolates from multiple patient samples. (a) 4 
pairs of normal and tumour endothelial isolates were analysed by microarray on an 
8x60k Agilent microarray chip. (b) A PCA plot demonstrates variation between 








5.6 Identification of lung TEM candidates   
For target identification, differentially expressed genes obtained from deep 
sequencing data were filtered with multiple criteria. 477 genes with log2 fold change 
magnitude > 1, a p-value < 0.5 and containing a transmembrane or signal peptide 
domain was generated. 
 
Differential gene expression analysis was performed on the microarray data using the 
program Limma and genes were filtered based on the same criterion as RNA-seq. 
This resulted in 584 genes. The intersection of the microarray and deep sequencing 
gene pools were assigned lung TEM candidates, consisting of 126 genes. 13 lung 
TEM candidates were chosen for further validation based on additional criteria 
including the level of association with endothelial cells, previously published work, 
intellectual property, sites of expression and relation to known genes with interesting 










5.7 Validation of lung TEM candidates in EC isolated from 
NSCLC patients  
To validate putative lung TEMs, primer sets of each candidate were designed. A 
quantitative real-time PCR was performed on four pairs of normal and tumour 
endothelial isolates from lung. Flotillin 2 was used as the house keeping gene to 
which the data was normalized. The double delta Ct method was used to compare 
expression levels in tumour relative to normal endothelial isolates.  
 
Figure 5.10 demonstrates that all candidates had elevated expression in tumour ECs 







Figure 5.10 Quantitative real-time PCR validation of lung TEM candidates in 




5.8 Expression of TEM candidates in angiogenic tissue and lung 
cancer 
Immunohistochemistry staining was performed on placental and lung tumour tissues 
using antibodies to the lung TEM candidates. Among the fourteen candidates, the six 
genes: BIRC5, GJB2, PCDH7, PROM2, ROS1 and STEAP1 showed endothelial 
expression in placenta which is a site of active angiogenesis (Figure 5.11). Lung 
tumour tissue was also immunostained and Figure 5.12 shows that these six 





Figure 5.11 Immunohistochemistry of lung TEM candidates on placental tissue. 





Figure 5.12 Immunohistochemistry of lung TEM candidates on lung cancer 





5.9 Conclusions  
A major barrier to effective treatments for lung cancer is the lack of well characterized 
markers or targets. In this chapter we aimed to identify novel lung cancer vascular 
targets by transcriptional profiling of lung endothelium. Two methodologies were 
investigated and compared to characterize healthy and cancerous lung endothelium. 
Laser microdissection technology proved problematic for isolating lung endothelial 
cells. Beside an inadequate endothelial enrichment, the poor RNA integrity and 
limited yield restricted downstream work. In contrast, the Ulex-bead isolation 
approach achieved excellent endothelial purity and RNA quality and yield from fresh 
clinical samples. Using this approach, deep sequencing technology was combined 
with microarray analysis to profile the transcriptome of endothelial isolates from 
tumour and healthy lung of multiple cancer patients. Differential gene expression 
analysis of the two data sets identified 126 TEM candidates. The subsequent qPCR 
validation on tumour and healthy endothelial isolates from multiple patients produced 
a short list of 13 genes. Immunohistochemistry staining on placental and lung tumour 
sections identified six lung vascular targets with strong endothelial expression, 
namely STEAP1, ROS1, PCDH7, BIRC5, GJB2 and PROM2. Further 


























TEMs localized at the plasma membrane or secreted into the extracellular matrix are 
accessible for targeting by antibody, and such antibodies can be either infused or 
generated de novo via vaccination with the TEM. An advantage of active vaccination 
is the possibility of generating both antibody production in situ and cytotoxic T-cell 
mediated immunity. In experimental mouse models, reduction of tumour growth has 
been demonstrated after vaccination with a range of endothelial expressed proteins 
including the vascular endothelial growth factor receptor (VEGFR) -2, 
Endoglin/CD105, Delta-like 4 (DLL4) and the extra domain-B of fibronectin 
(reviewed in [166], [67, 146]) 
 
Crucially important to the success of the immunotherapy is the selection of the TEM. 
The TEM should ideally be present throughout the tumour vasculature and show 
negligible expression on the normal vasculature. An example of such a TEM is Robo4. 
Expression of Robo4 on the vasculature in tumour but not healthy tissues identifies it 
as a potential target for immunotherapeutic approaches such as vaccination. Its 
expression is up-regulated by low shear stress, and it is present on the vessels of a 
number of tumour types including pancreatic, bladder, lung and prostate cancer [73, 
108, 109, 167, 168]. This chapter investigates the effect of Robo4 vaccination on 





6.2 Papain cleavage of human Robo4-Fc  
Prior to vaccination to a self-antigen, it is necessary to show that there is no 
pre-existing immunity. An ELISA assay was designed to investigate whether Robo4 
antibodies are present in serum from healthy people and cancer patients. In this assay, 
the ELISA plate was coated with pure Robo4 protein as the antigen. Robo4 protein 
was expressed fused to an Fc tag that allowed purification on a protein A column. 
Unfortunately the Fc tag was recognised by the secondary anti-human IgG antibody 
and so was first removed by papain digestion.  
 
Pilot experiments showed that although the Fc tag was cleaved off, the papain rapidly 
digested the remaining Robo4. To optimize the yield of cleaved Robo4, the cleavage 
reaction mix was sampled at a series of time points over one hour. Samples were 
resolved on acrylamide gel followed by coomassie staining. As shown in Figure 6.1, 
the top band (intact Robo4-Fc) gradually disappeared across the time points while the 
cleaved band at 50 kDa (cleaved Robo4) increased during the papain digestion. 40 





Figure 6.1 Optimization of papain cleavage of recombinant human Robo4-Fc. 
Intact human Robo4-Fc protein was cleaved in a papain digestion. The reaction mix 
was sampled at serial time points and run on a SDS PAGE gel following coomassie 
staining. The band between 75 – 100 kDa is the intact human Robo4-Fc protein while 















6.3 Depletion of Fc fragments after papain digestion of human 
Robo4-Fc protein 
To avoid cross reaction with the secondary anti-human Ig antibody in the ELISA assay, 
the papain cleaved Fc fragments from recombinant Robo4-Fc protein need to be 
removed. Protein G beads which have high affinity for human Fc were used to deplete 
the Fc fragments from the papain digested mix. After the papain reaction was 
quenched, protein G beads were added and incubated for 1 hour. The beads were then 
removed and the resulting supernatant contained Robo4 only. This supernatant was 
collected and analyzed by Western blot. A clean band of human or mouse Robo4 was 
detected at 50 kDa by the Robo4 antibody while both were absent when re-probed 
with human IgG antibody (Figure 6.2). The results show that, with the optimized 











Figure 6.2 Depletion of Fc fragments from papain cleaved human/mouse 
Robo4-Fc. The depletion of Fc fragments from papain cleaved human/mouse 
Robo4-Fc was performed using protein G beads. Beads to which the Fc fragments 
bound were spun down and the supernatant containing Robo4 only was collected and 
western blotted against human or mouse Robo4 antibody and human Fc antibody 
respectively. The upper figure is the western blot on papain cleaved human Robo4-Fc 
using human Robo4 and human Fc antibody. The lower figure is the western blot on 




6.4 Generation of a standard curve for assay of Robo4 antibodies 
in serum  
We first developed a standard curve for the ELISA in order to measure antibodies in 
serum. To optimize the amount of coating antigen (papain cleaved Robo4), 5-fold 
titration of coating antigen and a monoclonal antibody to human Robo4 - MR7 or a 
polyclonal antisera to mouse Robo4 (1 to 0.008 µg/ml and 25 to 0.2 µl respectively) 
was applied to the assay. The result shows that the minimum amount of coating 
antigen (5 µl) used gives a valid read out. The detection limit of the assay was found 







Figure 6.3 Standard curves for the assay of Robo4 antibodies in serum. 
Recombinant human or mouse Robo4-Fc protein underwent papain cleavage followed 
by Fc fragment depletion. Titration of papain cleaved Robo4 stock (25 µl ~ 0.2 µl) 
and antibody (1 µg / ml ~ 0.008 µg / ml) enables generation of a standard curve. (a) 
and (b) show the standard curve generated by papain cleaved human and mouse 
































































6.5 Assay for Robo4 antibody in serum from cancer patients and 
healthy individuals 
It is important to determine whether Robo4 antibody is present in the serum from 
healthy people and cancer patients. This is particularly critical for cancer patients, 
because overexpression of Robo4 in tumour vessels could potentially induce an 
immune response.  
 
An ELISA assay was used to determine whether Robo4 antibodies could be detected 
in the serum of colorectal cancer patients. ELISA wells were coated with Robo4 
protein. Serum samples at different dilutions were applied to the plate in a range from 
neat to a dilution of 1 in 25. Six serum samples from either healthy donors or cancer 
patients were tested in this assay. Robo4 monoclonal antibody (MR7) was employed 
as the positive control. As shown in Figure 6.4, there was no Robo4 antibody 






Figure 6.4 Assay of Robo4 antibody levels in serum from cancer patients. An 
ELISA plate was coated with papain cleaved human Robo4 and the neat serum from 6 
healthy donors or cancer patients were applied to each well. A Robo4-specific 
monoclonal antibody MR7 (R4 mAb) was used as the positive control with 5-fold 




6.6 Expression of mouse Robo4-Fc in 293T cells after calcium 
phosphate transfection. 
To vaccinate mice, pure mouse Robo4 protein was required. Plasmids with the 
extracellular domain of mouse Robo4 fused to a human Fc tag were obtained from 
Cancer Research Technology. Mouse Robo4-Fc-pIG was transfected into HEK 293T 
cells using calcium phosphate. As the recombinant protein was secreted from the cells, 
the conditioned media was collected and run through a protein A column that has high 
affinity for the Fc tag. Robo4-Fc loaded column was then eluted with a pH gradient 
on an FPLC machine. The purity of the protein was verified by western blot and 
coomassie staining.  
 
Abcam anti-human Robo4 antibody that cross reacts with mouse Robo4 revealed 
clear bands between 75 kDa ~ 100 kDa (Figure 6.5a). The purity of the protein was 
confirmed by coomassie staining (Figure 6.5b).  
 
The aim was to produce sufficient mouse Robo4 protein for mouse immunization. 
However the expression was lost a few days after transfection and the protein yield 
was limited. To overcome this, a stable cell line that expresses mouse Robo4 using a 





Figure 6.5 Coomassie stain and western blot of Robo4 fractions from FPLC 
purified mouse Robo4-Fc. (a) For western blot, 10 µl of each fraction was added to 
2 µl of 6x SDS loading buffer and 10 µl was loaded on to a 10% SDS PAGE gel. 
Western blot was performed using Abcam antisera which cross reacts with mouse 
Robo4. (b) Coomassie stain was performed on each fraction with 1 µg of human 
Robo4–Fc as the positive control. For coomassie stain, 30 µl of each fraction was 









6.7 Generation of a stable cell line expressing mouse Robo4 using 
lentivirus 
Lentiviral expression systems are widely used in the transduction of non-dividing 
cells. These systems provide long term expression of the delivered genes, and we 
adopted a lentiviral approach to generate a stable cell line that expressed mouse 
Robo4.  
 
Mouse Robo4-Fc was amplified by PCR from the Robo4 containing pIG vector and 
sub-cloned into a lentivector: pWPI, which contains a GFP tag after an IRES 
sequence. Lentivirus was produce by calcium phosphate transfection of 293T cells 
with the lentivector that contains mouse Robo4-Fc, packaging plasmid (psPAX2) and 
envelope plasmid (PMD2G). The transduction efficiency of 293T cells (87.62%) 
4-days post-transduction is shown. Transduced cells were sorted for GFP by flow 
cytometer and the percentage of the GFP positive cells (99.39%) is shown in Figure 
6.6a.  
 
Further experiments were performed to optimize the number of collections from the 
stable line. Five collections of conditioned media were analyzed by coomassie stain 
and all of them were confirmed to be mouse Robo4-Fc (Figure 6.6b). Quantification 
allowed comparison of the yield to the calcium phosphate method. The comparison 
showed that the stable cell line produced 4x the amount of protein (6 mg) compared to 






Figure 6.6 Generation of a stable cell line expressing Robo4 and the purification 
of recombinant Robo4 protein. (a) Generation of a stable cell line that expresses 
mouse Robo4-Fc by FACs sorting of GFP positive cells (FL1). 293T cells transduced 
by lentivirus were analyzed before and after FACs sorting. The number highlighted in 
the red box indicates the transduction efficiency (top profile) and the percentage of 
GPF
+
 cells after sorting (bottom profile). (b) Coomassie stain for Robo4 from media 
conditioned by the stable line expressing mouse Robo4-Fc. 10 ml of conditioned 
media was collected on alternate days for 10 days. Recombinant protein was purified 
using protein A beads. The protein bound beads were boiled in 50 µl of 1xSDS 
loading buffer and 25 µl was loaded on a 10% SDS PAGE gel.  
 
  Culture size Volume Yield Highest conc. of 1 ml elution 
Calcium phosphate 40 dishes 3 L 3 mg 0.8 mg/ml 
Lentiviral cell line 20 dishes 1.5 L 6 mg 3 mg/ml 
 
Table 3 Comparison of protein production by calcium phosphate transfection 






6.8 Immunization with Robo4 in mice using protein vaccination 
In order to break immune tolerance to Robo4, protein immunization was performed in 
C57B/6 mice. Freund’s complete adjuvant was used to achieve immunization because 
Robo4 is a self antigen and self antigens often show low immunogenicity. The 
antibody response was then characterized using the ELISA assay. Papain cleaved 
mouse Robo4 was used as the coating antigen. 
 
For immunization, six mice received 50 µg of mouse Robo4-Fc protein or Fc control 
subcutaneously at two-week intervals. Complete Freund’s adjuvant was used on day 0 
and incomplete Freund’s on day 14 (Figure 6.7a). Serum was collected on day 0, 14 
and 28 and assayed for Robo4 antibodies by ELISA. As shown in Figure 6.7b, a 
robust antibody response against Robo4 was induced by day 28 in the Robo4 
vaccinated groups, suggesting that tolerance to Robo4 had been broken by the 
immunization.  
 
Further characterization of the induced antibodies showed that there were high levels 
of IgG1, with lower titres of IgG3 and IgG2b (Figure 6.7c). Immunization with 
proteins tends to induce Ig class switching to the IgG1 isotype associated with T 











Figure 6.7 Vaccination of mice with mouse Robo4 generates a Robo4-specific IgG 
response. (a) Protocol for Robo4 vaccination prior to in vivo angiogenesis assays and 
tumour experiments. (b) Vaccination with Robo4-Fc induces Robo4-specific antibody 
production. Mice (C57B/6) were vaccinated with Fc or mouse Robo4-Fc protein 
injection according to the protocol in (a). Robo4 antibodies were determined by 
ELISA at day 14 and day 28. (c) Determination of antibody isotypes in control and 
Robo4 vaccinated mouse sera. Sera, harvested at day 28 from Fc or Robo4-Fc 
vaccinated mice, was diluted tenfold and used in an ELISA with secondary antibody 






6.9 Sponge implantation assay in Robo4 immunized mice 
Subcutaneous implantation of a sponge is a robust technique to study in vivo 
angiogenesis [170, 171]. To investigate whether there is an anti-angiogenic effect in 
Robo4 vaccinated mice, single sponges were implanted into Robo4 immunized and 
control mice. bFGF was delivered to the sponge on alternate days. At the end of the 
experiment, the implanted sponges were resected and fixed in formalin following 
paraffin embedding and sectioning. Hematoxylin and eosin staining was carried out to 
reveal the cellular morphology of the sponge implant. 
 
Invasion of the sponge by new vessels and fibrotic tissue was assessed by microscopic 
imaging. Pictures of whole sponges were captured and the area of invasion was 
analyzed. A dramatic reduction in invaded fibrotic tissue and blood vessels was 
observed in sponges from Robo4 vaccinated mice compared to controls. Two 
representative pictures from Robo4 vaccinated group and controls are shown in 
Figure 6.8a. The invaded area was quantitated using Image J software. The 
percentage of invaded area was quantitated for each individual sponge and results 
shown in Figure 6.8b. Comparison of the mean values showed, 77.6% of the control 
sponge was invaded by blood vessels and fibrotic tissue while only 36.2% of the 
Robo4 vaccinated group was invaded.  
 
The vessel density of each sponge was determined by counting vessel numbers in 
random fields. As shown in Figure 6.9a, there was a significant decrease of vessel 
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density in sponges from Robo4 vaccinated mice (average 2 vessels per field) 
compared to those from control mice (average 10 vessels per field).  
 
A noteworthy observation was that when comparing the size of the blood vessels in 
the invaded area between these two groups, large vessels were observed in sponges 
from control mice while these were rarely seen in sponges from Robo4 vaccinated 
mice (Figure 6.9a). Quantification of the actual vessel dimension from each group 
was performed using Image J software (Figure 6.9c). A significant decrease in vessel 
dimensions was seen in Robo4 vaccinated mice (4.5 x 10
3
 pixels) compared to that in 
control mice (9.3 x 10
3
 pixels).  
 
Taken together, an immune response against Robo4, and most likely Robo4-specific 












Figure 6.8 Sponge implantation assay in Robo4 vaccinated mice. (a) Sponges 
were harvested, sectioned, and stained with H&E. The invading blood vessels and 
fibrotic tissue were visualized under a light microscope (10X); (top). Pictures of the 
implanted sponges were taken on a light microscope and the invaded areas analysed 
using Image J software (bottom). Areas in red show the invaded areas which were 
quantified by the software. (b) The invaded area of each sponge from Robo4 
immunized or control mice was quantified using Image J software and the percentage 
of the invaded area versus the whole sponge was calculated. Invaded area as a 
percentage of the whole sponge was plotted for a representative section for each 









     
Figure 6.9 Comparison of vessel size between the sponges from Robo4 vaccinated 
and control mice. (a) Representative H&E stained sections show fewer and smaller 
vessels in Robo4-Fc vaccinated mice compared with control Fc vaccinated mice. (b) 
Vessel numbers from 3 random sections per mouse were quantitated and plotted, the 
mean and SEM are indicated (p <0.0001, Mann-Whitney test). (c) The area of 10 
random vessels per group was quantitated using ImageJ and plotted in x10
3
 pixels. 





6.10 Expression of Robo4 in the vasculature of the Lewis lung 
carcinoma tumour  
Since angiogenesis plays a key role in the growth of solid tumours, the effect of 
Robo4 vaccination on the growth of subcutaneously implanted mouse tumour cells 
was examined. Lewis lung carcinoma (LLC) is a highly aggressive cancer cell line 
derived from the C57Black/6 mouse strain. It is a widely used model for investigating 
effects on the tumour vasculature [172, 173]. To determine whether an immune 
response to Robo4 would target the tumour vessels in the LLC mouse model, 
immunostaining of Robo4 was performed on formalin fixed LLC tumour sections.  
 
Antisera to human Robo4 (Abcam) that cross reacts with mouse Robo4 was used. 
CD31 antibody was used as a positive control for the vasculature. Staining showed 
that Robo4 is indeed expressed in the vessels of Lewis lung carcinoma tumour 






Figure 6.10 Expression of Robo4 in the vasculature of the Lewis lung carcinoma 
tumour. Immunohistochemistry was performed on Lewis lung carcinoma tumour 
sections. CD31 or Robo4 antibody was used as the primary antibody. A similar 
staining pattern was observed in the tumour vasculature for both antibodies (This 
figure courtesy of Dr. F. Ahmed). 
 






6. 11 Effect of Robo4 vaccination on growth of Lewis lung 
carcinoma in mice 
To determine whether Robo4 vaccination affected tumour growth, a dose of 10
6
 LLC 
cells were implanted into Robo4 vaccinated and control (Fc) mice. The cells were 
injected subcutaneously on the back of the mice and the growth of tumour was 
measured three times a week. The tumour volume was calculated according to the 
formula described previously. A significant delay of tumour growth was seen in the 
Robo4 vaccinated mice compared with that in control mice (Figure 6.11).  
 
In order to elucidate the effect of the Robo4 specific immune response on the tumour 




Figure 6.11 Tumour growth in Robo4 vaccinated mice. Each mouse was implanted 
with 10
6
 Lewis lung carcinoma cells subcutaneously and the size of tumour measured 
three times weekly. Tumour volume was plotted and two-way ANOVA analysis of 




6.12 Increased vascular leakage and neutrophil infiltration in 
tumours grown in Robo4 vaccinated mice 
Fibrinogen deposition has been used as an indicator of increased vascular leakage 
[175]. To examine whether Robo4 vaccination had an effect on the tumour 
vasculature, an immunofluorescence staining of fibrinogen was performed on tumour 
sections from control or Robo4 vaccinated mice. The fibrinogen antibody was labeled 
with FITC (green). Stained sections were analyzed with a confocal microscope and 
images were captured of random fields for statistical analysis. The fluorescence of 
fibrinogen was quantitated using Image J software. Quantification showed there was a 
significant increase of extravasated fibrinogen in the tumours derived from Robo4 
vaccinated mice (Figure 6.12a), indicating increased vessel damage. Antibody to the 
neutrophil marker Gr-1 was used to stain tumour sections derived from control and 
Robo4 vaccinated mice. Images of random fields were taken on a confocal 
microscope. As shown in Figure 6.12b, increased neutrophil infiltration was observe 
in tumour tissue derived from Robo4 vaccinated mice confirming increased 





Figure 6.12 Staining of fibrinogen and neutrophils in Lewis lung tumour from 
control and Robo4 vaccinated mice. (a) Immunofluorescent staining of fibrinogen 
was performed using polyclonal fibrinogen antisera on 4 sections for 4 tumours per 
group. Quantification of the area positive for fibrinogen staining (green) determined 
using ImageJ. The mean and SEM are indicated (p <0.0001, Mann-Whitney test). (b) 
Neutrophil invasion was assessed by immunofluorescent staining with monoclonal 
anti-Ly6G and Ly-6C antibody. The number of infiltrating neutrophils (red) was 
counted from 4 sections for each of 4 independent tumours. The mean and SEM are 












6.13 Soluble Robo4 conjugated to a carrier protein can induce a 
rapid protective antibody response in the absence of adjuvants  
As strong adjuvants such as Freund’s adjuvant cannot be used in humans, the 
efficiency of a milder conjugate vaccine immunization protocol was tested. Mice were 
primed with chicken gamma globulin (CGG). Five weeks later, after immunological 
memory had developed, mice were immunized with soluble Robo4-Fc chemically 
crosslinked to CGG without further adjuvants. Simultaneously tumor growth was 
induced by subcutaneous injection of Lewis lung carcinoma cells (Figure 6.13a). 
Vaccination of primed animals with Robo4-Fc crosslinked to CGG led to production 
of high levels of Robo4-specific IgG (Figure 6.13b) and significant and sustained 
growth inhibition of the tumour (Figure 6.13c). Instead of a prophylactic vaccine, 
these findings suggest the possibility of developing a treatment vaccine using carrier 





Figure 6.13 Induction of protective Robo4-specific antibody in carrier-primed 
animals (a) Mice receiving primary immunization i.p. with chicken gamma globulin 
(CGG) in alum [176] were reimmunised 5 weeks later subcutaneously with Robo4-Fc 
crosslinked to CGG [154]. Simultaneously 10
6
 Lewis lung carcinoma cells were 
implanted subcutaneously. (b) Induction of Robo4-specific antibody two weeks post 
immunization with Robo4-CGG determined by ELISA. (c) Significant reduction in 
tumour growth in CGG primed and Robo4-Fc-CGG immunized animals compared to 





6.14 Tissue screen of Robo4 vaccinated mice 
Although Robo4 vaccinated mice showed promising anti-angiogenic effects in the 
sponge implantation and tumour growth models, in the view of the therapeutic 
opportunity, it is essential to know whether the immune response against Robo4 
impaired the normal vasculature. Organs including brain, heart, lung, liver, kidney and 
spleen were collected from both Robo4 immunized and control mice and H+E stained 
tissue sections.  
 
As shown in Figure 6.14, the tissues from Robo4 immunized mice remained intact 
and exhibited no obvious difference to that from the control mice in terms of the 
morphology of tissues and the vasculature. During the immunization period, no 
weight loss, abnormal appearance or behavior was observed in Robo4 immunized 






Figure 6.14 H+E staining of tissues from control and Robo4 vaccinated mice. 
Tissues including heart, lung, kidney, spleen, brain and liver were collected from 
control or Robo4 vaccinated mice. After fixation, paraffin embedding and sectioning, 





Apart from chemotherapy and radiotherapy, immunotherapy has been a major 
research focus in cancer. Vaccination is an attractive approach to treat cancer, 
particularly in the context of vascular targeting. A well defined target is needed as an 
antigen for the vaccine. Robo4 is a pre-validated TEM that has been shown to be 
restricted to the vasculature in many cancer types. Robo4 was investigated as a 
vaccine immunogen in animal models of cancer. A strong antibody response was 
induced by vaccination of soluble mouse Robo4 protein with Freund’s adjuvant, 
suggesting the immune tolerance to the self-antigen was successfully broken. The in 
vivo sponge implantation assay showed strong inhibition of angiogenesis in Robo4 
vaccinated mice compared to control Fc vaccinated group. Robo4 vaccinated mice 
also showed retarded tumour growth in a Lewis lung carcinoma model. To explore the 
clinical possibility of a Robo4 vaccine, we developed an alternative immunization 
approach to avoid the use of strong adjuvants such as Freund’s adjuvant. Mice were 
initially primed with CGG protein to develop immune memory and subsequently 
immunized with Robo4-CGG crosslinked complex in the absence of adjuvant. A 
strong antibody response was seen 14 days post-immunization. Tumour implanted on 
the day of immunization was inhibited in the Robo4 vaccinated mice compared with 
the control group. Histochemistry of organs derived from Robo4 vaccinated mice 
showed no apparent pathology. Taken together, these results suggest that vaccination 
















Considerable effort has been invested in identifying and validating novel targets 
which are restricted to tumour vessels and known as Tumour Endothelial Markers 
[177]. The study which provided the first proof of principle that vascular targeting can 
be used to eradicate solid tumours in mice came from the work of Burrows and 
Thorpe in 1993 [63]. In 1997, these studies were extended when Huang and Thorpe 
reported that targeting the inducible truncated form of tissue factor (tTF) in the 
tumour vasculature of mice by an antibody-tTF complex resulted in significant 
tumour regressions [64]. In 2002, Thorpe’s group proposed that the presence of 
anionic phospholipids on tumour vessels held potential for tumor vessel targeting and 
imaging [178] and more recently (2005), a monoclonal antibody against anionic 
phospholipids showed damage to the tumour vasculature and suppression of tumor 
growth in mouse models [179, 180]. The combined evidence strongly suggests that 
targeting molecules present in the tumour vasculature can lead to tumour shrinkage 
and cancer regression.  
 
A number of approaches have been developed to identify TEMs. One of the most 
direct screens for TEMs has been the isolation of endothelium from normal and 
tumour colon followed by immediate extraction of RNA and conversion to SAGE 
libraries for transcriptome differentiation analysis [74]. Nine TEM’s labeled TEM1 
through TEM9 were identified from this work. However further studies showed that 
TEM1, also known as endosialin, was not expressed by endothelium but enriched in 
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tumour associated fibroblasts and pericytes [181]. However TEM1 retains potential as 
a tumour target and functionally, endosialin null mice show defective angiogenesis in 
orthotopically implanted colon tumours [83]. More recently, a monoclonal antibody 
targeting TEM8 was reported to inhibit pathological angiogenesis and tumour growth 
in multiple cancer models [182]. The EDB domain of fibronectin has been used in a 
clinical trial as an anti-cancer target [79]. The EDB domain is present only in 
fibronectin expressed in the foetus or tumours. Specific antibodies to the EDB domain 
have been used in several animal models to show an antitumour effect when coupled 
to TNF-α [183] interferon-γ [184] photosensitizer [185], interleukin 12 [186] 
interleukin 15, GM-CSF [187] or interleukin 2 [188]. Annexin A and Robo4 were also 
successfully identified and characterized as TEMs and have been reviewed [79]. 
Nevertheless, the expression profile of these targets is often not as specific and 
widespread as was expected and many putative TEMs to date have not entered clinical 
trials [22]. As a result, there exists an urgent need for new TEMs.  
 
In Chapter three, a systematic approach was carried out to validate putative TEMs 
derived from a bioinformatics data mining prediction. Three candidates, CLEC14A, 
GBP4 and IKBKE were investigated.  
 
It is shown here that CLEC14A is a novel TEM. This was shown on a human cancer 
tissue array by both immunofluorescence and immunohistochemical analysis. 
Immunofluorescent images of CLEC14A showed highly specific CLEC14A 
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expression on tumour vessels in a wide range of cancers and no or very low 
expression found in the adjacent healthy tissues. The co-localization with the human 
endothelial marker Ulex lectin confirmed its endothelial expression in vivo. The 
elevation of CLEC14A was also confirmed in endothelial isolates from hepatocellular 
carcinoma compared with that from healthy liver tissue [109]. Substantial CLEC14A 
expression was found across a range of common tumour types, including 100% of the 
ovarian and liver cancer, 90% of bladder and prostate cancer and 80% of breast cancer. 
The subcellular localization study of CLEC14A in HUVEC showed that it is mainly 
expressed on the cell membrane [109], which is a desirable property because cell 
surface proteins are easier to target. These collective findings confirm that CLEC14A 
is a novel TEM.  
 
Guanylate binding proteins are the most abundant cellular proteins that belong to the 
GTPase superfamily. Seven members have been discovered in man: hGBP1-7 and all 
members are expressed by endothelial cells and can be induced by IFN-γ [88]. GBP1 
has been closely studied in the last ten years and showed inhibitory effects on 
endothelial cell proliferation, migration and tube formation in response to 
inflammatory cytokines [90, 189]. In contrast, there are few publications on GBP4 
and its expression profile and function remains unknown. Expression analysis in 
tumour / adjacent healthy tissues arrays showed that GBP4 is highly expressed on the 
tumour vascular, in some cases including the tumour cells. It is also of note that the 
expression of GBP4 was detected at a higher frequency in the adjacent healthy tissues 
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compared to CLEC14A. However, the term ‘adjacent healthy’ should be interpreted 
with some caution as the sections are from the same cancer patient. Therefore, when 
GBP4 expression was detected in adjacent healthy tissue, it may be due to the 
proximity of the tumour. In order to resolve the question of expression in healthy 
tissues, we performed a screen on tissue from healthy donors. No GBP4 expression 
was detected.  
 
Since evidence shows that long-term inflammation contributes to the initiation and 
development of cancer [190], we have reason to suggest that the expression of GBP4 
might be induced by inflammatory cytokines within the tumour microenvironment. To 
confirm this hypothesis, Dr. Mura performed a stimulation of IFN-γ or TNF-α on 
HUVEC and the results confirmed that the level of GBP4 indeed was strongly 
elevated in response to either IFN-γ or TNF-α treatment (unpublished data). However 
this result was partially contradictory to the finding from Sturzl’s group in 2007 where 
they reported GBP4 is only activated by IFN-γ but not by TNF-α [88].  
 
In conclusion, GBP4 exhibits specificity to vessels throughout the tumour in a wide 
range of cancers with complete absence in healthy tissues. Although expression of 
GBP4 was detected in other cell types within or adjacent to the tumour, it remains a 
promising TEM that requires further investigation. 
 
IKBKE is a relatively well-studied gene compared with CLEC14A and GBP4. The 
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expression profile of IKBKE suggests it is not a TEM due to its wide expression 
spectrum in healthy tissues. But interestingly, the expression of IKBKE was strongly 
detected in cells adjacent to the endothelium in healthy colon and healthy bladder 
tissues whereas in the case of carcinoma, IKBKE is enriched in the tumour vessels 
especially in the breast carcinomas, for which IKBKE is a validated oncogene [98]. 
Preliminary data showed that IKBKE siRNA knock down showed inhibition of 
HUVEC migration. This implies a role of IKBKE in controlling the transcription of 
genes that might be involved in endothelial cell migration. Although IKBKE is not a 
TEM in terms of its expression profile, it might play a role in mediating the motility 
of endothelial cells.  
 
In Chapter 4, the functional role of CLEC14A in endothelial biology was explored. 
Blocking the transcription of CLEC14A by siRNA resulted in diminished endothelial 
cell migration in wound healing assays and reduced tube formation in a Matrigel 
assay [109]. Work by Rho et al. published simultaneously to our work independently 
confirmed these findings [191]. Interestingly, a similar inhibitory effect on migration 
was observed when either the endothelial specific gene ECSCR [192] or a 
pre-validated TEM Robo4 was knocked down in HUVEC [104], indicating a 
relationship between these endothelial specific genes and endothelial cell motility. 
Such a phenotype was also observed when polyclonal antiserum to CLEC14A was 
added to the assays, which prompted the idea of generating a monoclonal antibody to 
CLEC14A that can inhibit HUVEC migration. Indeed, amongst the five CLEC14A 
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monoclonal antibodies (CRT1-5), CRT3 showed modest but statistically significant 
inhibition in a dose dependent manner. This suggests that CRT3 can be used to 
investigate the effect on angiogenesis in vivo.   
 
It has been shown that filopodia formation was strongly induced by ectopic 
overexpression of CLEC14A in 293T and CHO cells (R. Swain in [109]). As filopodia 
formation is a key feature of sprouting angiogenesis, one may speculate increased 
expression of CLEC14A could lead to an angiogenic phenotype. However, HUVEC 
migration was inhibited by overexpression of CLEC14A. These results suggest the 
expression level of CLEC14A in endothelial cells is critical for its motility. More 
interestingly, the same inhibitory effect was also observed when Robo4 was knocked 
down with siRNA or overexpressed in HUVEC [108]. 
 
Expression of CLEC14A in tumour vasculature suggests a role in pathological 
angiogenesis. However, CLEC14A also plays a role in physiological angiogenesis. 
Others have investigated the role of CLEC14A during zebrafish development.  The 
data showed that CLEC14A expression begins at 5 hpf which coincides with the 
appearance of haemangioblasts [109]. The zebrafish ortholog of CLEC14A was 
previously identified as a putative endothelial specific gene by microarray analysis of 
zebrafish cloche mutants that fail to undergo haematopoesis [193]. Also a recent study 
has shown that CLEC14A (called complement receptor C1qR-like gene) lies 
downstream of the transcription factor Etsrp, a factor required for vasculogenesis and 
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primitive myelopoiesis in the zebrafish [194]. This suggests that Etsrp may regulate 
heamangioblast migration by inducing CLEC14A expression. This is supported by 
data showing CLEC14A expression continues through the stages of development that 
involve angiogenesis. Furthermore, morpholino mediated knockdown of CLEC14A 
disrupts intersomitic vessels which are formed by sprouting angiogenesis from the 
dorsal aorta and this confirmed the role of CLEC14A in angiogenesis. Interestingly 
human CLEC14A mRNA injection rescued the vascular phenotype induced by 
knockdown of CLEC14A.  
 
CLEC14A KO mice showed no defects during development, although Rho et al. 
showed that the mouse ortholog of CLEC14A is expressed in endothelial cells during 
development [191]. This contradicts the observation in CLEC14A knockdown 
zebrafish, however it is likely due to the difference in species. Interestingly, an in vivo 
tumour challenge experiment by others in the group showed a growth delay of a 
subcutaneous Lewis lung carcinoma tumour in the CLEC14A KO mice compared 
with that in WT mice. This suggests CLEC14A may be dispensable in physiological 
angiogenesis in the mouse yet playing an essential role in tumour angiogenesis. It is 
of note that a family member of CLEC14A, endosialin or TEM1 KO mice also 
display normal developmental angiogenesis unless challenged orthotopically with 
colon tumour fragment, in which tumour growth was retarded compared with WT 
[83]. No difference was observed in body weight or fertility between wild type and 




Many factors modulate the endothelial transcriptome in tumours, including hypoxia, 
oxidative stress, activation of growth factors and cytokines as well as low shear stress 
caused by the ill formed vessels within the tumour. Low shear stress and turbulent 
flow have been demonstrated as mechanical factors that regulate endothelial gene 
expression [195, 196]. Endothelial cells express 20000 genes of which 3 percent are 
regulated by shear stress [197]. SAGE analysis of endothelial cells cultured in static 
conditions or shear stress showed a marked differential expression in genes involved 
in cell proliferation, angiogenesis, extracellular matrix and cell-cell adhesion 
molecules and ATP synthesis [198]. Reduced shear stress strongly upregulates 
expression of CLEC14A and Robo4 mRNA in HUVEC cells [109]. In our zebrafish 
work, CLEC14A is expressed until 24 hpf when blood circulation begins. One 
explanation for the loss of CLEC14A at later time points could be that it is down 
regulated by shear stress. This hypothesis would be consistent with increased 
CLEC14A expression in the low flow environment of the tumour endothelium. In 
contrast, GBP4 is upregulated by shear stress at the RNA level in HUVEC (S. Durrant, 
unpublished work). Thus, these findings suggest a link between the induction of 
TEMs and the low shear stress environment that is associated with the tumour 
vasculature.  
 
Lung cancer, as the leading cause of cancer related death, is still lacking a 
well-characterized vascular target. Although CLEC14A showed a high specificity and 
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a wide spectrum in tumours, its expression is low in lung cancer. In Chapter 5, 
expression profiling of lung endothelial cells isolated from NSCLC was performed 
using genomics technologies. A major obstacle that remains in the molecular profiling 
of endothelial cells is the difficulty of obtaining pure endothelial isolates. Previous 
molecular profiling work of lung endothelium was performed in mouse using in vivo 
fluorescent labeling of the vasculature to isolate ECs. In this study, Favre et al. 
isolated ECs from normal mouse lung and used the unpurified lung cells as the control, 
aiming at identifying endothelial specific genes [199]. A similar study was performed 
on colon endothelium which used long SAGE library sequencing to measure gene 
expression [74]. In this study, endothelial cells were isolated from human lung normal 
and tumour samples following downstream work involving deep sequencing and 
microarray technologies. Currently, deep sequencing technology has been intensively 
used in molecular profiling many tissue types and cell populations from different 
species. Yet not many studies have applied such technology to endothelium [200, 201], 
and not in the context of mRNA profiling of endothelial cells from lung cancer to 
identify putative vascular targets. Therefore our data provides novel insights into the 
molecular transcription signatures of endothelial cells isolated from fresh clinical 
samples.  
 
Elevated MMP activity often associates with active angiogenesis and tumour growth 
in cancer [202]. MMP2 and MMP9 have been reported as being overexpressed in 
various solid tumours and have been associated with tumour grade and malignancy 
192 
 
and associated with increased metastasis in lung cancer [202]. In fact, the expression 
of MMP7 and MMP9 were previously found to be significantly upregulated in 
NSCLC compared with that of normal lung and benign lung tumour [203]. The 
MMPs expression profile is consistent with these previous findings and support the 
potential therapeutic use of MMP inhibitors for lung cancer. Deep sequencing data 
also provided a snapshot of a panel of angiogenic associated gene including VEGF-A, 
IL8, Ang2, EPHB2, TEM2, TEM4 and TEM7 being elevated in lung tumour 
endothelium, confirming that tumour angiogenesis is a result of combined effects 
caused by multiple angiogenic factors and receptors.  
 
Differential gene expression analysis of deep sequencing combined with microarray 
of normal and tumour endothelium from multiple lung cancer patients has identified 
13 putative lung TEMs. Six putative lung TEMs including ROS1, STEAP1, BIRC5, 
GJB2, PCDH7 and PROM2 were validated by real-time qPCR and 
immunohistochemistry, displaying endothelial expression on placental and lung 
cancer tissues.  
 
ROS1 belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. 
ROS1 is a proto-oncogene and highly expressed in a variety of tumor cell lines 
[204-208]. Recently chromosomal rearrangement of ROS1 has been detected in a sub 
population of NSCLC patient [209-211]. Despite of intensive studies on ROS1 in lung 




STEAP1 (six-transmembrane epithelial antigen of prostate 1) was the first member of 
a family of metalloreductases identified as cell-surface antigens in prostate tissue [212, 
213]. Its expression is highly increased in prostate, breast, bladder, colon, ovarian 
cancers and in Ewing's sarcoma [214], indicating STEAP1 may function as an 
universal tumor antigen. Alves and colleagues showed that STEAP1 peptides can be 
used to stimulate CD8
+
 T cells in healthy people, enabling them to recognize STEAP1 
expressing tumor cells, suggesting that STEAP1 may be a useful target for cancer 
immunotherapy [215]. Similar to ROS1, research on STEAP1 was predominantly 
focuse on its role in tumour cells. Its expression and function in endothelial cells and 
angiogenesis remains unexplored.  
 
BIRC5 (baculoviral inhibitor of apoptosis repeat-containing 5) or survivin, belongs to 
the family of inhibitors of apoptosis. BIRC5 inhibits caspase activation to regulate 
apoptosis. Disruption of the BIRC5 signaling pathway leads to tumour cell apoptosis 
and growth delay. BIRC5 protein is present in a range of tumour cells and fetal tissues 
but is rarely detectable in healthy tissues [216]. One can speculate that the presence of 
BIRC5 on the lung tumour vasculature could be induced by the stressed endothelial 
cells which are struggling to survive in the abnormal tumour vasculature. 
 
GJB2 (Gap junction beta-2) also known as connexin-26, belongs to the Connexins 
family. Connexins are essential for many physiological processes and embryonic 
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development including the microvasculature. Mutations in connexins can cause 
functional and developmental abnormalities. Defects in GJB2 lead to the most 
common form of congenital deafness [217]. Thus, most GJB2 studies have centered 
on this field and very little is known about GJB2 in association with endothelial cells 
and lung cancer.  
 
PCDH7 and PROM2 are less studied genes compared with other identified targets.  
PCDH7 belongs to the protocadherin gene family, a subfamily of the cadherin 
superfamily. PCDH7 encodes a single transmembrane protein that is thought to 
function in cell-cell recognition and adhesion. PROM2 is a member of the prominin 
family of pentaspan membrane glycoproteins. The limited literature of these two 
targets makes them exceptionally attractive for further characterization.  
 
From a technical point of view, investigation of laser microdissection technology in 
this report has demonstrated several critical points suggesting that such technology is 
not suitable for isolating lung endothelium: 1. Vessel visualization on the slides 
caused RNA degradation. 2. The vessel mural cells were impossible to separate from 
the endothelium and this would compromise the purity of the cell population. 3. 
Frozen normal lung slides showed poor morphology which was due to the cavities in 
the tissue. In contrast, the Ulex-bead isolation approach has been proven an effective 
approach to obtain a pure endothelial population from lung. Because of the significant 





sequencing technology, which is a new technology and the results could be compared 
with microarray data.  
 
The ineffectiveness of the comman treatments for lung cancer prompted the search for 
alternative approaches for NSCLC. Although tyrosine kinase inhibitors of EGFR 
initially showed promising outcome in several trials, resistance was eventually 
developed in all patients [111]. The development of anti-angiogenic drugs such as 
VEGF (receptor) blockers has aroused general interest in the lung tumour vasculature. 
The use of such drugs in treating NSCLC patients has been investigated in early 
clinical trials. However, concerns have arisen from the inefficacy in tumour regression 
and lack of effective biomarkers for patient selection. Thus molecular profiling the 
tumour vasculature in lung cancer will not only enhance our understanding of 
molecules involved in this disease but also may provide biomarkers and targets that 
have therapeutic potential.  
 
Evidence has been presented that vaccination to antigens over-expressed on the 
tumour vasculature holds therapeutic potential [132, 133]. For example, a significant 
delay in tumour growth and increased median survival rate by oral DNA vaccination 
against VEGFR2 has been observed in mice [134-136]. Similar effects were seen 
when mice were immunized with VEGFR1 or VEGFR2 derived peptides [137, 138]. 
In Chapter 6, investigation of a pre-validated TEM Robo4 as a cancer vaccine 
immunogen has been carried out. Robo4 was firstly characterized as a TEM in a wide 
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range of human carcinomas and absent in normal tissues in 2002 [73]. In 2005, 
Sukhatme’s paper confirmed that Robo4 is a TEM in lung, liver and kidney [108]. 
Robo4 was reported to be expressed in mouse adult tissue including lung and brain by 
northern blot [107] however the expression level was not compared to that in tumours. 
A recent study has shown that the tumour vasculature in a mouse melanoma model 
can be imaged by magnetic resonance imaging (MRI) using Robo4 antibody coupled 
nanoparticles [218]. These findings, justify the attempt to induce an anti-Robo4 
antibody response by vaccination and investigate its effect on angiogenesis and 
tumour growth. 
 
Immune tolerance to Robo4 was successfully broken in mice using self-antigen, 
recombinant mouse Robo4 protein. This was the first attempt to induce a specific 
immune response against Robo4 in vivo. Protein immunization tends to induce Ig 
class switching to IgG1 isotype and this isotype is associated with T helper 2-type 
immunity [169]. After immunization, a high level of IgG1 was detected compared to 
other isotypes including IgG2b and IgG3. The subsequent sponge implantation 
experiment exhibited a dramatic anti-angiogenic effect. Thus, the immune response to 
Robo4 and most likely the Robo4-specifc antibody, interrupted the development of 
new blood vessels within the implanted sponges. Delay in Lewis lung carcinoma 
growth and tumour vascular damage was presumably the result of Robo4 antibodies 
that attack the tumour endothelium by mediating antibody dependent cell-mediated 
cytotoxicity. During this process, effector cells including monocytes or NK cells were 
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directed to the tumour vasculature by crosslinking of their Fc receptors to the induced 
immunoglobulin, which subsequently led to apoptosis of the target cells [219]. 
Similar effects have been demonstrated for B cell expressed CD20 as the target 
antigen, in which monoclonal IgG1 antibody caused B cell depletion by interactions 
with FcγRIII [220], expressed on natural killer cells [221].  
 
Instead of using Freunds adjuvant, conjugation of Robo4 to a foreign protein CGG 
resulted in a strong anti-Robo4 response and retarded tumour growth. This strategy 
overcame the absence of Robo4 specific T cell help due to central tolerance. In 
addition, pre-existing immunity to the CGG leads to rapid B cell activation through 
recruitment of help from CGG-specific memory T cells [176]. Hence conjugating 
Robo4 to carrier proteins routinely used in human conjugate vaccines such as tetanus 
or diphtheria toxoid, may produce a vaccine that would rapidly develop protective 
antibody responses. 
 
The promise of anti-vascular immunisation in a clinical setting has been shown by 
tumour regression in some patients with brain tumours inoculated with 
glutaraldehyde-fixed human umbilical vein endothelial cells (HUVECs) which had 
been cultured for a number of passages prior to use. These patients developed 
HUVEC-specific antibodies which, although the antibodies were not characterized, 
may have recognized Robo4. Robo4 is expressed by HUVEC in tissue culture due to 
the lack of fluid shear stress [109]. The use of whole endothelial cell vaccines has the 
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advantage of presenting a set of identified or unknown targets to the immune system. 
However because of the same property, the expression or presentation level of the 
‘real targets’ might be masked to a certain extent by other unrelated antigens.  
 
A key consideration for vascular targeting strategies is the effect these treatments 
might have on the normal vasculature. While in the HUVEC-immunised patients no 
adverse effects were observed, gastrointestinal bleeding was observed in a pancreatic 
cancer trial using vaccination to peptides from VEGFR-1 [222]. Given the importance 
of VEGFR signalling in tumour angiogenesis, and the emergence of VEGF targeted 
therapies, such as bevacizumab, as approved anti-cancer therapies, significant effort 
has gone into immune targeting of this signalling pathway (reviewed in [166]). 
Though effective, in some cases wound healing was negatively affected. Indeed 
prolonged use of VEGF-based anti-angiogenics has highlighted a role for VEGF 
signalling in the maintenance of the normal vasculature [223].  
 
Delta-like 4 is an endothelial expressed protein induced by hypoxia [224], it also 
plays a critical role in angiogenesis through its activation of Notch signalling [225]. 
DLL4 is expressed on the sprouting tip cells [226] and on vessels in a number of 
tumours, including breast cancer, colon cancer and glioblastoma [227-229], making it 
an attractive tumour vascular target. Vaccination against DLL4 using a DNA-based 
approach has shown anti-tumour effects [146], but its suitability as a target has been 
called into question as prolonged blockade of DLL4 signalling was found to actually 
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induce vascular neoplasms [230]. Vaccination of Robo4, as reported here shows there 
were no obvious delays in wound healing after sponge implantation, and histological 
analysis of heart, lung, kidney, spleen, brain or liver showed no differences between 
control and Robo4 vaccinated mice, which indicates that targeting Robo4 may be a 
safe immunotherapeutic intervention. It is worth mentioning that vaccination against 
self-antigen does not normally induce a permanent response. A recent study showed 
that antibody titres dropped to the baseline level seven months after the vaccination of 
EDB-fibronectin with Freund’s adjuvant [231]. 
 
TEM expression varies in different tumour types [109]. The extra-domain B of 
fibronectin is expressed in a high percentage of certain brain tumours such as 
meningiomas and in a half of lung cancers, but in less than a quarter of the breast, 
colon and pancreatic cancers examined [232]. In an experimental mouse system this 
antigen was also successfully used to reduce tumour growth when used as an 
immunogen, with no obvious adverse effects [67]. But the applicability of this, and 
indeed any other TEM, as a therapeutic target will be limited to those tumour types 
found expressing it. Robo4 was found expressed in over 60% of pancreatic, bladder, 
prostate, stomach, lung and kidney cancer, and in a lower percentage of a number of 
other common tumour types, suggesting that a Robo4 targeted vaccination strategy 
may be effective in a variety of cancers, including cancer of the pancreas and lung 
which remain difficult to treat [233, 234].  Variation in TEM expression in different 
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tumour types justifies the concurrent study of several as targets for novel anti-cancer 
therapies.  
 
Different strategies of immunotherapy have emerged to target the tumour vasculature. 
Abengozar et al. recently showed that EphrinB2 antibody treatment alone inhibited 
VEGF-mediated angiogenesis in a Matrigel plug assay and caused reduction in 
tumour vascular density and growth delay in a xenografted tumor model [235]. 
Photosensitiser conjugated antibody to EDB domain of fibronectin selectively 
disrupted tumour vasculature and led to complete tumour ablation in both mouse and 
human xenograft models [236]. Modified T cells such as the use of engineered 
chimeric antigen receptor (CAR) have also been investigated in vascular targeting. 
Chinnasamy and colleagues showed that transferred VEGFR2 CAR infected T cells 
resulted in tumour growth inhibition in multiple tumour models [66].  
 
Compared to the current variety of immunotherapy in vascular targeting, vaccination 
is a practical approach that has clear advantages. Because of the simplicity, 
vaccination is considered more cost-effective compared to other immunotherapeutic 
approaches such as antibody conjugates or engineered T cells which are labor 
intensive. Secondly, vaccination of TEMs harnesses the body’s own immune system 
to produce antibodies with anti-tumour effects which is less arduous for the patient 
than current popular approaches involving repeated infusion of therapeutic antibody. 
Depending on the type of delivery, it is possible to generate not only a humoral 
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response, but also cytotoxic T cell responses which can augment the anti-tumour 
effect [237].   
 
The function of Robo4 in endothelial cells has been studied over the last ten years but 
remains controversial. Proposed functions fall broadly into two categories and have 
been reviewed in Legg et al. [102]. (i) A pro-filopodia, pro-migratory, pro-angiogenic 
role and (ii) an anti-migratory stabilization of the existing vasculature role. Thus, in 
support of a pro-angiogenic function, Sheldon et al. showed that Robo4 knockdown 
by siRNA inhibited endothelial cell migration, tube formation and overexpression of 
Robo4 strongly induced filopodia in endothelial cells [104]. Kaur et al. performed a 
modified Boyden chamber assay on Robo4 knockdown cells and found a similar 
effect [238]. In contrast, work originating primarily from the laboratory of Dean Li 
has used knockout mice to show that Robo4 stabilised the vasculature in for example 
retinal injury. Thus, in mouse models of retinal and choroidal vascular disease, Robo4 
knockout mice showed higher vascular leakage and permeability in response to 
exogenously administered VEGF [239]. It is of interest that the endothelial 
transmembrane protein Unc5B has recently been shown to be a ligand for Robo4 
[240]. When Robo4 binds Unc5B on an adjacent endothelial cell, Unc5B releases an 
anti-migratory stabilizing signal. 
 
The apparently conflicting observations described above could be reconciled if the 
function of Robo4 were context dependant. We propose the working hypothesis that 
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in a tip cell, unligated Robo4 stimulates filopodia formation and migration, whereas in 
a phalanx cell it binds Unc5B on adjacent phalanx cells leading to an overall 
stabilization of the vasculature. Finally, the identification of Unc5B as a ligand of 
Robo4 could explain the inhibitory, anti-angiogenic effects of the extracellular domain 
of Robo4 previously described [106]. Unc5B is highly expressed on endothelial tip 




















1. Vandenbroucke, E., et al., Regulation of endothelial junctional permeability. Ann N Y Acad Sci, 
2008. 1123: p. 134-45. 
2. Minshall, R.D. and A.B. Malik, Transport across the endothelium: regulation of endothelial 
permeability. Handb Exp Pharmacol, 2006(176 Pt 1): p. 107-44. 
3. Sato, Y. and D.B. Rifkin, Inhibition of endothelial cell movement by pericytes and smooth 
muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin 
during co-culture. J Cell Biol, 1989. 109(1): p. 309-15. 
4. Vanhoutte, P.M., et al., Endothelial dysfunction and vascular disease. Acta Physiol (Oxf), 2009. 
196(2): p. 193-222. 
5. Carmeliet, P. and R.K. Jain, Molecular mechanisms and clinical applications of angiogenesis. 
Nature, 2011. 473(7347): p. 298-307. 
6. Chung, A.S. and N. Ferrara, Developmental and pathological angiogenesis. Annu Rev Cell Dev 
Dev Biol, 2011. 27: p. 563-84. 
7. Gerhardt, H., et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J 
Cell Biol, 2003. 161(6): p. 1163-77. 
8. Mazzone, M., et al., Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits 
metastasis via endothelial normalization. Cell, 2009. 136(5): p. 839-51. 
9. Risau, W., Mechanisms of angiogenesis. Nature, 1997. 386(6626): p. 671-4. 
10. Swift, M.R. and B.M. Weinstein, Arterial-venous specification during development. Circ Res, 
2009. 104(5): p. 576-88. 
11. Adams, R.H. and K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis. Nat 
Nat Rev Mol Cell Biol, 2007. 8(6): p. 464-78. 
12. Jain, R.K., Molecular regulation of vessel maturation. Nat Med, 2003. 9(6): p. 685-93. 
13. Potente, M., H. Gerhardt, and P. Carmeliet, Basic and therapeutic aspects of angiogenesis. Cell, 
2011. 146(6): p. 873-87. 
14. Mignatti, P. and D.B. Rifkin, Plasminogen activators and matrix metalloproteinases in 
angiogenesis. Enzyme Protein, 1996. 49(1-3): p. 117-37. 
15. Moses, M.A., The regulation of neovascularization of matrix metalloproteinases and their 
inhibitors. Stem Cells, 1997. 15(3): p. 180-9. 
16. Lamalice, L., F. Le Boeuf, and J. Huot, Endothelial cell migration during angiogenesis. Circ 
Res, 2007. 100(6): p. 782-94. 
17. Makanya, A.N., R. Hlushchuk, and V.G. Djonov, Intussusceptive angiogenesis and its role in 
vascular morphogenesis, patterning, and remodeling. Angiogenesis, 2009. 12(2): p. 113-23. 
18. Burri, P.H., R. Hlushchuk, and V. Djonov, Intussusceptive angiogenesis: its emergence, its 
characteristics, and its significance. Dev Dyn, 2004. 231(3): p. 474-88. 
19. Fang, S. and P. Salven, Stem cells in tumor angiogenesis. J Mol Cell Cardiol, 2011. 50(2): p. 
290-5. 
20. AMP-Lab, http://www.amplab.de/angiogenesis.html: p. Assay of angiogenesis. 
21. Gimbrone, M.A., Jr., et al., Tumor growth and neovascularization: an experimental model using 
using the rabbit cornea. J Natl Cancer Inst, 1974. 52(2): p. 413-27. 
22. Heath, V.L. and R. Bicknell, Anticancer strategies involving the vasculature. Nat Rev Clin 
205 
 
Oncol, 2009. 6(7): p. 395-404. 
23. Chung, A.S., J. Lee, and N. Ferrara, Targeting the tumour vasculature: insights from 
physiological angiogenesis. Nat Rev Cancer, 2010. 10(7): p. 505-14. 
24. Nussenbaum, F. and I.M. Herman, Tumor angiogenesis: insights and innovations. J Oncol, 
2010. 2010: p. 132641. 
25. Folkman, J., Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971. 285(21): p. 
1182-6. 
26. Davidoff, A.M. and J.J. Kandel, Antiangiogenic therapy for the treatment of pediatric solid 
malignancies. Semin Pediatr Surg, 2004. 13(1): p. 53-60. 
27. Kerbel, R. and J. Folkman, Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 
2002. 2(10): p. 727-39. 
28. Ferrara, N., Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol, 2009. 29(6): p. 
789-91. 
29. Kim, K.J., et al., Inhibition of vascular endothelial growth factor-induced angiogenesis 
suppresses tumour growth in vivo. Nature, 1993. 362(6423): p. 841-4. 
30. Ellis, L.M. and D.J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat 
Rev Cancer, 2008. 8(8): p. 579-91. 
31. Ferrara, N. and T. Davis-Smyth, The biology of vascular endothelial growth factor. Endocr Rev, 
1997. 18(1): p. 4-25. 
32. Hanahan, D. and J. Folkman, Patterns and emerging mechanisms of the angiogenic switch 
during tumorigenesis. Cell, 1996. 86(3): p. 353-64. 
33. Ferrara, N., VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2002. 2(10): 
p. 795-803. 
34. Carmeliet, P., et al., Abnormal blood vessel development and lethality in embryos lacking a 
single VEGF allele. Nature, 1996. 380(6573): p. 435-9. 
35. Ferrara, N., et al., Heterozygous embryonic lethality induced by targeted inactivation of the 
VEGF gene. Nature, 1996. 380(6573): p. 439-42. 
36. Lohela, M., et al., VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. 
Curr Opin Cell Biol, 2009. 21(2): p. 154-65. 
37. Liu, Y., et al., Hypoxia regulates vascular endothelial growth factor gene expression in 
endothelial cells. Identification of a 5' enhancer. Circ Res, 1995. 77(3): p. 638-43. 
38. Alitalo, K. and P. Carmeliet, Molecular mechanisms of lymphangiogenesis in health and 
disease. Cancer Cell, 2002. 1(3): p. 219-27. 
39. Hirakawa, S., et al., VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and 
promotes lymphatic metastasis. J Exp Med, 2005. 201(7): p. 1089-99. 
40. Waltenberger, J., et al., Different signal transduction properties of KDR and Flt1, two receptors 
for vascular endothelial growth factor. J Biol Chem, 1994. 269(43): p. 26988-95. 
41. Seetharam, L., et al., A unique signal transduction from FLT tyrosine kinase, a receptor for 
vascular endothelial growth factor VEGF. Oncogene, 1995. 10(1): p. 135-47. 
42. Hiratsuka, S., et al., Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor 
receptor-1) in pathological angiogenesis. Cancer Res, 2001. 61(3): p. 1207-13. 
43. Hiratsuka, S., et al., MMP9 induction by vascular endothelial growth factor receptor-1 is 
involved in lung-specific metastasis. Cancer Cell, 2002. 2(4): p. 289-300. 
44. Kaplan, R.N., et al., VEGFR1-positive haematopoietic bone marrow progenitors initiate the 
206 
 
pre-metastatic niche. Nature, 2005. 438(7069): p. 820-7. 
45. Karkkainen, M.J., et al., Vascular endothelial growth factor C is required for sprouting of the 
first lymphatic vessels from embryonic veins. Nat Immunol, 2004. 5(1): p. 74-80. 
46. Karkkainen, M.J., et al., Missense mutations interfere with VEGFR-3 signalling in primary 
lymphoedema. Nat Genet, 2000. 25(2): p. 153-9. 
47. Ogawa, S., et al., A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), 
preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without 
heparin-binding domain. J Biol Chem, 1998. 273(47): p. 31273-82. 
48. Kiba, A., et al., VEGFR-2-specific ligand VEGF-E induces non-edematous 
hyper-vascularization in mice. Biochem Biophys Res Commun, 2003. 301(2): p. 371-7. 
49. Zheng, Y., et al., Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without 
significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc 
Biol, 2006. 26(9): p. 2019-26. 
50. William D. Figg, J.F., Angiogenesis - An Integrative Approach From Science to Medicine. 2008: 
p. 90. 
51. Ferrara, N., VEGF as a therapeutic target in cancer. Oncology, 2005. 69 Suppl 3: p. 11-6. 
52. Kazazi-Hyseni, F., J.H. Beijnen, and J.H. Schellens, Bevacizumab. Oncologist, 2010. 15(8): p. 
819-25. 
53. Raja, M.S., et al., Ranibizumab treatment for neovascular age-related macular degeneration in 
patients with good baseline visual acuity (better than 6/12): 12-month outcomes. Br J 
Ophthalmol, 2010. 94(11): p. 1543-5. 
54. Pieramici, D.J. and R.L. Avery, Ranibizumab: treatment in patients with neovascular 
age-related macular degeneration. Expert Opin Biol Ther, 2006. 6(11): p. 1237-45. 
55. Friberg, T.R., et al., Pegaptanib sodium as maintenance therapy in neovascular age-related 
macular degeneration: the LEVEL study. Br J Ophthalmol, 2010. 94(12): p. 1611-7. 
56. Hernandez-Pastor, L.J., et al., Cost-effectiveness of ranibizumab compared with pegaptanib in 
neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol, 2010. 
248(4): p. 467-76. 
57. Crawford, Y. and N. Ferrara, Tumor and stromal pathways mediating refractoriness/resistance 
to anti-angiogenic therapies. Trends Pharmacol Sci, 2009. 30(12): p. 624-30. 
58. Claes, A. and W. Leenders, Vessel normalization by VEGF inhibition. A complex story. Cancer 
Biol Ther, 2008. 7(7): p. 1014-6. 
59. Carmeliet, P. and R.K. Jain, Principles and mechanisms of vessel normalization for cancer and 
other angiogenic diseases. Nat Rev Drug Discov, 2011. 10(6): p. 417-27. 
60. Ebos, J.M., et al., Accelerated metastasis after short-term treatment with a potent inhibitor of 
tumor angiogenesis. Cancer Cell, 2009. 15(3): p. 232-9. 
61. Paez-Ribes, M., et al., Antiangiogenic therapy elicits malignant progression of tumors to 
increased local invasion and distant metastasis. Cancer Cell, 2009. 15(3): p. 220-31. 
62. Loges, S., et al., Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis 
revisited. Cancer Cell, 2009. 15(3): p. 167-70. 
63. Burrows, F.J. and P.E. Thorpe, Eradication of large solid tumors in mice with an immunotoxin 
directed against tumor vasculature. Proc Natl Acad Sci U S A, 1993. 90(19): p. 8996-9000. 
64. Huang, X., et al., Tumor infarction in mice by antibody-directed targeting of tissue factor to 
tumor vasculature. Science, 1997. 275(5299): p. 547-50. 
207 
 
65. He, J., et al., Antiphosphatidylserine antibody combined with irradiation damages tumor blood 
vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res, 2009. 
15(22): p. 6871-80. 
66. Chinnasamy, D., et al., Gene therapy using genetically modified lymphocytes targeting 
VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest, 2010. 
120(11): p. 3953-68. 
67. Huijbers, E.J., et al., Vaccination against the extra domain-B of fibronectin as a novel tumor 
therapy. FASEB J, 2010. 24(11): p. 4535-44. 
68. Siemann, D.W., The unique characteristics of tumor vasculature and preclinical evidence for its 
its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev, 2011. 37(1): p. 
63-74. 
69. Dachs, G.U. and D.J. Chaplin, Microenvironmental control of gene expression: implications for 
for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol, 1998. 8(3): p. 
208-16. 
70. Helmlinger, G., et al., Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution 
measurements reveal a lack of correlation. Nat Med, 1997. 3(2): p. 177-82. 
71. Padera, T.P., et al., Pathology: cancer cells compress intratumour vessels. Nature, 2004. 
427(6976): p. 695. 
72. Bicknell, R. and A.L. Harris, Novel angiogenic signaling pathways and vascular targets. Annu 
Rev Pharmacol Toxicol, 2004. 44: p. 219-38. 
73. Huminiecki, L., et al., Magic roundabout is a new member of the roundabout receptor family 
that is endothelial specific and expressed at sites of active angiogenesis. Genomics, 2002. 79(4): 
p. 547-52. 
74. St Croix, B., et al., Genes expressed in human tumor endothelium. Science, 2000. 289(5482): p. 
1197-202. 
75. Ho, M., et al., Identification of endothelial cell genes by combined database mining and 
microarray analysis. Physiol Genomics, 2003. 13(3): p. 249-62. 
76. Oh, P., et al., Subtractive proteomic mapping of the endothelial surface in lung and solid 
tumours for tissue-specific therapy. Nature, 2004. 429(6992): p. 629-35. 
77. Huminiecki, L. and R. Bicknell, In silico cloning of novel endothelial-specific genes. Genome 
Res, 2000. 10(11): p. 1796-806. 
78. Herbert, J.M., et al., A novel method of differential gene expression analysis using multiple 
cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics, 2008. 
2008. 9: p. 153. 
79. Neri, D. and R. Bicknell, Tumour vascular targeting. Nat Rev Cancer, 2005. 5(6): p. 436-46. 
80. Zelensky, A.N. and J.E. Gready, The C-type lectin-like domain superfamily. FEBS J, 2005. 
272(24): p. 6179-217. 
81. Drickamer, K., C-type lectin-like domains. Curr Opin Struct Biol, 1999. 9(5): p. 585-90. 
82. Cambi, A. and C. Figdor, Necrosis: C-type lectins sense cell death. Curr Biol, 2009. 19(9): p. 
R375-8. 
83. Nanda, A., et al., Tumor endothelial marker 1 (Tem1) functions in the growth and progression of 
abdominal tumors. Proc Natl Acad Sci U S A, 2006. 103(9): p. 3351-6. 
84. Greenlee, M.C., S.A. Sullivan, and S.S. Bohlson, CD93 and related family members: their role 
in innate immunity. Curr Drug Targets, 2008. 9(2): p. 130-8. 
208 
 
85. Maruyama, I., C.E. Bell, and P.W. Majerus, Thrombomodulin is found on endothelium of 
arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J 
Cell Biol, 1985. 101(2): p. 363-71. 
86. Esmon, C.T., Thrombomodulin as a model of molecular mechanisms that modulate protease 
specificity and function at the vessel surface. FASEB J, 1995. 9(10): p. 946-55. 
87. McCormick, S.M., et al., DNA microarray reveals changes in gene expression of shear stressed 
human umbilical vein endothelial cells. Proc Natl Acad Sci U S A, 2001. 98(16): p. 8955-60. 
88. Tripal, P., et al., Unique features of different members of the human guanylate-binding protein 
family. J Interferon Cytokine Res, 2007. 27(1): p. 44-52. 
89. Naschberger, E., et al., Nuclear factor-kappaB motif and interferon-alpha-stimulated response 
element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory 
cytokines in endothelial cells. Biochem J, 2004. 379(Pt 2): p. 409-20. 
90. Guenzi, E., et al., The helical domain of GBP-1 mediates the inhibition of endothelial cell 
proliferation by inflammatory cytokines. EMBO J, 2001. 20(20): p. 5568-77. 
91. Lipnik, K., et al., Interferon gamma-induced human guanylate binding protein 1 inhibits 
mammary tumor growth in mice. Mol Med. 16(5-6): p. 177-87. 
92. Guimaraes, D.P., et al., Interferon-inducible guanylate binding protein (GBP)-2: a novel 
p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer, 2009. 
124(2): p. 272-9. 
93. Fellenberg, F., et al., GBP-5 splicing variants: New guanylate-binding proteins with 
tumor-associated expression and antigenicity. J Invest Dermatol, 2004. 122(6): p. 1510-7. 
94. Hayden, M.S. and S. Ghosh, Signaling to NF-kappaB. Genes Dev, 2004. 18(18): p. 2195-224. 
95. Tenoever, B.R., et al., Multiple functions of the IKK-related kinase IKKepsilon in 
interferon-mediated antiviral immunity. Science, 2007. 315(5816): p. 1274-8. 
96. Fitzgerald, K.A., et al., IKKepsilon and TBK1 are essential components of the IRF3 signaling 
pathway. Nat Immunol, 2003. 4(5): p. 491-6. 
97. Sharma, S., et al., Triggering the interferon antiviral response through an IKK-related pathway. 
Science, 2003. 300(5622): p. 1148-51. 
98. Boehm, J.S., et al., Integrative genomic approaches identify IKBKE as a breast cancer 
oncogene. Cell, 2007. 129(6): p. 1065-79. 
99. Hutti, J.E., et al., Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene 
oncogene IKKepsilon promotes cell transformation. Mol Cell, 2009. 34(4): p. 461-72. 
100. Guo, J.P., et al., Deregulation of IKBKE is associated with tumor progression, poor prognosis, 
and cisplatin resistance in ovarian cancer. Am J Pathol, 2009. 175(1): p. 324-33. 
101. Kidd, T., et al., Roundabout controls axon crossing of the CNS midline and defines a novel 
subfamily of evolutionarily conserved guidance receptors. Cell, 1998. 92(2): p. 205-15. 
102. Legg, J.A., et al., Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell 
migration. Angiogenesis, 2008. 11(1): p. 13-21. 
103. Zhuang, X., et al., Shear stress, tip cells and regulators of endothelial migration. Biochem Soc 
Trans, 2011. 39(6): p. 1571-5. 
104. Sheldon, H., et al., Active involvement of Robo1 and Robo4 in filopodia formation and 
endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. 
FASEB J, 2009. 23(2): p. 513-22. 
105. Kaur, S., et al., Silencing of directional migration in roundabout4 knockdown endothelial cells. 
209 
 
BMC Cell Biol, 2008. 9: p. 61. 
106. Suchting, S., et al., Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell 
migration. FASEB J, 2005. 19(1): p. 121-3. 
107. Park, K.W., et al., Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev 
Dev Biol, 2003. 261(1): p. 251-67. 
108. Seth, P., et al., Magic roundabout, a tumor endothelial marker: expression and signaling. 
Biochem Biophys Res Commun, 2005. 332(2): p. 533-41. 
109. Mura, M., et al., Identification and angiogenic role of the novel tumor endothelial marker 
CLEC14A. Oncogene, 2012. 31(3): p. 293-305. 
110. Lanza, K.S.B.A.H.S.G.M., MR Angiogenesis Imaging with Robo4- versus αvbeta3- targeted 
Nanoparticles in the B16/F10 Mouse Melanoma Model. 2010. 
111. Lovly, C.M. and D.P. Carbone, Lung cancer in 2010: One size does not fit all. Nat Rev Clin 
Oncol, 2011. 8(2): p. 68-70. 
112. Gimbrone, M.A., Jr., R.S. Cotran, and J. Folkman, Human vascular endothelial cells in culture. 
Growth and DNA synthesis. J Cell Biol, 1974. 60(3): p. 673-84. 
113. Jaffe, E.A., et al., Culture of human endothelial cells derived from umbilical veins. 
Identification by morphologic and immunologic criteria. J Clin Invest, 1973. 52(11): p. 
2745-56. 
114. Durr, E., et al., Direct proteomic mapping of the lung microvascular endothelial cell surface in 
vivo and in cell culture. Nat Biotechnol, 2004. 22(8): p. 985-92. 
115. Kaneko, T., et al., Gene expression analysis of immunostained endothelial cells isolated from 
formaldehyde-fixated paraffin embedded tumors using laser capture microdissection--a 
technical report. Microsc Res Tech, 2009. 72(12): p. 908-12. 
116. Kinnecom, K. and J.S. Pachter, Selective capture of endothelial and perivascular cells from 
brain microvessels using laser capture microdissection. Brain Res Brain Res Protoc, 2005. 
16(1-3): p. 1-9. 
117. Cunnea, P., et al., Gene expression analysis of the microvascular compartment in multiple 
sclerosis using laser microdissected blood vessels. Acta Neuropathol, 2010. 119(5): p. 601-15. 
118. Hormia, M., V.P. Lehto, and I. Virtanen, Identification of UEA I-binding surface glycoproteins 
of cultured human endothelial cells. Cell Biol Int Rep, 1983. 7(6): p. 467-75. 
119. Holthofer, H., et al., Ulex europaeus I lectin as a marker for vascular endothelium in human 
tissues. Lab Invest, 1982. 47(1): p. 60-6. 
120. Cha, M.S., D.K. Rah, and K.H. Lee, Isolation and pure culture of microvascular endothelial 
cells from the fetal skin. Yonsei Med J, 1996. 37(3): p. 186-93. 
121. Grimwood, J., R. Bicknell, and M.C. Rees, The isolation, characterization and culture of 
human decidual endothelium. Hum Reprod, 1995. 10(8): p. 2142-8. 
122. Jackson, C.J., et al., Binding of human endothelium to Ulex europaeus I-coated Dynabeads: 
application to the isolation of microvascular endothelium. J Cell Sci, 1990. 96 ( Pt 2): p. 
257-62. 
123. Rafii, S., et al., Isolation and characterization of human bone marrow microvascular 
endothelial cells: hematopoietic progenitor cell adhesion. Blood, 1994. 84(1): p. 10-9. 
124. Schatz, F., et al., Human endometrial endothelial cells: isolation, characterization, and 
inflammatory-mediated expression of tissue factor and type 1 plasminogen activator inhibitor. 
Biol Reprod, 2000. 62(3): p. 691-7. 
210 
 
125. Rohrbeck, A. and J. Borlak, Cancer genomics identifies regulatory gene networks associated 
with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1. PLoS 
PLoS One, 2009. 4(10): p. e7315. 
126. Slevin, M., et al., Identification of a 'snapshot' of co-expressed angiogenic markers in 
laser-dissected vessels from unstable carotid plaques with targeted arrays. J Vasc Res, 2010. 
47(4): p. 323-35. 
127. Buckanovich, R.J., et al., Use of immuno-LCM to identify the in situ expression profile of 
cellular constituents of the tumor microenvironment. Cancer Biol Ther, 2006. 5(6): p. 635-42. 
128. Metzker, M.L., Sequencing technologies - the next generation. Nat Rev Genet, 2010. 11(1): p. 
31-46. 
129. Tavakoli, J. and J.B. Aragon-Ching, Mechanisms of drug resistance to vascular endothelial 
growth factor (VEGF) inhibitors. Anticancer Agents Med Chem, 2010. 10(8): p. 593-600. 
130. Cheever, M.A. and C.S. Higano, PROVENGE (Sipuleucel-T) in prostate cancer: the first 
FDA-approved therapeutic cancer vaccine. Clin Cancer Res, 2011. 17(11): p. 3520-6. 
131. Abul K. Abbas, A.H.L., Basic Immunology - Functons and Disorers of the Immune System. 
2007: p. 179-180. 
132. Wada, S., et al., Rationale for antiangiogenic cancer therapy with vaccination using epitope 
peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res, 2005. 
65(11): p. 4939-46. 
133. Zhou, H., et al., T cell-mediated suppression of angiogenesis results in tumor protective 
immunity. Blood, 2005. 106(6): p. 2026-32. 
134. Petrovan, R.J., et al., DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL 
LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2007. 27(5): p. 1095-100. 
135. Reisfeld, R.A., et al., DNA vaccines designed to inhibit tumor growth by suppression of 
angiogenesis. Int Arch Allergy Immunol, 2004. 133(3): p. 295-304. 
136. Reisfeld, R.A., et al., DNA vaccines suppress tumor growth and metastases by the induction of 
anti-angiogenesis. Immunol Rev, 2004. 199: p. 181-90. 
137. Ishizaki, H., et al., Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope 
peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res, 
2006. 12(19): p. 5841-9. 
138. Dong, Y., et al., Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 
that can inhibit angiogenesis and tumor growth. J Immunother, 2006. 29(1): p. 32-40. 
139. Lyons, J.M., 3rd, et al., The role of VEGF pathways in human physiologic and pathologic 
angiogenesis. J Surg Res, 2010. 159(1): p. 517-27. 
140. He, Q.M., et al., Inhibition of tumor growth with a vaccine based on xenogeneic homologous 
fibroblast growth factor receptor-1 in mice. J Biol Chem, 2003. 278(24): p. 21831-6. 
141. Ramage, J.M., et al., Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific 
to the endothelial antigen Tie-2. Int J Cancer, 2004. 110(2): p. 245-50. 
142. Lee, S.H., et al., Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. 
Cancer Immunol Immunother, 2006. 55(12): p. 1565-74. 
143. Lou, Y.Y., et al., Immunogene therapy of tumors with a vaccine based on the ligand-binding 
domain of chicken homologous integrin beta3. Immunol Invest, 2002. 31(1): p. 51-69. 
144. Holmgren, L., et al., A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses 
tumor growth. Proc Natl Acad Sci U S A, 2006. 103(24): p. 9208-13. 
211 
 
145. Wood, L.M., et al., Targeting tumor vasculature with novel Listeria-based vaccines directed 
against CD105. Cancer Immunol Immunother, 2011. 60(7): p. 931-42. 
146. Haller, B.K., et al., Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell 
antigen delta-like ligand 4 in mammary carcinoma. Oncogene, 2010. 29(30): p. 4276-86. 
147. Stura E.A., F.G.G., Wilson I.A, Crystallization of Antibodies and Antibody-Antigen Complexes. 
Immunomethods, 1993. 3: p. 164-179. 
148. Dwyer, M.A., et al., Expression and characterization of a DNase I-Fc fusion enzyme. J Biol 
Chem, 1999. 274(14): p. 9738-43. 
149. Trapnell, C., L. Pachter, and S.L. Salzberg, TopHat: discovering splice junctions with RNA-Seq. 
Bioinformatics, 2009. 25(9): p. 1105-11. 
150. Li, H., et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics, 2009. 25(16): 
25(16): p. 2078-9. 
151. Anders, S. HTSeq: Analysing high-throughput sequencing data with Python.  2010; Available 
from: http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html. 
152. Anders, S. and W. Huber, Differential expression analysis for sequence count data. Genome 
Biol, 2010. 11(10): p. R106. 
153. Attia, M.A. and D.W. Weiss, Immunology of spontaneous mammary carcinomas in mice. V. 
Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor 
virus. Cancer Res, 1966. 26(8): p. 1787-800. 
154. Garside, P., et al., Visualization of specific B and T lymphocyte interactions in the lymph node. 
Science, 1998. 281(5373): p. 96-9. 
155. Andersen, C.L., J.L. Jensen, and T.F. Orntoft, Normalization of real-time quantitative reverse 
transcription-PCR data: a model-based variance estimation approach to identify genes suited 
for normalization, applied to bladder and colon cancer data sets. Cancer Res, 2004. 64(15): p. 
5245-50. 
156. Jacobs, J.P., C.M. Jones, and J.P. Baille, Characteristics of a human diploid cell designated 
MRC-5. Nature, 1970. 227(5254): p. 168-70. 
157. Verissimo, A.R., et al., Functionally defining the endothelial transcriptome, from Robo4 to 
ECSCR. Biochem Soc Trans, 2009. 37(Pt 6): p. 1214-7. 
158. Taraboletti, G. and R. Giavazzi, Modelling approaches for angiogenesis. Eur J Cancer, 2004. 
40(6): p. 881-9. 
159. Liang, C.C., A.Y. Park, and J.L. Guan, In vitro scratch assay: a convenient and inexpensive 
method for analysis of cell migration in vitro. Nat Protoc, 2007. 2(2): p. 329-33. 
160. Lloyd, K.C., A knockout mouse resource for the biomedical research community. Ann N Y Acad 
Acad Sci, 2011. 1245(1): p. 24-6. 
161. Clement-Ziza, M., et al., Stabilization of RNA during laser capture microdissection by 
performing experiments under argon atmosphere or using ethanol as a solvent in staining 
solutions. RNA, 2008. 14(12): p. 2698-704. 
162. Fleige, S., et al., Comparison of relative mRNA quantification models and the impact of RNA 
integrity in quantitative real-time RT-PCR. Biotechnol Lett, 2006. 28(19): p. 1601-13. 
163. Fleige, S. and M.W. Pfaffl, RNA integrity and the effect on the real-time qRT-PCR performance. 
Mol Aspects Med, 2006. 27(2-3): p. 126-39. 
164. Sottile, J., Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta, 2004. 
1654(1): p. 13-22. 
212 
 
165. Wang, D., J.C. Anderson, and C.L. Gladson, The role of the extracellular matrix in 
angiogenesis in malignant glioma tumors. Brain Pathol, 2005. 15(4): p. 318-26. 
166. Matejuk, A., et al., Vaccines targeting the neovasculature of tumors. Vasc Cell, 2011. 3(1): p. 7. 
167. Grone, J., et al., Robo1/Robo4: differential expression of angiogenic markers in colorectal 
cancer. Oncol Rep, 2006. 15(6): p. 1437-43. 
168. Marlow, R., et al., Vascular Robo4 restricts proangiogenic VEGF signaling in breast. Proc Natl 
Acad Sci U S A, 2010. 107(23): p. 10520-5. 
169. Toellner, K.M., et al., T helper 1 (Th1) and Th2 characteristics start to develop during T cell 
priming and are associated with an immediate ability to induce immunoglobulin class switching. 
J Exp Med, 1998. 187(8): p. 1193-204. 
170. Plunkett, M.L. and J.A. Hailey, An in vivo quantitative angiogenesis model using tumor cells 
entrapped in alginate. Lab Invest, 1990. 62(4): p. 510-7. 
171. Dellian, M., et al., Quantitation and physiological characterization of angiogenic vessels in 
mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular 
permeability factor, and host microenvironment. Am J Pathol, 1996. 149(1): p. 59-71. 
172. Shojaei, F., et al., Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ 
myeloid cells. Nat Biotechnol, 2007. 25(8): p. 911-20. 
173. Benny, O., et al., An orally delivered small-molecule formulation with antiangiogenic and 
anticancer activity. Nat Biotechnol, 2008. 26(7): p. 799-807. 
174. Allport, J.R. and R. Weissleder, Murine Lewis lung carcinoma-derived endothelium expresses 
markers of endothelial activation and requires tumor-specific extracellular matrix in vitro. 
Neoplasia, 2003. 5(3): p. 205-17. 
175. Tyagi, N., et al., Fibrinogen induces endothelial cell permeability. Mol Cell Biochem, 2008. 
307(1-2): p. 13-22. 
176. Toellner, K.-M., et al., Immunoglobulin switch transcript production in vivo related to the site 
and time of antigen-specific B cell activation. Journal of Experimental Medicine, 1996. 183(5): 
p. 2303-2312. 
177. Nanda, A. and B. St Croix, Tumor endothelial markers: new targets for cancer therapy. Curr 
Opin Oncol, 2004. 16(1): p. 44-9. 
178. Ran, S., A. Downes, and P.E. Thorpe, Increased exposure of anionic phospholipids on the 
surface of tumor blood vessels. Cancer Res, 2002. 62(21): p. 6132-40. 
179. Huang, X., M. Bennett, and P.E. Thorpe, A monoclonal antibody that binds anionic 
phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human 
breast tumors in mice. Cancer Res, 2005. 65(10): p. 4408-16. 
180. Ran, S., et al., Antitumor effects of a monoclonal antibody that binds anionic phospholipids on 
the surface of tumor blood vessels in mice. Clin Cancer Res, 2005. 11(4): p. 1551-62. 
181. MacFadyen, J.R., et al., Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not 
not selectively expressed on tumour endothelium. FEBS Lett, 2005. 579(12): p. 2569-75. 
182. Chaudhary, A., et al., TEM8/ANTXR1 blockade inhibits pathological angiogenesis and 
potentiates tumoricidal responses against multiple cancer types. Cancer Cell, 2012. 21(2): p. 
212-26. 
183. Borsi, L., et al., Selective targeted delivery of TNFalpha to tumor blood vessels. Blood, 2003. 
102(13): p. 4384-92. 
184. Ebbinghaus, C., et al., Engineered vascular-targeting antibody-interferon-gamma fusion 
213 
 
protein for cancer therapy. Int J Cancer, 2005. 116(2): p. 304-13. 
185. Fabbrini, M., et al., Selective occlusion of tumor blood vessels by targeted delivery of an 
antibody-photosensitizer conjugate. Int J Cancer, 2006. 118(7): p. 1805-13. 
186. Gafner, V., E. Trachsel, and D. Neri, An engineered antibody-interleukin-12 fusion protein with 
enhanced tumor vascular targeting properties. Int J Cancer, 2006. 119(9): p. 2205-12. 
187. Kaspar, M., E. Trachsel, and D. Neri, The antibody-mediated targeted delivery of interleukin-15 
interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. 
Cancer Res, 2007. 67(10): p. 4940-8. 
188. Wagner, K., et al., The targeted immunocytokine L19-IL2 efficiently inhibits the growth of 
orthotopic pancreatic cancer. Clin Cancer Res, 2008. 14(15): p. 4951-60. 
189. Guenzi, E., et al., The guanylate binding protein-1 GTPase controls the invasive and angiogenic 
angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J, 
2003. 22(15): p. 3772-82. 
190. Schetter, A.J., N.H. Heegaard, and C.C. Harris, Inflammation and cancer: interweaving 
microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31(1): p. 37-49. 
191. Rho, S.S., et al., Clec14a is specifically expressed in endothelial cells and mediates cell to cell 
adhesion. Biochem Biophys Res Commun, 2011. 404(1): p. 103-8. 
192. Armstrong, L.J., et al., ECSM2, an endothelial specific filamin a binding protein that mediates 
chemotaxis. Arterioscler Thromb Vasc Biol, 2008. 28(9): p. 1640-6. 
193. Sumanas, S., T. Jorniak, and S. Lin, Identification of novel vascular endothelial-specific genes 
by the microarray analysis of the zebrafish cloche mutants. Blood, 2005. 106(2): p. 534-41. 
194. Gomez, G.A., et al., Discovery and characterization of novel vascular and hematopoietic genes 
downstream of etsrp in zebrafish. PLoS One, 2009. 4(3): p. e4994. 
195. Wasserman, S.M. and J.N. Topper, Adaptation of the endothelium to fluid flow: in vitro analyses 
analyses of gene expression and in vivo implications. Vasc Med, 2004. 9(1): p. 35-45. 
196. Matharu, N.M., et al., Inflammatory responses of endothelial cells experiencing reduction in 
flow after conditioning by shear stress. J Cell Physiol, 2008. 216(3): p. 732-41. 
197. Ando, J. and K. Yamamoto, Vascular mechanobiology: endothelial cell responses to fluid shear 
stress. Circ J, 2009. 73(11): p. 1983-92. 
198. Chu, T.J. and D.G. Peters, Serial analysis of the vascular endothelial transcriptome under static 
static and shear stress conditions. Physiol Genomics, 2008. 34(2): p. 185-92. 
199. Favre, C.J., et al., Expression of genes involved in vascular development and angiogenesis in 
endothelial cells of adult lung. Am J Physiol Heart Circ Physiol, 2003. 285(5): p. H1917-38. 
200. Voellenkle, C., et al., Deep-sequencing of endothelial cells exposed to hypoxia reveals the 
complexity of known and novel microRNAs. RNA, 2012. 18(3): p. 472-84. 
201. Guduric-Fuchs, J., et al., Deep sequencing reveals predominant expression of miR-21 amongst 
the small noncoding RNAs in retinal microvascular endothelial cells. J Cell Biochem, 2012. 
202. John, A. and G. Tuszynski, The role of matrix metalloproteinases in tumor angiogenesis and 
tumor metastasis. Pathol Oncol Res, 2001. 7(1): p. 14-23. 
203. Safranek, J., et al., Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of 
patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer 
Res, 2009. 29(7): p. 2513-7. 
204. Birchmeier, C., et al., Characterization of ROS1 cDNA from a human glioblastoma cell line. 
Proc Natl Acad Sci U S A, 1990. 87(12): p. 4799-803. 
214 
 
205. Birchmeier, C., S. Sharma, and M. Wigler, Expression and rearrangement of the ROS1 gene in 
human glioblastoma cells. Proc Natl Acad Sci U S A, 1987. 84(24): p. 9270-4. 
206. Maxwell, M., et al., Overexpression of the ros1 gene in primary human gliomas may contribute 
to malignant progression. Int J Oncol, 1996. 8(4): p. 713-8. 
207. Sharma, S., et al., Characterization of the ros1-gene products expressed in human glioblastoma 
cell lines. Oncogene Res, 1989. 5(2): p. 91-100. 
208. Zhao, J.F. and S. Sharma, Expression of the ROS1 oncogene for tyrosine receptor kinase in adult 
adult human meningiomas. Cancer Genet Cytogenet, 1995. 83(2): p. 148-54. 
209. ROS1 Gene Rearrangement Is Identified in NSCLC. Cancer Discov, 2012. 2(2): p. OF9. 
210. Bergethon, K., et al., ROS1 rearrangements define a unique molecular class of lung cancers. J 
Clin Oncol, 2012. 30(8): p. 863-70. 
211. Janne, P.A. and M. Meyerson, ROS1 rearrangements in lung cancer: a new genomic subset of 
lung adenocarcinoma. J Clin Oncol, 2012. 30(8): p. 878-9. 
212. Yang, D., et al., Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell 
antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly 
expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res, 
2001. 61(15): p. 5857-60. 
213. Hubert, R.S., et al., STEAP: a prostate-specific cell-surface antigen highly expressed in human 
prostate tumors. Proc Natl Acad Sci U S A, 1999. 96(25): p. 14523-8. 
214. Gomes, I.M., C.J. Maia, and C.R. Santos, STEAP Proteins: From Structure to Applications in 
Cancer Therapy. Mol Cancer Res, 2012. 10(5): p. 573-87. 
215. Alves, P.M., et al., STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer 
Immunol Immunother, 2006. 55(12): p. 1515-23. 
216. Sah, N.K., et al., Structural, functional and therapeutic biology of survivin. Cancer Lett, 2006. 
244(2): p. 164-71. 
217. Apps, S.A., W.A. Rankin, and A.P. Kurmis, Connexin 26 mutations in autosomal recessive 
deafness disorders: a review. Int J Audiol, 2007. 46(2): p. 75-81. 
218. Boles, K.S., et al., MR angiogenesis imaging with Robo4- vs. {alpha}V{beta}3-targeted 
nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 
219. JV, R., Fc receptors. Fundamental Immunology, 2003: p. 685-700. 
220. Hamaguchi, Y., et al., Antibody isotype-specific engagement of Fcgamma receptors regulates B 
lymphocyte depletion during CD20 immunotherapy. J Exp Med, 2006. 203(3): p. 743-53. 
221. Nimmerjahn, F. and J.V. Ravetch, Fcgamma receptors: old friends and new family members. 
Immunity, 2006. 24(1): p. 19-28. 
222. Nagayama, H., et al., Gastrointestinal bleeding during anti-angiogenic peptide vaccination in 
combination with gemcitabine for advanced pancreatic cancer. Clin J Gastroenterol, 2010. 3(6): 
p. 307-317. 
223. Kamba, T. and D.M. McDonald, Mechanisms of adverse effects of anti-VEGF therapy for 
cancer. Br J Cancer, 2007. 96(12): p. 1788-95. 
224. Mailhos, C., et al., Delta4, an endothelial specific notch ligand expressed at sites of 
physiological and tumor angiogenesis. Differentiation, 2001. 69(2-3): p. 135-44. 
225. Noguera-Troise, I., et al., Blockade of Dll4 inhibits tumour growth by promoting non-productive 
non-productive angiogenesis. Nature, 2006. 444(7122): p. 1032-7. 
226. Hellstrom, M., et al., Dll4 signalling through Notch1 regulates formation of tip cells during 
215 
 
angiogenesis. Nature, 2007. 445(7129): p. 776-80. 
227. Jubb, A.M., et al., Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in 
glioblastoma. Histopathology, 2012. 60(5): p. 740-7. 
228. Jubb, A.M., et al., Expression of vascular notch ligand delta-like 4 and inflammatory markers in 
in breast cancer. Am J Pathol, 2010. 176(4): p. 2019-28. 
229. Jubb, A.M., et al., Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon 
cancer. Br J Cancer, 2009. 101(10): p. 1749-57. 
230. Yan, M., et al., Chronic DLL4 blockade induces vascular neoplasms. Nature, 2010. 463(7282): 
p. E6-7. 
231. Huijbers, E.J., et al., The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can 
replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development. 
Vaccine, 2012. 30(2): p. 225-30. 
232. Carnemolla, B., et al., A tumor-associated fibronectin isoform generated by alternative splicing 
of messenger RNA precursors. J Cell Biol, 1989. 108(3): p. 1139-48. 
233. Onn, A. and R.S. Herbst, Molecular targeted therapy for lung cancer. Lancet, 2005. 366(9496): 
p. 1507-8. 
234. Xiong, H.Q., K. Carr, and J.L. Abbruzzese, Cytotoxic chemotherapy for pancreatic cancer: 
Advances to date and future directions. Drugs, 2006. 66(8): p. 1059-72. 
235. Abengozar, M.A., et al., Blocking ephrin-B2 with highly specific antibodies inhibits 
angiogenesis, lymphangiogenesis, and tumor growth. Blood, 2012. 
236. Palumbo, A., et al., A chemically modified antibody mediates complete eradication of tumours 
by selective disruption of tumour blood vessels. Br J Cancer, 2011. 104(7): p. 1106-15. 
237. Guojun, W., et al., A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of 
breast cancer growth in vivo. Endocr Relat Cancer, 2008. 15(1): p. 149-59. 
238. Kaur, S., et al., Robo4 signaling in endothelial cells implies attraction guidance mechanisms. J 
Biol Chem, 2006. 281(16): p. 11347-56. 
239. Jones, C.A., et al., Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis 
and endothelial hyperpermeability. Nat Med, 2008. 14(4): p. 448-53. 
240. Koch, A.W., et al., Robo4 maintains vessel integrity and inhibits angiogenesis by interacting 
with UNC5B. Dev Cell, 2011. 20(1): p. 33-46. 
241. Lu, X., et al., The netrin receptor UNC5B mediates guidance events controlling morphogenesis 
of the vascular system. Nature, 2004. 432(7014): p. 179-86. 
242. Larrivee, B., et al., Activation of the UNC5B receptor by Netrin-1 inhibits sprouting 
angiogenesis. Genes Dev, 2007. 21(19): p. 2433-47. 
 
 
 
 
